,PageNo,Text
0,page_0,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 1 de 123 PRODIGE 59 - (FFCD 1707 ) – DURIGAST A randomized phase II study evaluating FOLFIRI + dur valumab vs FOLFIRI + durvalumab and tremelimumab in second -line treatment of patients with advanced gastric or gastro -oesophageal junction adenocarcinoma Randomized – non-comparative – multicenter phase II N° EudraCT : 2018 -002014 -13 An intergroup trial: FFCD – UNICANCER -GI – GERCOR Principal investigator (FFCD) : Pr. David Tougeron CHU de Poitiers Service d'H épato -gastro -entérologie 2 Rue de la Milétrie 86021 POITIERS FRANCE Phone : +33 (0)5 49 44 37 51 Fax : +33 (0)5 49 44 48 60 Email : david.tougeron@chu -poitiers.fr Co-principal investigator (FFCD) : Pr. Frédéric Di Fiore CHU Charles Nicolle Service d'Oncologie 1 Rue Germont 76031 ROUEN FRANCE Phone : + 33 (0)2 32 88 86 10 Fax : +33 (0)2 32 88 86 69 Email : frederic.di -fiore@chu -rouen.fr Co-principal investigator (GERCOR): Pr. Chri stophe Louvet Institut Mutualiste Montsouris 42 Boulevard Jourdan 75014 PARIS FRANCE Phone : + 33 (0)1 56 61 60 35 Fax : +33 (0)1 56 61 69 60 Email : christophe.louvet@imm.fr Co-principal investigator (UNICANCER GI): Dr. Farid El Hajbi Centre Oscar Lambret Département d’oncologie générale 3 Rue Frédéric Combemale BP 307 - 59020 Lille CEDEX FRANCE Phone : + 33 (0) 3 20 29 59 42 Fax : +33 (0) 3 20 29 55 00 Email : f-elhajbi@o -lambret .fr COMMITTE E OF REDACTION : David Tougeron (Poit iers, CHU ), Frédéric Di Fiore (Rouen, CHU) , Karine le Malicot (Dijon , FFCD ), Pierre Laurent -Puig (Paris HEGP) , Frédéric Bibeau (Caen, CH U), Christophe Louvet (Paris, Montsouris) , Farid El Hajbi (Lille, CAC) , Thierry Lecomte (Tours, CHU) , Thomas Aparicio (Paris, Saint -Louis) , Astrid Lièvre (Rennes, CHU ), Rosine Guimbaud (Toulouse, CHU) , Stefano Kim (Besançon , CHU), Emilie Barbier (Dijon , FFCD ), Sabrina Pierre (Dijon , FFCD ), Daniel Gonzalez (Dijon , FFCD ) BIOLOGICAL COMMIT TEE : Pierre -Laurent Puig (Paris) , David Tougeron (Poitiers), Frédéric Di Fiore (Rouen), Frédéric Bibeau (Caen), Thierry Lecomte (Tours), Thomas Aparicio (Paris), Astrid Lièvre (Rennes) , Harry Sokol (Paris) SPONSOR AND DATA CENTER : Fédération Francophone de Cancérologie Digestive (FFCD) - Faculté de Médecine - 7, Boulevard Jeanne d’Arc - BP 87900 - 21079 Dijon Cedex - France Executive director: Cécile GIRAULT Tél. : +33 (0)3 80 66 80 13 – Fax : +33 (0)3 80 38 18 41 Courriel : cecile.girault@u -bourgogne.fr Statistician: Karine LE MALICOT Tél. : +33 (0) 3 80 39 34 71 – Fax : +33 (0)3 80 38 18 41 Courriel : karine.le -malicot@u -bourgogne.fr Project manager: Lila GABA Tél. : +33 (0)3 80 39 34 83 – Fax : +33 (0)3 80 38 18 41 Courriel : lila.gaba@u -bourgogne.fr Confidential This document is the property of the Fédération Francophone de Cancérologie Digestive and may not be transferred, reproduced, published or used, in whole or in part, without the federation's express authorization."
1,page_1,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 2 de 123 TABLE OF CONTENTS 1. STUDY OBJECTIVE ................................ ................................ ................................ ...................... 14 1.1. Safety run -in phases objectives ................................ ................................ ................................ .......................... 14 1.2. Primary objective of phase II only ................................ ................................ ................................ ...................... 14 1.3. Secondary objectives for phase II study ................................ ................................ ................................ .............. 14 2. PATIENT SELECTION ON REGISTRATION/RANDOMI ZATION ................................ ..... 14 2.1. Inclusion criteria ................................ ................................ ................................ ................................ ................ 14 2.2. Non-inclusion criteria ................................ ................................ ................................ ................................ ........ 15 3. INCLUSI ON ASSESSMENT ................................ ................................ ................................ ......... 16 4. REGISTRATION/RANDOMI ZATION ................................ ................................ ....................... 17 5. STUDY DE SIGN ................................ ................................ ................................ ............................. 18 5.1. Safety run -in ................................ ................................ ................................ ................................ ...................... 18 5.2. Phase II study ................................ ................................ ................................ ................................ ..................... 18 6. TREATMENTS ................................ ................................ ................................ ............................... 19 6.1. Description, packaging and labeling of durvalumab ................................ ................................ ........................... 19 6.2. Description, packaging and labeling of tremelimumab ................................ ................................ ....................... 20 6.3. FOLFIRI + durvalumab (1st and 2nd steps of the safety run -in phase and Arm A) ................................ ............... 21 6.4. FOLFIRI + durvalumab + tremelimumab (2nd step of the safety run -in phase an d Arm B) ................................ .. 21 7. DOSE ADJUSTMENT BASE D ON TOXICITY ................................ ................................ ......... 23 7.1. Criteria that must be met before each subsequent cycle (D1 of each cycle) ................................ ......................... 23 7.2. Dose adjustment based on toxicities observed during the rest period ................................ ................................ .. 23 7.3. Dose adjustment based on infusion -related reaction ................................ ................................ ........................... 24 7.4. Dose adjustment of FOLFIRI ................................ ................................ ................................ ............................. 24 7.5. Management of Immune -mediated adverse event (imAE) ................................ ................................ .................. 26 7.6. Partial treatments stop ................................ ................................ ................................ ................................ ........ 35 7.7. Premedications, concomitant treatments and contraindicated treatments ................................ ............................. 36 7.7.1. Neutropenia ................................ ................................ ................................ ................................ .............. 36 7.7.2. Contraindicated treatments (see SmPCs and IB of each protocol’s molecular entities) ............................. 36 8. LOGISTICS OF THE BIO LOGICAL STUDY (FOR P HASE II ONLY) ................................ 36 9. PATIENT MONITORING ................................ ................................ ................................ ............. 37 9.1. During treatment ................................ ................................ ................................ ................................ ................ 37 9.1.1. Before each administration of treatment ................................ ................................ ................................ .... 37 9.1.2. Evaluation every 8 weeks until radiological progr ession ................................ ................................ ........... 38 9.2. After treatment discontinuation ................................ ................................ ................................ .......................... 38 9.2.1. Within 30 days for evaluating the toxicity of the last treatment ................................ ................................ . 38 9.2.2. After premature discontinuation of treatment other than for radiological progression * .............................. 39 9.2.3. After treatment discontinuation because of radiological progression ................................ ......................... 39 10. SUBSEQUENT TREATMENT S ................................ ................................ ................................ ... 39 11. MANAGEME NT OF SERIOUS ADVERS E EVENTS ................................ ............................... 39 12. STATISTICAL ANALYSIS ................................ ................................ ................................ ........... 42 12.1. Safety analyses (safety run -in phase) ................................ ................................ ................................ .................. 42 12.2. Endpoints for phase II study ................................ ................................ ................................ ............................... 42 12.2.1. Primary efficacy endpoint ................................ ................................ ................................ ......................... 42 12.2.2. Secondary endpoints ................................ ................................ ................................ ................................ . 42 12.3. Samp le size justification, statistical hypothesis ................................ ................................ ................................ ... 43 12.4. Statistical analysis for phase II study ................................ ................................ ................................ .................. 44 12.4.1. Population definition ................................ ................................ ................................ ................................ 44 12.4.2. Endpoint evaluation ................................ ................................ ................................ ................................ .. 44 13. STUDY COMMITTEES ................................ ................................ ................................ ................. 45 13.1. Independent data monitoring committee ................................ ................................ ................................ ............. 45 13.2. Steering committee ................................ ................................ ................................ ................................ ............ 45 13.3. Medical review ................................ ................................ ................................ ................................ .................. 45 13.4. Biological research committee ................................ ................................ ................................ ........................... 45 14. BACKGROUND INFORMATI ON AND RATIONALE FOR THE TRIAL ............................ 46 15. REFERENCES ................................ ................................ ................................ ................................ 48 16. ADMINISTRATIVE CONSI DERATIONS ................................ ................................ .................. 49 17. RULES FOR PUBLICATIO N ................................ ................................ ................................ ....... 51 18. APPENDICES ................................ ................................ ................................ ................................ .. 51 APPENDIX 1: CLINICAL AND BIOLOGICAL INFOR MED CONSENT ................................ .... 52 APPENDIX 2: BIOLOGIC AL STUDIES ................................ ................................ ............................ 77"
2,page_2,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 3 de 123 APPENDIX 3: QUALITY OF LIFE – QLQ -C30 ................................ ................................ ................ 80 APPENDIX 4: QUALITY OF LIFE - STO -22 ................................ ................................ .................... 81 APPENDIX 5: ECOG PER FORMANCE STATUS – CALCULATION OF CLEAR ANCE ......... 82 APPENDIX 6 : RECIST CRITERIA, V ERSION 1.1 ................................ ................................ .......... 83 APPENDIX 7: IRECIST CRITERIA OF IMMUNOLO GICAL RESPONSE ................................ . 85 APPENDIX 8: ASSESSME NT OF TOXICITIES ................................ ................................ ............... 89 APPENDIX 9: SUMMARY OF CHARACTERISTICS P RODUCT AND INVESTIVA TOR’S BROCHURE ................................ ................................ ................................ ................................ .......... 111 APPENDIX 10: AUTHORI ZED AND PROHIBITED C ONCOMITTANT MEDICATI ONS .... 112 APPENDIX 11: SERIOUS ADVERSE EVENT REPORT FORM ................................ ................. 114 APPENDIX 12: RULES F OR PUBLICATION FOR P RODIGE TRIALS ................................ .... 118 APPENDIX 13: INSURAN CE CERTIFICATE ................................ ................................ ................ 120 APPENDIX 14: APPROVA L OF THE IRB ................................ ................................ ...................... 121 APPENDIX 15: ANSM AU THORIZATION ................................ ................................ ..................... 123"
3,page_3,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 4 de 123 LIST OF ABBREVIATIONS Abbreviation or special term Explanation AChE Acetylcholine esterase ADA Anti-drug antibody AE Adverse event AESI Adverse event of special interest ALK Anaplastic lymphoma kinase ALT Alanine aminotransferase ANC Absolute neutrophil count APF12 Proportion of patients alive and progression free at 12 months from randomization AST Aspartate aminotransferase AUC Area under the curve AUC 0-28day Area under the plasma drug concentration -time curve from time zero to Day 28 post-dose AUC ss Area under the plasma drug concentration -time curve at steady state BICR Blinded Independent Central Review BoR Best objective response BP Blood pressure C Cycle CBC Complete blood count CD Cluster of differentiation CI Confidence interval CL Clearance Cmax Maximum plasma concentration Cmax,ss Maximum plasma concentration at steady state CR Complete response CSA Clinical study agreement CSR Clinical study report CT Computed tomography CTCAE Common Terminology Criteria for Adverse Event CTLA -4 Cytotoxic T –lymphocyte -associated antigen 4 Ctrough,ss Trough concentration at steady state CXCL Chemokine (C -X-C motif) ligand DoR Duration of response EC Ethics Committee, synonymous to Institutional Review Board and Independent Ethics Committee ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group eCRF Electronic case report form EDoR Expected duration of response EGFR Epiderma l growth factor receptor EU European Union FAS Full analysis set FDA Food and Drug Administration GCP Good Clinical Practice GI Gastrointestinal GMP Good Manufacturing Practice hCG Human chorionic gonadotropin HIV Human immunodeficiency virus HR Hazard ratio IB Investigator’s Brochure ICF Informed consent form ICH International Conference on Harmoniz ation IDMC Independent Data Monitoring Committee IFN Interferon IgE Immunoglobulin E IgG Immunoglobulin G IHC Immunohistochemistry IL Interleukin ILD Interstitial Lung Disease ILS Interstitial lung disease"
4,page_4,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 5 de 123 IM Intramuscular IMT Immunomodulatory therapy IP Investigational product irAE Immune -related adverse event IRB Institutional Review Board iRECIST Immune -related Response Evaluation Criteria in Solid Tumors ITT Intent -to-Treat IV Intravenous IVRS Interactive Voice Response System IWRS Interactive Web Response System LFT Liver function tests mAb Monoclonal antibody MDSC Myeloid -derived suppressor cell MedDRA Medical Dictionary for Regulatory Activities MHLW Minister of Health, Labor, and Welfare miRNA Micro -ribonucleic acid MRI Magnetic resonance imaging NCI National Cancer Institute NE Not evaluable NSCLC Non–small -cell lung cancer OAE Other significant adverse event ORR Objective response rate OS Overall survival PBMC Peripheral blood mononuclear cell PD Progressive disease PD-1 Programmed cell death 1 PD-L1 Programmed cell death ligand 1 PD-L2 Programmed cell death ligand 2 PDx Pharmacodynamic(s) PFS Progression -free survival PFS2 Time to second progression PGx Pharmacogenetic research PJP Pneumocystis jiroveci Pneumonia PK Pharmacokinetic(s) PR Partial response QTcF QT interval corrected for heart rate using Fridericia’s formula RECIST 1.1 Response Evaluation Criteria in Solid Tumors, version 1.1 RNA Ribonucleic acid RR Response rate RT-QPCR Reverse transcription quantitative polymerase chain reaction SAE Serious adverse event SAP Statistical analysis plan SAS Safety analysis set SD Stable disease SNP Single nucleotide polymorphism SoC Standard of Care sPD-L1 Soluble programmed cell death ligand 1 T3 Triiodothyronine T4 Thyroxine TSH Thyroid -stimulating hormone TNF Tumor necrosis factor ULN Upper limit of normal US United States WBDC Web-Based Data Capture WHO World Health Organization"
5,page_5,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 6 de 123 FFCD CONTACTS FOR TH E STUDY NAME FUNCTION TEL (+33) FAX (+33) EMAIL FFCD DATA CENTER Cécile GIRAULT Executive Director (0)3 80 39 33 87 (0)3 80 38 18 41 cecile.girault@u - bourgogne.fr Marie MOREAU Clinical Operation leader (0)3 80 39 34 04 (0)3 80 38 18 41 marie.moreau@u - bourgogne.fr Operational team lila GABA Project manager (0)3 80 39 34 83 (0)3 80 38 18 41 lila.gaba@u- bourgogne.fr Caroline CHOINE - POURET CRA coordinator (0)4 69 18 19 02 (0)9 74 44 22 47 caroline.choine@u - bourgogne.fr Coralie DEVORSINE Assistant project manager (0)3 80 39 34 86 (0)3 80 38 18 41 coralie.devorsine@u - bourgogne.fr Carole MONTERYMARD Data manager (0)3 80 39 34 84 (0)3 80 38 18 41 carole.monterymard@u -bourgogne.fr Karine Le MALICOT Biostatistician (0)3 80 39 34 71 (0)3 80 38 18 41 Karine.Le -Malicot@u - bourgogne.fr Camille FLECK Pharmacovigilance (0)3 80 29 55 80 (0)3 80 38 18 41 vigilance.ec@chu - dijon.fr
6,page_6,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 7 de 123 PRODIGE 59 - (FFCD 1707 ) – DURIGAST A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second -line treatment of patients with advanced gastric or gastro -oesophageal junction adenocarcinoma EudraCT no. 2018 -002014 -13 Version 2.0–04/08 /2020 This version of the protocol has been approved by: The sponsor: Cécile Girault Date: 04.08.2020 Signature: The coordinator: Prof. David Tougeron Date: 04.08.2020 Signature: I the undersigned, Dr ./Pr……………. ……. having taken note of the pre -requisites of this research and of the protocol and its appendi ces, certify that I will undertake to conduct this trial in compliance with Good Clinical Practice and in accordance with the applicable provisions of the French Pu blic Health Code. I particularly undertake to: - comply with the protocol as well as any amendments of which the sponsor notifies me - supervise the research in the center, train my colleagues in conducting the research, and provide a list of the names of my colleagues - obtain the status of patients from the vital records office at the time of analysis or if the sponsor so requests if patients are lost to follow -up - have each patient sign a written consent form once I have familiarized the patient with the inf ormation sheet. This I undertake to do before any procedure is performed for the research - report any serious adverse events or new facts within 24 hours of their being brought to my attention in accordance with the protocol's instructions - comply with the inclusion and non -inclusion criteria as well as with the start and end dates of the trial - participate in the biological section of the trial and dispatch the samples according to the guidelines - fill in all items of the CRF and ensure that data collection i s up to standard and that the products are properly managed - retain the data and documents relating to the trial for 15 years after the trial has ended - inform the sponsor of any conflict of interest that may damage my scientific independence within the framework of the research - immediately inform the sponsor of any legal action, whether amicable or contentious, brought by a person participating in the research or by that person's assignees in which the sponsor may be held accountable - accept periodic visits from the sponsor's representatives and make all source documents and materials relating to the research available to them so that they may verify the quality of data recorded in the CRF. Accept audits by the sponsor or one of its rep resentatives and/or inspections by the health authorities - reply by phone or email to requests for corrections or clarifications concerning the CRF - accord the FFCD CRA the time necessary for signing forms, answering any questions and carrying out correctiv e actions Date: Signature: CENTER'S STAMP : Send the original to the FFCD Randomization, Management and Analysis Center – 7 bd Jeanne d’Arc – BP 87900 – 21079 Dijon Cedex, France"
7,page_7,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 8 de 123 SYNOPSIS Title PRODIGE 59 - (FFCD 1707 ) – DURIGAST A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second -line treatment of patients with advanced gastric or gastro -oesophageal junction adenocarcinoma Sponsor French Federation of Digestive Oncology (FFCD) Design Safety Run -In and m ulticenter randomized phase II non-comparative open -label study Study objectives Safety Run -In phase : Validate the good tolerability of treatments combination in 2 steps: - 1st step : treated 5 patients with FOLFIRI (irinotecan at 180 mg/m² ) + durvalumab - 2nd step: randomized 6 patients between FOLFIRI (irinotecan at 180 mg/m² ) + durvalumab v ersus FOLFIRI (irinotecan at 150 mg/m² ) + durvalumab + tremelimumab (3 patients per arm) Patients will be treated in 5 expert centers with a huge experience in the use of immune checkpoints inhibitors. Inclusions will be stopped at each step for safety analyses . Phase II study: Primary objective : - Percentage of patients alive and without progression at 4 months of FOLFIRI plus durvalumab versus FOLFIRI plus durvalumab plus tremelimumab in patients with advanced -stage gastric or gastro -oesophageal junction adenocarcinoma and who progressed after a first line chemotherapy (based on RECIST 1. 1 rating scale evaluated by the investigator ). Secondary objectives : - Percentage of patients alive and without progression at 4 months according to centralized review - Overall survival (OS) - Time to strategy failure - Safety profile - Quality of life (QoL) - Time to progression (TTP) , progression -free survival ( median PFS) , best objective response rate ( BRR) and disease control rate (DCR) according to the investigator and centralized review (according RECIST V1.1 and iRECIST criteria ) - Efficacy endpoints (OS, PFS, TTP, BRR and DCR) according to the expression of PD-L1 and others biomarkers (see biological study) Inclusion criteria - Age ≥ 18 years . - Body weight > 30kg . - Histologically proven advanced -stage unresectable adenocarcinoma of the stomach or the GEJ (Siewert II or III). - Known MSS/MSI status or t umor tissue available (frozen or paraffin -embedded, primary tumors or metastases) in order to allow determination of MSS/MSI status. The investigator needs to ensure that tumor tissues will be sent after patient randomization . - Failure to platinium -based 1st line therapy with or without trastuzumab, or early recurrent disease after surgery with neo -adjuvant and/or adjuvant platinium -based chemotherapy (within 6 months of the end of chemotherapy ) or progression during neo-adjuvant and/or adjuvant platinium -based chemotherapy . - Eligible for a second -line treatment with irinotecan and 5 -FU. - Measurable or non -measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . - Eastern Cooperative Oncology Group (ECOG) performance status 0 -1. - Adequate organ function: ANC ≥ 1.5 x 109/L, haemoglobin ≥ 9 g/dL, platelets ≥ 100 x 109/L, AST/ALT ≤ 3 x ULN (≤ 5 x ULN in case of liver metastase(s)), GGT ≤ 3 x ULN (≤ 5 x ULN in case of liver metastase(s)), bilirubin ≤ 1.5 x ULN, creatinin clearance > 40 mL/min (MDRD). - Evidence of post -menopausal status or negative urinary or serum pregnancy test for female pre -menopausal patients. - Man and woman who childbearing potential agrees to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 6 months after the last treatment intake. - Patient is able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol -specific procedures performed."
8,page_8,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 9 de 123 Non-inclusion criteria - Concurrent enrolment in another clinical study – unless it is an observational study or during the follow -up period of an interventional study. - Receipt of the last dose of anticancer therapy ≤ 2 weeks prior to the first dose of study drug. - Radiotherapy within 4 weeks prior to the first dose of treatment . - History of chronic inflammatory bowel disease (IBD) . - Current or prior bowel obstruction within 28 days before the first dose of study drugs . - Any unresolved significant toxicity NCI CTCAE v4.0 ≥ grade 2 fr om previous anticancer therapy (excepted neuropathy and alopecia) - Concurrent use of hormonal therapy for non –cancer -related conditions is acceptable - Major surgical procedure ( e.g. exploratory laparoscopy is not considered as a major surgical procedure ) within 28 days prior to the first dose of treatment. - Prior allogeneic bone marrow transplantation or prior solid organ transplantation. - Active or prior documented auto immune or inflammatory disorders (patients with alopecia, vitiligo, controlled hypo or hyperthyroidism, any chronic skin condition not requiring immunosuppressant therapy are eligible). Patients without active disease in the last 5 years may be included . - Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastroint estinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent . - Severe cardiac disorders within 6 months. - Severe liver dysfunction - History of idiopathic pulmonary fibrosis, drug -induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT -scan. - History of leptomeningeal carcinoma tosis or symptomatic or untreated brain metastase(s) . Patients whose brain metastase (s) have been treated may participate if any neurologic symptoms that developed either as a result of the brain metastases or their treatment are resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent for at least 14 days prior to the start of treatment . - Positive test for HIV, active hepatitis B or hepatitis C, active tuberculosis. - History of active primary immunodeficiency - Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs (excepted: intranasal, inhaled, topical steroids or local steroid injection –at physiologic do se does not exceed 10 mg/day of prednisone or its equivalent – steroids as premedication for hypersensitivity reactions). - Receipt of live attenuated vaccine within 30 days prior to the first dose of treatment - Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. In order to check all the contraindications of each drugs , please refer to the updated versions of the SmPCs presented in Appendix 9. - Current or prior use of St. John's Wort within 14 days before the first dose of study drugs (St. John's Wort is not allowed during participation in the trial). - Treatment with sorivudine or analogs (brivudine). - Treatment with phenytoin or analogs. - Prior treatment with irinotecan, anti -PD1, anti PD -L1, anti -CLTA4 or other immunotherapy for cancer treatment - Known Uridine Diphosphate Glucuronyltransferase (UGT1A1) enzyme deficiency - Partial or complete DPD deficiency (Uracilemia ≥ 16 ng/ml) - Active infection requiring intravenous antibiotics at the time of Day 1 of Cycle 1. - Other malignancy within 5 years prior to study enrolment, except for localized cancer in situ , basal or squamous cell skin cancer. - Pregnant or breastfeeding female patient ."
9,page_9,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 10 de 123 Study treatment Safety Run -in phase 1st step: Administered in 5 patients FOLFIRI plus durvalumab - Durvalumab: 1500 mg by 1 -hour IV infusion . Every 4 weeks until progression - FOLFIRI (1 course every 2 weeks, until progression): - Irinotecan: 180 mg/m² by 2 -hour IV infusion, - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion, - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus, - Continuous 5 -FU: 2400 mg/m² by 46 -hour IV infusion 2nd step: Administered in 6 patients (3 patients per arm) FOLFIRI plus durvalumab - Durvalumab: 1500 mg by 1 -hour IV infusion . Every 4 weeks until progression - FOLFIRI (1 course every 2 weeks, until progression): - Irinotecan: 180 mg/m² by 2 -hour IV infusion, - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion, - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus, - Continuous 5 -FU: 2400 mg/m² by 46 -hour IV infusion FOLFIRI plus durvalumab plus tremelimumab Induction treatment: 4 cycles (i.e. 1 course every 4 weeks ) - Durvalumab: 1500 mg by 1 -hour IV infusion - Every 4 weeks . - Tremelimumab: 75 mg by 1 -hour IV infusion - Every 4 weeks (for only 4 cycles ). - FOLFIRI (1 course every 2 weeks, until progression): - Irinotecan: 150 mg/m² by 2-hour IV infusion - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus - Continuous 5 -FU: 2400 mg/m² by 46 -hour IV infusion Tremelimumab is administered for 4 c ourses (4 months) and then patient will continue to receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control, tremelimumab can be re -introduce d at investigator discretion. Patient must have 2 weeks of washout period of first -line treatment before receiving the treatment in the trial. Treatment will be repeated every 4 weeks until disease progression, unacceptable toxicity or patient’s refusal. All drugs (irinotecan, folinic acid and 5 -FU) except durvalumab and tremelimumab will be used in the context of their marketed authorization or recommendations (Thésaurus National de Cancé rologie Digestive (www.tncd.org )) in France. Thus, durvalumab and tremelimumab will be provided in this clinical trial. A pharmacovigilance follow -up will be implemented during the study. Phase II: Arm A: FOLFIRI plus durvalumab - Durvalumab: 1500 mg by 1 -hour IV infusion . Every 4 weeks until progression - FOLFIRI (1 course every 2 weeks, until progression): - Irinotecan: 180 mg/m² by 2 -hour IV infusion, - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion, - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus, - Continuous 5 -FU: 2400 mg/m² by 46 -hour IV infusion Arm B: FOLFIRI plus durvalumab plus tremelimumab Induction treatment: 4 cycles (i.e. 1 course every 4 weeks ) - Durvalumab: 1500 mg by 1 -hour IV infusion - Every 4 weeks . - Tremelimumab: 75 mg by 1 -hour IV infusion - Every 4 weeks (for only 4 cycles ). - FOLFIRI (1 course every 2 weeks, until progression): - Irinotecan: 180 mg/m² by 2 -hour IV infusion - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus - Continuous 5 -FU: 2400 mg/m² by 46 -hour IV infusion"
10,page_10,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 11 de 123 In arm B: tremelimumab is administered for 4 c ourses (4 months) and then patient will continue to receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control, tremelimumab can be re -introduce at investigator discretion. Patient must have 2 weeks of washout period o f first -line treatment before receiving the treatment in the trial. Treatment will be repeated every 4 weeks until disease progression, unacceptable toxicity or patient’s refusal. All drugs (irinotecan, folinic acid and 5 -FU) except durvalumab and tremeli mumab will be used in the context of their marketed authorization or recommendations (Thésaurus National de Cancé rologie Digestive (www.tncd.org )) in France. Thus, durvalumab and tremelimumab will be provided in this clinical trial. A pharmacovigilance fol low-up will be implemented during the study. Safety analysis For s afety run-in phase s, patients will be treated in 5 expert centers with a huge experience in the use of immune checkpoints inhibitors . 1st step: In order to check the good tolerability of FOLFIRI plus durvalumab combination, 5 patients will be treated by FOLFIRI (irinotecan 180mg/m²) plus durvalumab (1500 mg) in 5 expert centers. The inclusion will be stopped at 5 patients . When the 5th patient wi ll have received 2 cycles of treatment , the safety analysis will be done with all the safety data available at this date. The review will be done by an Independent Data Monitoring Committee (IDMC). The decision of IDMC and the data available will be sent to ANSM. We will wait the ANSM approval to re -open the inclusion of patients. 2nd step: 3 patients per arm will be randomized to receive either FOLFIRI (irinotecan 180 mg/m²) plus durvalumab (1500 mg) or FOLFIRI ( irinotecan 150 mg/m²) plus durvalumab (1500 mg) plus tremelimumab (75 mg). These 6 patients will be treated in the same 5 expert centers. When the 6th patient will have received 2 cycles of treatment , the safety analysis will be done with all the safety data available at this date (for the 11 patien ts included in th ese safety run -in phase s). The review will be done by an Independent Data Monitoring Committee (IDMC). The decision of IDMC and the data available will be sent to ANSM. We will wait the ANSM approval to open the phase II trial. Randomization The safety run -in will be done for the first step on an open -labeled part on 5 patients. A simple enrollment process will be performed for the first step of safety run -in. For the second step of safety run -in (3 patients per arm) and the phase II, the same randomization process will be performed as described hereinafter . The randomiz ation will be done using minimiz ation technique according to the ratio 1:1 and the following factors will be considered for the stratification: - Center - Duration of disease control with previous first -line chem otherapy (no disease control vs < 3 months vs ≥ 3 months) Sample size calculation No statistical hypotheses for the safety run -in phases . A total of 11 patients will be included in the 2 step s before the randomized phase II will begin. The clinical hypotheses for the randomized phase II study are: - H0: 50% of patients alive and without progression at 4 months is not acceptable. - H1: 70% of patients alive and without progression at 4 months is expected. With a risk α (one-sided) of 5%, a power of 85% and according to the binomial -exact design, 44 evaluable patients are needed by arms (i.e. patients randomized and with at least one dose of products taken) . Assuming 5% of non -evaluable patients or lost to follow -up, 47 patients will be included by arms ( 94 patients in total ). Taking into account the 11 patients included in the safety run -in phases , 105 patients will be included in the trial."
11,page_11,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 12 de 123 Statistical analysis (generality) Safety run-in: Listing of baseline patient characteristics , treatment s and safety data will be provided to IDMC (as well to ANSM) at the time of the analyses includ ing dose of treatments, toxicities and serious adverse events. Phase II study: Primary endpoint will be analysed on the modified intent -to-treat population (patients with at least one dose of treatment). All the baseline characteristics will be described on the overall population and by treatment arm. Description of toxicities and other baseline vari ables will be done using usual statistics: for continuous variables: mean, standard deviation, median, inter-quartile interval and range , and for categorical variables frequencies and percentages. Survival analyses will be estimated using Kaplan -Meier met hod. A detailed Statistical Analysis Plan will be written before the database lock. Biological study Only for r andomized p hase II : - Blood (plas ma) and tumor samples will be collected in all patients in order to allow translational research projects (Centre de Ressource Biologique EPIGENETEC, UMR -S 1147, Paris, France, Headed by Prof. Pierre Laurent -Puig) in order to identify predictive biomarkers of treatment efficacy including at least (for more details see “ancillary studies” ): microsatellite insta bility (tumor DNA and immunohistochemistry) , immune response (including PD -L1 and PD -L2) and immune score (immunohistochemistry) , circulating tumor DNA (baseline and kinetic) , tumor mutation load and gastric molecular sub -groups. - Stool samples will be collected prospectively in all patients in order to allow analysis of microbiota (16S rRNA to identification of bacteria composing the intestinal microbiota of patients ). Number of patients Safety Run -in phases : 11 patients ; Randomized p hase II study : 94 patients Overall study (safety run -in and phase II) : 105 patients Duration of inclusion and length of participation for each patient Theoretical rate of inclusion: 4 per month Safety run -in: 5 expert centers selected Safety analysis of the first 11 patients included: – Q1 2019 to Q1 2020 Phase II study: Number of centers: 50 (around 30 active centers) Theoretical start of inclusion: Q1 2020 Theoretical end of inclusion: Q1 2022 End of the trial (primary and secondary endpoint analysis): Q2 2023"
12,page_12,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 13 de 123 p: phase II only items are indicated and highlighted in red *: DPD deficiency assessment following INCa and HAS recommendations (Avis n°2018.0053/AC/SEAP du 28 novembre 2018) ** : The investigator need to ensure that tumor tissues are available and sent after the patient randomization ***: CBC , platelets, liver panel ( bilirubin (total and conjugated), ALT, AST, ALP , GGT , LDH), serum creatinine, creatinine clearance (MDRD - Appendix 5), TSH, blood protein, albumin, prealbumin, CRP, coagulation (PT , PTT ), serum electrolyte s (sodium, potassium, calcium, magnesium) , lipase , glucose, urea, urinalysis (urine strip – check of the protein level, if more than 2 crosses then check the proteinurea on 24h) . ****: Within 3 weeks prior to randomization *****: CBC, platelets, urea, liver panel (bilirubin (total and conjugated), ALT, AST, ALP, GGT), bilirubin (t otal and conjugated), serum electrolytes (sodium, potassium, calcium, magnesium), serum creatinine, creatinine clearance (MDRD - Appendix 5). ***** *: For women with childbearing potential a pregnancy test will be performed each month during the treatment d uration *******: Use same technique in each imaging examination as that of the initial evaluation. Send an anonymized copy of images in CD -ROM format to FFCD, 7 bd Jeanne d’Arc, BP 87900, 21079 DIJON cedex (centralized review for the secondary end point and the ancillary study ) **** ****: Blood sample at 4 weeks for ancillary studies 1 Brain imaging is required only at baseline by CT -scan (or brain MRI if injected CT -scan contraindicated) . Imaging of brain lesion (s) by CT -scan or MRI is required every 8 weeks during treatmentif present at baseline EXAMINATION AND FOLLOW -UP SCHEDULE BEFORE TREATMENT DURING TREATMENT and in case of treatment stop without radiological progression (e.g. toxicity or patient refusal) AFTER TREATMENT END (for radiological progression) During the 14 days preceding the start of treatment Before each course of treatment Every 8 weeks (at each evaluation) Every 2-3 months up to death Clinical and biological informed consent X Biopsies or tumor block, fixed in paraffin X** CLINICAL EXAMINATION Weight, height, body surface area, BP, pulse, temperature X X X ECOG Performance statut X X X Evaluation of toxicities NCI-CTC Version 4.0 (Appendix 8 ) X X (and 30 days after end of treatment) X (until 12 months after the end of treatment) QLQ -C30 and STO -22 questionnaires ( Appendix 3 ,4) p X X BIOLOGICAL ASSESSMENT Laboratory assessment X*** X**** * X*** Hepatitis B,C and HIV test X Pregnancy test X X***** * CAE and CA 19.9 markers X X DPD status * X**** PARACLINICAL REVIEWS Brain1 and t horaco -abdominal -pelvic CT scan or MRI X**** X**** *** X ECG X**** Determination of MSI/MSS status or tumoral block available X BIOLOGICAL STUDY Blood samples (2 tubes/sample) p X X****** ** Stools p X (5 days before first course) X (only at W8 – 5 days before the evaluation) FUTURE LINES Start and end dates of treatment and the type of treatment of the subsequent lines will be completed in the CRF X"
13,page_13,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 14 de 123 1. . STUDY OBJECTIVE 1.1. Safety run -in phases objectives Validate the good tolerability of treatments combination in 2 steps: - 1st step: treated 5 patients with FOLFIRI (irinotecan at 180 mg/m²) + durvalumab - 2nd step: randomized 6 patients between FOLFIRI (irinotecan at 180 mg/m²) + durvalumab versus FOLFIRI (irinotecan at 150 mg/m² ) + durvalumab + tremelimumab (3 patients per arm) Patients will be treated in 5 expert centers with a huge experience in the use of immune checkpoints inhibitors. Inclusions will be stopped at each step for safety analyses. 1.2. Primary objective of phase II only Percentage of patients alive and without progression at 4 months of FOLFIRI plus durvalumab versus FOLFIRI plus durvalumab plu s tremelimumab in patients with advanced -stage gastric or gastro -oesophageal junction adenocarcinoma and who progressed after a first line chemotherapy (based on RECIST 1.1 rating scale evaluated by the investigator ). 1.3. Secondary objectives for phase II stud y - Percentage of patients alive and without progression at 4 months according to centralized review - Overall survival (OS) - Time to strategy failure - Safety profile - Quality of life (QoL) - Time to progression (TTP), the progression -free survival (median PFS), the best objective response rate (BRR) and disease control rate (DCR) according to the investigator and centralized review (according RECIST V1.1 and iRECIST criteria) - Efficacy endpoint s (OS, PFS, TTP, BRR and DCR) according to the expression PD -L1 and others biomarkers (see biological study) Phase II only: Ancillary biological studies (optional) Blood and tumor samples will be collected in all patients in order to allow translational research projects (Centre de Ressource Biologique EPIGENETEC, UMR -S 1147, Paris, France, Heade d by Prof. Pierre Laurent -Puig) : - Biomarkers analysis (for more detail s see “ancillary studies” – Appendix 2): microsatellite instability, immune response/immune score, circulating tumor DNA, tumor mutation load, gastric molecular sub -groups, expression and/or amplification of PD -L1 and PD -L2). - Stool samples will be colle cted prospectively in all patients in order to allow analysis of microbiota (16S rRNA to identification of bacteria composing the intestinal microbiota of patients). 2. PATI ENT SELECTION ON REG ISTRATION /RANDOMIZATION Inclusion and non -inclusion criteria are the same for the safety run -in phases and the randomized phase II trial. 2.1. Inclusion criteria - Age ≥ 18 years. - Body weight > 30kg. - Histologically proven advanced -stage unresectable adenocarcinoma of the stomach or the GEJ (Siewert II or III)."
14,page_14,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 15 de 123 - Known MSS/MSI status or tumor tissue available (frozen or paraffin -embedded, primary tumors or metastases) in order to allow determination of MSS/MSI status. The investigator needs to ensure that tumor tissues will be sent after patient randomization. - Failure to platinium -based 1st line therapy with or without trastuzumab or early recurrent disease after surgery with neo -adjuvant and/or adjuvant platinium -based chemotherapy (within 6 months of the end of chemotherapy) or progression during neo -adjuvant and /or adjuvant platinium -based chemotherapy. - Eligible for a second -line treatment with irinotecan and 5 -FU. - Measurable or non -measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). - Eastern Cooperative Oncology Group (ECOG) performance status 0 -1. - Adequate organ function: ANC ≥ 1.5 x 109/L, haemoglobin ≥ 9 g/dL, platelets ≥ 100 x 109/L, AST/ALT ≤ 3 x ULN (≤ 5 x ULN in case of liver metastase(s)), GGT ≤ 3 x ULN (≤ 5 x ULN in case of liver metastase(s)), bilirubin ≤ 1.5 x ULN, creatinin clearance > 40 mL/min (MDRD). Evidence of post -menopausal status or negative urinary or serum pregnancy test for female pre - menopausal patients. - Man and woman who childbearing potential agrees to use two methods (one for the patient and o ne for the partner) of medically acceptable forms of contraception during the study and for 6 months after the last treatment intake. - Patient is able to understand, sign, and date the written informed consent form at the screening visit prior to any protoc ol-specific procedures performed. 2.2. Non-inclusion criteria - Concurrent enrolment in another clinical study – unless it is an observational study or during the follow - up period of an interventional study. - Receipt of the last dose of anticancer therapy ≤ 2 weeks prior to the first dose of study drug. - Radiotherapy within 4 weeks prior to the first dose of treatment. - History of chronic inflammatory bowel disease (IBD) . - Current or prior bowel obstruction within 28 days before the first dose of study drugs . - Any unresolved significant toxicity NCI CTCAE v4.0 ≥ grade 2 from previous anticancer therapy (excepted neuropathy and alopecia) . - Concurrent use of hormonal therapy for non –cancer -related conditions is acceptable - Major surgical procedure (e.g. exploratory l aparoscopy is not considered as a major surgical procedure) within 28 days prior to the first dose of treatment. - Prior allogeneic bone marrow transplantation or prior solid organ transplantation. - Active or prior documented autoimmune or inflammatory disord ers (patients with alopecia, vitiligo, controlled hypo or hyperthyroidism, any chronic skin condition not requiring immunosuppressant therapy are eligible). Patients without active disease in the last 5 years may be included. - Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associ ated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent. - Severe cardiac disorder s within 6 months. - Severe liver dysfunction - History of idiopathic pulmonary fibrosis, drug -induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT -scan. - History of leptomeningeal carcinomatosis or symptomatic or untreated brain metastase(s). Patients whose brain metastase(s) have been treated may participate if any neurologic symptoms that developed either as a result of the brain metastases or their treatment are resolved or be stable either, without the use of s teroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent for at least 14 days prior to the start of treatment. - - Positive test for HIV, active hepatitis B or hepatitis C, active tuberculosis. - History of active primary immunodefi ciency - Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs (excepted: intranasal, inhaled, topical steroids or local steroid injection –at physiologic dose does not exceed 10 mg/day of prednisone or its equivalent – steroids as premedication for hypersensitivity reactions)."
15,page_15,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 16 de 123 - Receipt of live attenuated vaccine within 30 days prior to the first dose of treatment - Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. In order to check all the contraindications of each drugs, please refer to the updated versions of the SmPCs presented in Appendix 9. - Current or prior use of St. John's Wort within 14 days before the first dose of study drugs (St. John's Wort is not allowe d during participation in the trial). - Treatment with sorivudine or analogs (brivudine). - Treatment with phenytoin or analogs. - Prior treatment with irinotecan, anti -PD1, anti PD -L1, anti -CLTA4 or other immunotherapy for cancer treatment regardless of treatme nt arm assignment. - Known Uridine Diphosphate Glucuronyltransferase (UGT1A1) enzyme deficiency - Partial or complete DPD deficiency (Uracilemia ≥ 16 ng/ml) - Active infection requiring intravenous antibiotics at the time of Day 1 of Cycle 1. - Other malignancy within 5 years prior to study enrolment, except for localized cancer in situ , basal or squamous cell skin cancer. - Pregnant or breastfeeding female patient. 3. INCLUSION ASSESSMENT The inclusion assessment must be conducted during the 14 days before registration /randomization. This does not apply to morphological examinations and ECG , which may be conducted during the 3 weeks before registration/ randomization . Quality -of-life questionnaires – PHASE II ONLY - QLQ -C30 version 3.0 – QLQ -STO22 questionnaires: to be complet ed by the patient before randomization (same day or within 1 4 days before randomization but in any case at least before the first course of treatment) Clinical exa mination: - Measurement of weight, height and body surface area - ECOG performance status (Appendix 5) - Vital signs: BP, puls e, temperature Laboratory assessment at lea st 14 days before registration/ randomization, comprising: - CBC , platelets, TP - Liver panel comprising GGT , ALP, AST, ALT, total and conjugated bilirubin, and LDH - Creatinine and creatinine clearance (MDRD ) - (Appendix 5 ) - TSH (T3,T4) , blood protein, albumin, prealbumin and CRP - Coagulation (PT, PTT) - Lipase , glucose - Serum electrolytes (sodium, potassium, calcium, magnesium) , urea - Hepatitis B, C and HIV test - CEA , CA19 -9 markers - Pregnancy test if women of childbearing age - Urine Strip (proteinurea) - DPD deficiency assessment following INCa and HAS recommendations (Avis n°20 18.0053/AC/SEAP du 28 novembre 2018) Morphological examinations and ECG within 3 weeks prior to registration/ randomization : - Brain and thoracic -abdominal -pelvic CT-scan ( TAP CT-scan or abdominal MRI + brain MRI + thoracic CT-scan without injection if injected CT-scan contraindicated) - ECG"
16,page_16,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 17 de 123 For Phase II only : Send an anonymous copy of CD ROM to the FFCD, 7 bd Jeanne d’Arc, BP 87900, 21079 DIJON CEDEX (centralized review for secondary criteri a) The investigator needs to ensure that tumor blocks (or tissues) are available and sent after the patient randomization (see Chapter 9 for logistics). Sending the pre -filled letter to your anatomopathologist and t he anatomopatologist fax to t he FFCD the sample sheet at the +33 (0)3 80 38 18 41 . FFCD sends a max letter for sending tumor blocks to Centre de Ressources Biologiques EPIGENETEC (Unité UMR -S 1147 , 45, rue des Saints -Pères - 75006 PARIS, France) For the biological ancillary study - Cell- free DNA tubes of blood are taken : o before the firs t treatment course o at 4 weeks (D28) o at progression - Stool sample o 1 sample – in the 5 days prior the 1st course of treatment (W0) o 1 sample – in the 5 days prior the 3rd course of treatment (W8) The rational and logistics of this study are des cribed in Appendix 2 and Chapter 9 . 4. REGISTRATION /RANDOMIZ ATION For the fir st step of the safety run -in a registration of patient will be performed . The randomization procedure will be performed only for the 2nd step of the safety run -in phase and for the Phase II study. For both registration and randomization, the process remain s the same and is described herein after. After the consent form signature and the validati on of the initial baseline assessment s results , eligible patients will be registered /randomized at the FFCD data center, CRGA ( Centre de Ra ndomisation – Gestion – Analyse) . The investigator will fax the completed and signed registration /randomization form to the FFCD data center: Monday to Friday from 9 am to 6 pm Fax: + 33 (0)3 80 38 18 41 /Tel: + 33 (0)3 80 66 80 13 A registration /randomization confirmation will be sent back to the investigator and to the pharmacist with the patient registration number and the arm allocated by the randomization. After registration /randomization, trea tment should begin as soon as possible and within a maximum period of 10 days. A case report form will be sent automatically after each registration /randomization and at the center’s opening. Stratification The randomization will be done using minimizatio n technique according to the ratio 1:1 and the following factors will be considered for the stratification: - Center - Duration of disease control to previous first -line chemotherapy (no disease control vs < 3 months vs ≥ 3 months) Immunotherapy patient card The investigator can give an “immunotherapy patient card ” once the patient registration /randomization performed. This card will inform that the patient is being treated by immunotherapy and will follow the patient throughout the clinical study . This is useful especially if the patient must be treated urgently in another center ."
17,page_17,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 18 de 123 5. STUDY DESIGN 5.1. Safety run -in 1st step: 5 patients will be included first acco rding to the following treatment regimen : 2nd step: 6 patients ( 3 patients per arm ) will be randomized according to the following treatment regimen : Tremelimumab is administered for 4 cycles (4 months) and then patient will continue to receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control, tremelimumab can be re - introduce d at investigator discretion for 4 courses . Only one re -introduction is authorized. Patient must have 2 weeks of washout period of first -line treatment before treatment in the trial (4 weeks if investigational prod uct in first -line setting, previous immunotherapy is not allowed) . Treatment will be repeated every 4 weeks until disease progression, unacceptable toxicity or patient’s refusal. 5.2. Phase II study"
18,page_18,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 19 de 123 In arm B: Tremelimumab is administered for 4 cycles (4 months) and then patient will continue to receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control, tremelimumab can be re -introduce d at investigator discretion for 4 courses . Only one re -introduction is authorized. Patient must have 2 weeks of washout period of first -line treatment before treatment in the trial (4 weeks if investigational product in first -line setting, previous immunotherapy is not allowed) . Treatment will be repeated every 4 weeks u ntil disease progression, unacceptable toxicity or patient’s refusal. 6. TREATMENTS Both durvalumab and tremelimumab will be provided by FFCD whereas 5 -FU, folinic acid and irinotecan will be sampled on commercial stock. 6.1. Description, packaging and labeling of durvalumab Durvalumab will be supplied by FFCD as a 500 -mg vial solution for infusion after dilution. The solutio n contains 50 mg/mL durvalumab , 26 mM histidine/histidine hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0. The nominal fill volume is 10.0 mL. Investigational product vials are stored at 2°C to 8°C and must not be frozen. D rug product should be kept in secondary packaging until use to prevent excessive light exposure. The dose of durvalumab for administration must be prepared by the Investigator’s or site’s designated investigational product manager using aseptic technique. Total time from needle punctur e of the durvalumab vial to the start of administration should not exceed: • 24 hours at 2°C to 8°C • 4 hours at room temperature Infusion solution must be allowed to equilibrate to room temperature prior to commencement of administration. A dose of 1500 mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v)"
19,page_19,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 20 de 123 saline or 5% (w/v) dextrose, with a f inal durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2 - or 0.22 -μm in -line filter. Add 30.0 mL of durvalumab ( i.e. 1500 mg of durvalumab ) to the IV bag. The IV bag size should be selected such th at the final concentration is within 1 to 15 mg/mL. Mix the bag by gently inverting to ensure homogeneity of the dose in the bag. If weight falls to ≤ 30 kg weight -based dosing at 20 mg/kg will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2 - or 0.22 -μm in -line filter. Standard infusion time is 1 hour. In the event that there are interruptions d uring infusion, the total allowed infusion time should not exceed 8 hours at room temperature. Do not co -administer other drugs through the same infusion line. The IV line will be flushed with a volume of IV diluent equal to the priming volume of the inf usion set used after the contents of the IV bag are fully administered, or complete the infusion according to institutional policy to ensure the full dose is administered and document if the line was not flushed. If either preparation time or infusion time exceeds the time limits a new dose must be prepared from new vials. Durvalumab does not contain preservatives, and any unused portion must be discarded. 6.2. Description, packaging and labeling of tremelimumab Tremelimumab will be supplied by FFCD as a 400 -mg or a 25 -mg vial solution for infusion after dilution. The solution contains 20 mg/mL tremelimumab, 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.27 mM disodium edetate dihydrate, and 0.02% weight/volume (w/v) polysorb ate 80; it has a pH of 5.5 and a density of 1.034 g/mL . The n ominal fill volume is 20.0 mL for the 400 -mg vial and 1.25 mL for the 25 -mg vial . Investigational product vials are stored at 2°C to 8°C and must not be frozen. Drug product should be kept in original container until use to prevent prolonged light exposure. The dose of tremelimumab for administration must be prepared by the Investigator’s or sit e’s designated investigational product manager using aseptic technique. Total time from needle puncture of the tremelimumab vial to the start of administration should not exceed: • 24 hours at 2°C to 8°C • 4 hours at room temperature Infusion solution must be allowed to equilibrate to room temperature prior to commencement of administration. A dose of 75 mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final tremelimumab concentration ranging from 0.10 to 10 mg/mL, and delivered through an IV ad ministration set with a 0.2 - or 0.22 -μm in -line filter. Add 3.8 mL (ie,75 mg of tremelimumab, with the dose volume rounded to the nearest tenth mL) to the IV bag. The IV bag size should be selected such that the final concentration is within 0.10 to 10 mg/ mL. Mix the bag by gently inverting to ensure homogeneity of the dose in the bag. If weight falls to ≤ 30 kg, weight -based dosing at 1 mg/kg will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final tremelimumab concentration ranging from 0.10 to 10 mg/mL, and delivered through an IV administration set with a 0.2 - or 0.22 -μm in -line filter. Standard infusion time is 1 hour. In the event that there are interruptions during infusion, the total allowed infusion time should not exceed 8 hours at room temperature. Do not co -administer other drugs through the sa me infusion line. The IV line will be flushed with a volume of IV diluent equal to the priming volume of the infusion set used after the contents of the IV bag are fully administered, or complete the infusion according to institutional policy to ensure the full dose is administered and document if the line was not flushed. If either preparation time or infusion time exceeds the time limits a new dose must be prepared from new vials. Tremelimumab does not contain preservatives, and any unused portion must be discarded."
20,page_20,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 21 de 123 6.3. FOLFIRI + durvalumab (1st and 2nd steps of the safety run -in phase and Arm A ) No prophylac tic treatment is necessary for d urvalumab. Prophylactic treatment for FOLFIRI is administered according the standard centre clinical practice. Primary prophylaxis with G -CSF is not necessary but is allowed, notably if febrile neutropenia occurred during first-line therapy. Secondary prophylaxis wi th G-CSF is left up to the investigator’s judgment and according to hematological toxicity of chemotherapy and the patient’s clinical characteristics. Recommendation on dose capping: Centers will perform dose capping according to their habits. It might be recommended to do not cap the dose at 2m² if the patient presents an important muscle mass. However, if the patient presents an important fat mass, a 2m² capping might be considered. - Durvalumab : 1500 mg by 1 -hour IV infusion – 1 course every 4 weeks (= 1 cycle ) - FOLFIRI – one course every 2 weeks : - Irinotecan: 180 mg/m² by 2 -hours IV infusion - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus - Continuous 5 -FU: 2400 mg/m² by 46-hours IV infusion A minimum o f 30 minutes should be observed between durvalumab and FOLFIRI administration. 6.4. FOLFIRI + durvalumab + tremelimumab (2nd step of the safety run -in phase and Arm B) No prophylac tic treatment is necessary for durvalumab and t remelimumab. Prophylactic treatment for FOLFIRI is administered according the standard center clinical practice. Primary prophylaxis with G -CSF is not necessary but is allowed, notably if febrile neutropenia occurred during first-line therapy. Secondary prophylaxis with G -CSF is left up to the investigator’s judgement and according to haematological toxicity of chemotherapy and the patient’s clinical characteristics. Recommendation on irinotecan, folinic acid, 5-FU bolus and continuous 5 -FU dose capping. Centers will perform dose capping according to their habits. It might be recommended to do not cap the dose at a body surface area of 2 m² if the patient presents an important muscle mass. However, if the patient presents an important fat mass, a 2 m² capping might be considered. 6.4.1. For the 2nd step of the safety run -in phase - Tremelimumab : 75 mg by 1 -hour IV infusion – 1 cycle ( i.e. every 4 weeks) for only 4 cycles"
21,page_21,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 22 de 123 - Durvalumab : 1500 mg by 1 -hour IV infusion – 1 cycle ( i.e. every 4 weeks) - FOLFIRI – one course every 2 weeks : - Irinotecan: 150 mg/m² by 2-hours IV infusion - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus - Continuous 5 -FU: 2400 mg/m² by 46 -hours IV infusion A minimum of 30 minutes should be observed between durvalumab administration and FOLFIRI. Tremelimumab will be administered first; the durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab inf usion. Standard infusion time for each is 1 hour. In the event that there are interruptions during infusion, the total allowed time should not exceed 8 hours at room temperature per infusion. If there are no clinically significant concerns after the firs t cycle, then, at the discretion of the i nvestigator, all other cycles of durvalumab can be given immediately after the tremelimumab infusion has finished . 6.4.2. For the phase II study - Tremelimumab : 75 mg by 1 -hour IV infusion – 1 cycle ( i.e. every 4 weeks) for only 4 cycles - Durvalumab : 1500 mg by 1 -hour IV infusion – 1 cycle ( i.e. every 4 weeks) - FOLFIRI – one course every 2 weeks : - Irinotecan: 180 mg/m² by 2 -hour IV infusion - Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2 -hours IV infusion - 5-FU bolus: 400 mg/m² by 10 -minutes IV bolus - Continuous 5 -FU: 2400 mg/m² by 46 -hours IV infusion A minimum of 30 minutes should be observed between durvalumab administration and FOLFIRI."
22,page_22,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 23 de 123 Tremelimumab will be administered first; the durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion. Standard infusion time for each is 1 hour. In the event that there are interruptions during infusion, the total allowed time should not exce ed 8 hours at room temperature per infusion. If there are no clinically significant concerns after the first cycle, then, at the discretion of the i nvestigator, all other cycles of durvalumab can be given immediately after the tremelimumab infusion has fin ished . 7. DOSE ADJUSTMENT BASE D ON TOXICITY The toxicities requiring dose adjustments will all be evaluated according to the scale NCI -CTCAE v4.0 (Appendix 8). Dose adjustments based on toxicity are the same for the 1st and 2nd step of the safety run -in phase s and randomized phase II study. 7.1. Criteria that must be met before each subsequent cycle (D1 of each cycle) G-CSF primary prophylaxis in both arms will be at the investigator discretion according to the previous hematological toxicities and the clinical characteristics of the patient. Definition of febril e neutropenia : fever > 38.5 °C in medu llary hypoplasia period (ANC < 500/mm3) Criteria that must to be met before each subsequent c ourse of treatment for chemotherapy : - ANC ≥ 1500 /mm3 - Platelet count ≥ 100 000/mm3 - Digestive toxicities ≤ grade 1 As long as these criteria have not been met, symptomatic treatm ent should be optimised and a C BC will be conducted every 7 days until obtaining the required levels . The treatment is delayed until recovering . Concerning administration of durvalumab ± tremelimumab, patients should not experienced severe immune - related adverse event (see paragraph 7.4). Criteri a for stopping treatment : Treatment may be discontinued if the investigator considers that it is necessary, in case of major toxicity which no longer makes it possible to continue treatment, in case of a serious or unexpected event requiring discontinuation of treatment, disease progression, withdrawal of consent, refusal of patient or in case of pregnancy. If treatment is delayed more than 4 courses (56 days), the study treatment will be discontinued, but patient will continue to be followed in the setting of the protocol. 7.2. Dose adjustment based on toxicities observed during the rest period Dosage adjustments are needed depending on the maximum grade of toxicity observed between courses of treatment . The treatments will only beg in when the criteria required before implementation of any new treatment is obtained (see paragraph 7.1). The occurrence of grade 4 toxicity (excluding hematologic toxicities or other manageable toxicity) shall require the permanent discontinuation of the study treatments unless the investigator considers that there is an interest for the patient to continue with the rest of t he treatment when the alleged responsibility of the toxicity observed is not deducted. The recourse treatments will be at the discretion of the investigator. In all cases, the patient will continue to be monitored as part of the protocol according to the p rotocol schedule . If one drug is stopped due to toxicity, other drugs will continue to be administered."
23,page_23,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 24 de 123 Regimen allowed 5-FU/LV Irinotecan Durvalumab Tremelimumab X X X X X X X X X X X X Regimen not allowed 5-FU/LV Irinotecan Durvalumab Tremelimumab X X X X X X X X X X X X X X X X X X 7.3. Dose adjustment based on infusion -related reaction In the event of a ≤ grade 2 infusion -related reaction, the infusion rate of study drug may be decreased by 50% or interrupted until resolution of the event and re -initiated at 50% of the initial rate until completion of the infusion. For patients with a ≤ grade 2 infusion -related reaction, subsequent infusions may be administered at 50% of the initial rate. Acetaminop hen and/or an antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator. If the infusion -related reaction is ≥ grade 3 or higher in severity, study drug will be disc ontinued. For management of patients who experience an infusion reaction, please refer to the toxicity and management guidelines in Appendix 8 . As with any antibody, allergic reactions to dose administration are possible. Appropriate drugs and medical equipment to treat acute anaphylactic reactions must be immediately available, and study personnel must be trained to recognize and treat anaphylaxis. The study site must have immediate access to emergency resuscitation teams and equipment in addition to the a bility to admit patients to an intensive care unit if necessary . 7.4. Dose adjustment of FOLFIRI Please refer to the references to the updated SmPCs for the products used for issues of patient management, particularly with respect to contraindications, warnin gs and precautions for use, dose adjustment in the event of toxicity, monitoring of patients, duration of contraception and medicinal products that are forbidden or to be used with precautions. The links to updated versions of the SmPCs are provided in App endix 9 of this protocol. Dose adjustment of FOLFIRI according to the higher hematological toxicity occurring the day of the course. In case of grade 4 or febrile neutropenia, the course must be reported until grade ≤1. Grade toxicity (NCI -CTCAE v4 ) 5-FU Irinote can"
24,page_24,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 25 de 123 Neutropenia, thrombo cytopenia Grade 2a Grade 3a Grade 4b Febril e neutropeniab - Bolus reduction of 50% - Bolus suppression, reduction of 25% of continuous 5 -FU - Bolus suppression, reduction of 25% of continuous 5 -FU - Bolus suppression, reduction of 25% of continuous 5 -FU - No modification - No modification - Reduction of 25% - Reduction of 25% a Discuss about G-CSF prescription if persistence of neutropenia < 1500/mm3 after 1-week postponement b Discuss about G-CSF prescription if Grade 4 neutropenia or febril e neutropenia Dose adjustment of FOLFIRI according to maximal toxicity in the intercourse Grade toxicity (NCI -CTCAE v4 ) 5-FU Irinote can Neutropenia, thrombo cytopenia Grade 2 Grade 3 Grade 4b Febril e neutropeniab - No modification - No modification - Bolus suppression - Bolus suppression, reduction of 25% of continuous 5 -FU - No modification - No modification - No modification - Reduction of 25% a Discuss about G-CSF prescription if Grade 4 neutropenia or febril e neutropenia Other toxicities according to maximal toxicity in the intercourse Grade toxicity (NCI -CTCAE v4 ) 5-FU Irinote can Diarrhea despite maximum symptomatic treatment Grade 2 Grade 3 Grade 4 - Bolus reduction of 50% - Bolus suppression, reduction of 50% of continuous 5 -FU - Discuss discontinuation of chemotherapy or only irinotecan if recurrence despite dose reduction - Reduction of 25% - Reduction of 25% - Discuss discontinuation of chemotherapy if recurrence despite dose reduction Mucositis Grade 2 Grade 3 Grade 4 - Bolus reduction of 50% -Bolus suppression, reduction of 25% of continuous 5 -FU - Discuss discontinuation of chemotherapy or only irinotecan if recurrence despite dose reduction - No modification - No modification - Discuss discontinuation of chemotherapy if recurrence despite dose reduction Vomiting Grade 3 Grade 4 - Reduction of 25% of continuous 5 -FU - Discuss discontinuation of chemotherapy or only irinotecan if recurrence despite dose reduction - Reduction of 25% - Discuss discontinuation of chemotherapy if recurrence despite dose reduction"
25,page_25,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 26 de 123 Hand -foot syndrom Grade 2 Grade 3 - Reduction of 25% of continuous 5 -FU - Bolus reduction of 50%, reduction of 50% of continuous 5-FU - No modification - No modification Non hematological toxicities Grade 3 Grade 4 - Bolus re duction of 25% and 25% of continuous 5-FU - Discuss discontinuation of chemotherapy or only irinotecan if recurrence despite dose reduction - Reduction de 25% - Discuss discontinuation of chemotherapy if recurrence despite dose reduction 7.5. Management of Immune -mediated adverse event (imAE) Guidelines for the management of immune -mediated reactions, infusion -related reactions, and non -immune - mediated reactions for durvalumab are provided in the durvalumab/tremelimumab Toxicity Management Guidelines (TMGs). Patients should be thoroughly evaluated and appropriate efforts should be made to rule out neoplasic, infectious, metabolic, toxin or other etiologic causes of the i mAE. Serologic, immunologic and histologic (biopsy) data, as appropriate, should be used to support an i mAE diagnosis. In the absence of a clear alternative etiology, events should be considered potentially immune related . All toxicities will be graded according to NCI CTCAE, Version 4. The investigators must make every effort to differentiate c hemotherapy -related side effects from those due to immunotherapy. Diarrhea/digestive toxicities could be related to 5-FU, irinotecan, durvalumab and/or tremelimumab. Then urgent GI consult and imaging and/or colonoscopy is required, as appropriate, since treatment will be different according to the drug involved in gastrointestinal toxicity. The characteristics of side effects can differentiate those due to immunotherapy from those due to chemotherapy. Diarrhea/digestive toxicities due to chemotherapy (5-FU and/or irinotecan) usually appear a few days after chemotherapy , with quick improvement with anti -diarrhea treatment. By contrast, diarrhea/digestive toxicities due to immunotherapy usually appear weeks after immunotherapy initiation , with low efficacy o f anti -diarrhea treatment. In most cases a colonoscopy with biopsies is needed to differentiate both and used appropriate treatment (immunotherapy stop and at least prednisone 1 to 2 mg/kg/day PO or IV equivalent). Most others toxicities are specific of im munotherapy and never related to chemotherapy (pulmonary, endocrine, hepatic imAEs…). Main toxicities are listed hereinafter. Please refers also to the Toxicity Management guidelines provided appendix 8 of the protocol, if patients have other imAEs. Each updated version of the Toxicity Management Guidelines will be also provided by the sponsor. Gastrointestinal i mAEs Severity of Diarrhea/Colitis (NCI -CTCAE v4) Management Follow -up Grade 1 Diarrhea: < 4 over baseline per day Colitis: a symptomatic No dose modifications. Consider symptomatic (e.g. loperamide ). Monitor closely for worsening symptoms."
26,page_26,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 27 de 123 Grade 2 Diarrhea: 4 to 6 over baseline per day Colitis: a bdominal pain; mucus or blood in stool Hold Durvalumab or Durvalumab/Tremelimumab regimen until resolution to Grade ≤1  If toxicity worsens, then treat as Grade 3 or Grade 4. If toxicity improves to Grade ≤1, then Durvalumab or Durvalumab/Tremelimumab regimen can be resumed after completion of steroid taper. Consider symptomatic treatment, including hydration, electrolyte replacement, dietary changes (e.g., American Dietetic Association colitis diet), and loperamide and/or budesonide. Promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. If event is not responsive within 3 to 5 days or worsens despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, GI consult should be obtained for consideration of further workup, such as imaging and/or colonoscopy, to confirm colitis and rule out perforation, and prompt treatment wit h IV methylprednisolone 2 to 4 mg/kg/day started. If still no improvement within 3 to 5 days despite 2 to 4 mg/kg IV methylprednisolone, promptly start immunosuppressives such as infliximab at 5 mg/kg once every 2 weeksa. Caution: it is important to rule o ut bowel perforation and refer to infliximab label for general guidance before using infliximab. Consider, as necessary, discussing with study physician if no resolution to Grade ≤1 in 3 to 4 days. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals and anti -pneumocystis jiroveci Pneumonia treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a Grade 3 to 4 Diarrhea (Grade 3 ): ≥7 over baseline per day Colitis (Grade 3 ): severe abdominal pai n, change in bowel habits, medical intervention indicated, peritoneal signs Grade 4 diarrhea : life threatening consequences Grade 3 Permanently discontinue study drug/study regimen for Grade 3 if toxicity does not improve to Grade ≤1 within 14 days; study drug/study regimen can be resumed after completion of steroid taper. Grade 4 Permanently discontinue study drug/study regimen. Promptly initiate empiric IV methylprednisolone 2 to 4 mg/kg/day or equivalent. Monitor stool frequency and volume and maintain hydration. Urgent GI consult and imaging and/or colonoscopy as appropriate. If still no improvement within 3 to 5 days of IV methylprednisolone 2 to 4 mg/kg/day or equivalent, promptl y start further immunosuppressives (e.g., infliximab at 5 mg/kg once every 2 weeks). Caution : Ensure GI consult to rule out bowel perforation and refer to infliximab label for general guidance before using infliximab. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a aASCO Educational Book 2015 “Man aging Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. Dermatologic i mAEs Grade of Rash (NCI -CTCAE v4) Management Follow -up Any Grade (refer to NCI CTCAE v 4 for definition of severity/grade depending on type of skin rash) General Guidance For Any Grade : − Monitor for signs and symptoms of dermatitis (rash and pruritus). IF THERE IS ANY BULLOUS FORMATION, THE STUDY PHYSICIAN SHOULD BE CONTACTED AND STUDY DRUG DISCONTINUED. Grade 1 Covering ≤ 10% body surface area No dose modificati ons. For Grade 1: Consider symptomatic treatment, including oral antipruritics (e.g., diphenhydramine or hydroxyzine) and topical therapy (e.g., urea cream)."
27,page_27,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 28 de 123 Grade 2 Covering 10 -30 % body surface area For persistent (>1 to 2 weeks) Grade 2 events, hold scheduled study drug/study regimen until resolution to Grade ≤1 or baseline.  If toxicity worsens, then treat as Grade 3. If toxicity improves to Grade ≤1 or baseline, then resume drug/study regimen after completion of steroid taper. For Grade 2: − Obtain dermatology consult. − Consider symptomatic treatment, including oral antipruritics (e.g., diphenhydramine or hydroxyzine) and topical therapy (e.g., urea cream). − Consider moderate -strength topical steroid. − If no improvement of rash/skin lesions occurs withi n 3 to 5 days or is worsening despite symptomatic treatment and/or use of moderate strength topical steroid, consider, as necessary, discussing with study physician and promptly start systemic steroids such as prednisone 1 to 2 mg/kg/day PO or IV equivalen t. Consider skin biopsy if the event is persiste nt for >1 to 2 weeks or recurs. Grade 3 or 4 Covering > 30% body surface area; life threatening consequences For Grade 3: Hold study drug/study regimen until resolution to Grade ≤1 or baseline. If temporaril y holding the study drug/study regimen does not provide improvement of the Grade 3 skin rash to Grade ≤1 or baseline within 30 days, then permanently discontinue study drug/study regimen. For Grade 4: Permanently discontinue study drug/study regimen. For Grade 3 or 4: − Dermatology advise . − Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day or equivalent. − Consider hospitalization. − Monitor extent of rash [Rule of Nines]. − Consider skin biopsy (preferably more than 1) as clinically feasible. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti - PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a Consid er, as necessary, discussing with study physician. aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. Pulmonary imAE s Grade of Pneumonitis (NCI -CTCAE v4) Management Follow -up Grade 1 Radiographic changes only No dose modifications required. However, consider holding study drug/study regimen dose as clinically appropriate and during diagnostic work -up for other etiologies. Monitor and closely follow up in 2 to 4 days for clinical sympt oms, pulse oximetry (resting and exertion), and laboratory work -up and then as clinically indicated. Consider Pulmonary and Infectious disease consult. Grade 2 Mild to moderate new symptoms Hold study drug/study regimen dose until Grade 2 resolution to Grade ≤1.  If toxicity worsens, then treat as Grade 3 or Grade 4. If toxicity improves to Grade ≤1, then the decision to reinitiate study drug/study regimen will be based upon treating physician’s clinical judgment and after completion of steroid taper. Mon itor symptoms dail y and consider hospitalization. Promptly start systemic steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV equivale nt). Reimage as clinically indicated. If no improvement within 3 to 5 days, additional workup should be considered and prompt treatment with IV methylpredni solone 2 to 4 mg/kg/day started If still no improvement within 3 to 5 days despite IV methylprednisolone at 2 to 4 mg/kg/day, promptly start immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general gu idance before using infliximab. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungal s, or anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related"
28,page_28,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 29 de 123 infections [ Category 2B recommendation])a Consider pulmonary and infectious disease consult. Consider, as necessary, discussing with study physician. Grade 3 to 4 Severe new symptoms; New/worsening hypoxia; life-threatening Permanently discontinue study drug/study regimen. Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day or equivalent. Obtain Pulmonary and Infectious disease consult; consider, as ne cessary, discussing with study physician. Hospitalize the patient. Supportive care (e.g., oxygen). If no improvement within 3 to 5 days, additional workup should be considered and prompt treatment with additional immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks’ dose) started. Caution: rule out sepsis and refer to infliximab label for general guidance before using infliximab. Once the patient is improving, gradually taper steroids over ≥28 days and consider pr ophylactic antibiotics, antifungals, and, in particular, anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antib ody Side Effects” by Michael Postow MD. Renal imAE s Grade of Liver Test Elevation (NCI -CTCAE v4) Management Follow -up Grade 1 Creatinine increased > ULN to 1.5 x ULN No dose modifications. Monitor serum creatinine weekly and any accompanying symptoms.  If creatinine returns to baseline, resume its regular monitoring per study protocol.  If creatinine worsens, depending on the severity, treat as Grade 2, 3, or 4. Consider symptomatic treatment, including hydration, electrolyte replacement, and diuretics. Grade 2 Creatinine increased > 1.5 and ≤ 3 x ULN Hold study drug/study regimen until resolution to Grade ≤1 or baseline.  If toxicity worsens, then treat as Grade 3 or 4. If toxicity improves to Grade ≤1 or baseline, then resume study drug/study regimen after completion of steroid taper. Consider symptomatic treatment, including hydration, electrolyte replacement, and diuretics. Carefully monitor serum creatinine every 2 to 3 days and as clinically warranted. Consult nephrologist and consider renal biopsy if clinically indicated. If event is persistent (>3 to 5 days) or worsens, promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. If event is not responsive within 3 to 5 days or worsens despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional workup should be considered and prompt treatment with IV methylprednisolone at 2 to 4 mg/kg/day started. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP trea tment (refer to current NCCN guidelines for treatment of cancer -related infections [ Category 2B recommendation]).a When event returns to baseline, resume study drug/study regimen and routine serum creatinine monitoring per study protocol. Grade 3 to 4 Creatinine increased > 6 x ULN Permanently discontinue study drug/study regimen. Carefully monitor serum creatinine on daily basis. Consult nephrologist and consider renal biopsy if clinically indicated. Promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. If event is not responsive within 3 to 5 days or worsens"
29,page_29,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 30 de 123 despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional workup should be considered and prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day started. Once the patie nt is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [ Category 2B recommendation])a aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. Hepatic imAE s Grade of Liver Test Elevation (NCI -CTCAE v4) Management Follow -up Grade 1 Grade 1 AST or ALT > ULN to 3.0 x ULN and/or total bilirubin > ULN to 1.5 x ULN No dose modifications. If it worsens, then treat as Grade 2 event. Continue l iver function tests monitoring per protocol. Grade 2 AST or ALT > 3.0 to ≤ 5 x ULN and/or total bilirubin > 1.5 to ≤ 3 x ULN Hold study drug/study regimen dose until Grade 2 resolution to Grade ≤1. If toxicity worsens, then treat as Grade 3 or Grade 4. If toxicity improves to Grade ≤1 or baseline, resume study drug/study regimen after completion of steroid taper. Regular and frequent checking of LFTs (e.g., twice a week ) until elevations of these are improving or resolved. If no resolution to Grade ≤1 in 1 to 2 days, consider, as necessary, discussing with study physician. If event is persistent (>3 to 5 days) or worsens, promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. If still no improvement within 3 to 5 days despite 1 to 2 mg/kg/day of prednisone PO or IV equivalent, consider additional work up and start prompt treatment with IV methylpredniso lone 2 to 4 mg/kg/day. If still no improvement within 3 to 5 days despite 2 to 4 mg/kg/day of IV methylprednisolone, promptly start immunosuppressives (i.e., mycophenolate mofetil).a Discuss with study physician if mycophenolate mofetil is not available. Infliximab should NOT be used. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [ Category 2B recommendation]).a Grade 3 to 4 AST or ALT > 5 x ULN and/or total bilirubin > 3 x ULN For elevations in transaminases ≤8 × ULN, or elevations in bilirubin ≤5 × ULN: Hold study drug/study regimen dose until resolution to Grade ≤1 or baseline Resume study drug/study regimen if elevations downgrade to Grade ≤1 or baseline within 14 days and after completion of steroid taper. Permanently discontinue study drug/study regimen if the elevations do not downgrade to Grade ≤1 or baseline within 14 days For elevations in transaminases >8 × ULN or elevations in biliru bin >5 × ULN, discontinue study drug/study regimen. Permanently discontinue study drug/study regimen for any case meeting Hy’s law criteria (AST and/or ALT >3 × ULN + bilirubin >2 × ULN witho ut initial findings of cholestasis Promptly initiate empiric IV methylprednisolone at 1 to 4 mg/kg/day or equivalent. If still no improvement within 3 to 5 days despite 1 to 4 mg/kg/day methylprednisolone IV or equivalent, promptly start treatment with immunosuppressive therapy (i.e., mycophenolate mofetil). Discuss with study physician if mycophenolate is not available. Infliximab should NOT be used. Perform hepatology consult, abdominal workup, and imaging as appropriate. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a"
30,page_30,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 31 de 123 (i.e., elevated ALP ) and in the absence of any alternative cause.b For Grade 4: Permanently discontinue study drug/study regimen. aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. bFDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury – Premarketing Clinical Evaluation. Cardiac imAE s Myocarditis Management Follow -up Grade 1 : asymptomatic with laboratory (e.g., BNP) or cardiac imaging abnormalities No dose modifications required unless clinical suspicion is high, in which case hold study drug/study regimen dose during diagnostic work -up for other etiologies. If study drug/study regimen is held, resume after complete resolution to Grade 0. Monitor and closely follow up in once or t wice a week for clinical symptoms, BNP, cardiac enzymes, ECG, ECHO, pulse oximetry (resting and exertion), and laboratory work -up as clinically indicated. Consider using steroids if clinical suspicion is high. Grade 2: Symptoms with mild to moderate activ ity or exertion Grade 3: Severe with symptoms at rest or with minimal activity or exertion; intervention indicated Grade 4: Life-threatening consequences; urgent intervention indicated (e.g., continuous IV therapy or mechanical hemodynamic support) If Grade 2 -- Hold study drug/study regimen dose until resolution to Grade 0. If toxicity rapidly improves to Grade 0, then the decision to reinitiate study drug/study regimen will be based upon treating physician’s clinical judgment and after completion of s teroid taper. If toxicity does not rapidly improve, permanently discontinue study drug/study regimen. If Grade 3 -4, permanently discontinue study drug/study regimen. Monitor symptoms daily, hospitalize. Promptly start IV methylprednisolone 2 to 4 mg/kg/da y or equivalent after Cardiology consultation has determined whether and when to complete diagnostic procedures including a cardiac biopsy. Supportive care (e.g., oxygen). If no improvement within 3 to 5 days despite IV methylprednisolone at 2 to 4 mg/kg/d ay, promptly start immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general guidance before using infliximab. Once the patient is imp roving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. Endocrine imAE s Endocrine Disorder Management Follow -up Grade 1 No dose modifications. Monitor patient with appropriate endocrine function tests. For suspected hypophysitis/hypopituitarism, consider consultation of an endocrinologist to guide assessment of early -morning ACTH, cortisol, TSH and free T4; also consider gonadotropins, sex hormones, and prolactin levels, as well as cosyntropin stimulation test (though it may not be useful in diagnosing early secondary adrenal insufficiency). If TSH < 0.5 × LLN, or TSH >2 × ULN, or consistently out of range in 2 subsequent measurements, include free T4 at subsequent cycles as clinically indicated and consider consultation of an endocrinologist. Grade 2 For Grade 2 endocrinopathy other than hypothyroidism and Type 1 diabetes mellitus, hold study drug/study regimen dose until patient is clinically stable. If toxicity worsens, then treat as Grade 3 or Grade 4. Study drug/study regimen can be resumed once event stabilizes and after For Grade 2 (including those with symptomatic endocrinopathy): Consult endocrinologist to guide evaluation of endocrine function and, as indicated by suspected endocrinopathy and as clinically indicated, consider pituitary scan. For all patients with abnormal endocrine work up, except those with isolated hypothyroidism or Type 1 DM, and as guided by an endocrinologist, consider short -term corticosteroids (e.g., 1 to 2 mg/kg/day"
31,page_31,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 32 de 123 completion of steroid taper. Patients with endocrinopathies who may require prolonged or continued steroid replacement (e.g., adrenal insufficiency) can be retreated with study drug/stu dy regimen on the following conditions: 1. The event stabilizes and is controlled. 2. The patient is clinically stable as per investigator or treating physician’s clinical judgement. 3. Doses of prednisone are ≤10 mg/day or equivalent. methylprednisolone or IV equivalent) and prompt initiation of treatment with relevant hormone replacement (e. g., hydrocortisone, sex hormones). Isolated hypothyroidism may be treated with replacement therapy, without study drug/study regimen interruption, and without corticosteroids. Isolated Type 1 diabetes mellitus (DM) may be treated with appropriate diabetic therapy, without study drug/study regimen interruption, and without corticosteroids. Once patients on steroids are improving, gradually taper immunosuppressive steroids (as appropriate and with guidance of endocrinologist) over ≥28 days and consider prophy lactic antibiotics, antifungals, and anti - PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation ]).a For patients with normal endocrine workup (laboratory assessment or MRI scans), repeat labo ratory assessments/MRI as clinically indicated. Grade 3 or 4 For Grade 3 or 4 endocrinopathy other than hypothyroidism and Type 1 diabetes mellitus, hold study drug/study regimen dose until endocrinopathy symptom(s) are controlled. Study drug/study regimen can be resumed once event stabilizes and after completion of steroid taper. Patients with endocrinopathies who may require prolonged or continued steroid replacement (e.g., adrenal insufficiency) can be retreated with study drug/study regimen on th e following conditions: 1. The event stabilizes and is controlled. 2. The patient is clinically stable as per investigator or treating physician’s clinical judgement. 3. Doses of prednisone are ≤10 mg/day or equivalent. Consult endocrinologist to guide evaluation of endocrine function and, as indicated by suspected endocrinopathy and as clinically indicated, consider pituitary scan. Hospitalization recommended. For all p atients with abnormal endocrine work up, except those with isolated hypothyroidism or Type 1 DM, and as guided by an endocrinologist, promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day or equivalent, as well as relevant hormone replacement (e.g., hydrocortisone, sex hormones). For adrenal cris is, severe dehydration, hypotension, or shock, immediately initiate IV corticosteroids with mineralocorticoid activity. Isolated hypothyroidism may be treated with replacement therapy, without study drug/study regimen interruption, and without corticostero ids. Isolated Type 1 diabetes mellitus may be treated with appropriate diabetic therapy, without study drug/study regimen interruption, and without corticosteroids. Once patients on steroids are improving, gradually taper immunosuppressive steroids (as app ropriate and with guidance of endocrinologist) over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [ Category 2B recommendation]).a aASCO Educ ational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. Neurotoxicity imAE s Neurotoxicity Management Follow -up Grade 1 No dose modifications. Patients should be evaluated to rule out any alternative etiology (e.g., disease progression, infections, metabolic syndromes, or medications). Monitor patient for general symptoms (headache, nausea, vertigo, behavior change, or weakness). Consider appropriate diagnostic testing (e.g., electromyogram and nerve conduction investigations). Perform symptomatic treatment with neurological consult as appropriate. Grade 2 For acute motor neuropathies or neurotoxicity, hold study drug/study regimen dose until resolution to Grade ≤1. For sensory neuropathy/neuropathic Consider, as necessary, discussing with the study physician. Obtain neurology consult. Sensory neuropathy/neuropathic pain may be managed by appropriate medications (e.g., gabapentin or"
32,page_32,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 33 de 123 pain, consider holding study drug/study regimen dose until resolution to Grade ≤1. If toxicity worsens, then treat as Grade 3 or 4. Study drug/study regimen can be resumed once event improves to Grade ≤1 and after completion of steroid taper. duloxetine). Promptly start systemic steroids prednisone 1 to 2 mg/kg/day PO or IV equivalent. If no improvement within 3 to 5 days despite 1 to 2 mg/kg/day prednisone PO or IV equivalent, consider additional workup and promptly treat with additional immunosuppressive therapy (e.g., IV immunoglobulin ). Grade 3 or 4 For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to Grade ≤1 within 30 days. For Grade 4: Permanently discontinue study drug/study regimen. Consider, as necessary, discussing with study physician. Obtain neurology consult. Consider hospitalization. Promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day or equivalent. If no improvement within 3 to 5 days despite IV corticosteroids, consider additi onal workup and promptly treat with additional immunosuppressants (e.g., IV immunoglobulin ). Once stable, gradually taper steroids over ≥28 days. Peripheral neuromotor syndromes (such as Guillain -Barre and myasthenia gravis) Management Follow -up Grade 1 (Asymptomatic) No dose modifications. Consider, as necessary, discussing with the study physician. Care should be taken to monitor patients for sentinel symptoms of a potential decompensation Obtain a neurology consult. Grade 2 ( Moderate symptoms; limiting instrumental activities of daily living [ADL s]) Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if it does not resolve to Grade ≤1 within 30 days or if there are signs of respirato ry insufficiency or autonomic instability. Consider, as necessary, discussing with the study physician. Care should be taken to monitor patients for sentinel symptoms of a potential decompensation as described above. Obtain a neurology consult Sensory neur opathy/neuropathic pain may be managed by appropriate medications (e.g., gabapentin or duloxetine). MYASTHENIA GRAVIS: Steroids may be successfully used to treat myasthenia gravis. It is important to consider that steroid therapy (especially with high dose s) may result in transient worsening of myasthenia and should typically be administered in a monitored setting under supervision of a neurologist. Patients unable to tolerate steroids may be candidates for treatment with plasmapheresis or IV immunoglobulin (IG). Such decisions are best made in consultation with a neurologist, taking into account the unique needs of each patient. If myasthenia gravis -like neurotoxicity is present, consider starting acetylcholinesterase (AChE ) inhibitor therapy in addition to steroids. Such therapy, if successful, can also serve to reinforce the diagnosis. GUILLAIN -BARRE: It is important to consider here that the use of steroids as the primary treatment of Guillain -Barre is not typically considered effective. Patients requirin g treatment should be started with IV IG and followed by plasmapheresis if not responsive to IV IG. Grade 3 or 4 ( Severe symptoms; limiting self care ADL or life- threatening consequences ) For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE For Grade 3 or 4 (severe or life -threatening events): Consider, as necessary, discussing with study physician. Recommend hospitalization. Monitor symptoms and obtain neurological consult."
33,page_33,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 34 de 123 does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency or autonomic instability. For Grade 4: Permanently discontinue study drug/study re gimen. MYASTHENIA GRAVIS: Steroids may be successfully used to treat myasthenia gravis. They should typically be administered in a monitored setting under supervision of a neurologist. Patients unable to tolerate steroids may be candidates for treatment with plasmapheresis or IV IG. If myasthenia gravis -like neurotoxicity present, consider starting AChE inhibitor therapy in addition to steroids. Such therapy, if successful, can also serve to reinforce the diagnosis. GUILLAIN -BARRE: It is important to consider here that the use of steroids as the primary treatment of Guillai n-Barre is not typically considered effective. Patients requiring treatment should be started with IV IG and followed by plasmapheresis if not responsive to IV IG. Others imAEs Myositis/Polymyositis (“Poly/myositis”) Management Follow -up Grade 1 (mild pain) No dose modifications. Monitor and closely follow up in 2 to 4 days for clinical symptoms and initiate evaluation as clinically indicated. Consider neurology consult. Consider, as necessary, discussing with the study physician. Grade 2 (moderate pain associated with weakness; pain limiting instrumental activities of daily living [ADLs]) Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if it does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency. Monitor symptoms daily and consider hospitalization. Obtain Neurology consult, and initiate evaluation. Consider, as necessary, discussing with the study physician. If clinical course is rapidly progress ive (particularly if difficulty breathing and/or trouble swallowing), promptly start IV methylprednisolone 2 to 4 mg/kg/day systemic steroids along with receiving input from neurology consultant If clinical course is not rapidly progressive, start systemi c steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV equivalent); if no improvement within 3 to 5 days, continue additional work up and start treatment with IV methylprednisolone 2 to 4 mg/kg/day . If after start of IV methylprednisolone at 2 to 4 mg/kg/d ay there is no improvement within 3 to 5 days, consider start of immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general gu idance be fore using infliximab. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -Pneumocystis jirovecii pneumonia treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a Grade 3 or 4 (pain associated with severe weakness; limiting self-care ADLs ) For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency. Monitor symptoms closely; recommend hospitalization. Obtain neurology co nsult, and complete full evaluation. Consider, as necessary, discussing with the study physician. Promptly start IV methylprednisolone 2 to 4 mg/kg/day systemic steroids along with receiving input from neurology consultant."
34,page_34,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 35 de 123 For Grade 4: Permanently discontinue study drug/study regimen. If after start of IV methylprednisolone at 2 to 4 mg/kg/day there is no improvement within 3 to 5 days, consider start of immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infl iximab label for general guidance before using infliximab. Consider whether patient may require IV IG, plasmapheresis. Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -Pneumoc ystis jirovecii pneumonia treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. 7.6. Partial treatments stop The treatment regimen must include at the beginning FOLFIRI plus durvalumab +/ - tremelimumab, depending on treatment arm, but if severe toxicities occur some drugs can be stopped while the other drugs continued. Regimen allowed 5-FU/LV Irinotecan Durvalumab Tremelimumab X X X X X X X X X X X X Regimen not allowed 5-FU/LV Irinotecan Durvalumab Tremelimumab X X X X X X X X X X X X X X X X X X Main toxicities that will induce a partial treatment stop are: - Immune -mediated adverse event grade 3 -4 may need durvalumab +/ - tremelimumab stop: FOLFIRI can be continued alone. - Severe digestive toxicities due to chemotherapy may need irinotecan +/ - 5FU stop : 5FU plus durvaluma b +/- tremelimumab can be continued or durvalumab (with or without tremelimumab ) alone."
35,page_35,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 36 de 123 7.7. Premedications, c oncomitant treatments and contraindicated treatments 7.7.1. Neutropenia Treatments considered to be necessary for the patient's well -being can be administered at the investigator's discre tion (anti -emetic, anti -diarrh eic etc.). The indication for primary prophylaxis with G -CSF will be at the discretion of the investigator, hematological toxicities during f irst-line chemotherapy and according to the patient's clinical characteristics. In case of severe neutropenia, i.e. grade 3 -4, patients are at high risk of febrile neutropenia and infection especially in the case of concomitant diarrhea. If these symptoms appear, dosage adjust ments are planned in the next course of treatment, and the prescription of hematopoietic growth factors should be considered. 7.7.2. Contraindicated treatments (see S mPCs and IB of each protocol’s molecular entities) Durvalumab: Appendix 10 to see prohibited medications Tremelimumab : Appendix 10 to see prohibited medications 5FU: yellow fever vaccine, attenuated live vaccine, prophylactic phenytoin. When combined with warfarin more frequent monitoring of INR Irinotecan: drugs with St. Jo hn's wort , yellow fever vaccine. 8. LOGISTICS OF THE BIO LOGICAL STUDY (FOR PHASE II ONLY) For patients who signed the biological informed consent, the details of the biological study (circulating DNA , stool and tumor sample) is in Appendix 2 . Samples needed - 2 blood “cell -free DNA” tubes will be sampled - 2 blood tubes just before the 1st treatment course - 2 blood tube s just before the 3rd course - 2 at progression (before the 1st course of L3) Blood samples will be used for extracting the DNA from the plasma (circulating tumor DNA) . Sending tubes , via the box su pplied at opening of the center : Centre de Ressources Biologiques EPIGENETEC Unité UMR -S 1147 45, rue des Saints -Pères - 75006 PARIS (France) Headed by Pr. Pierre LAURENT -PUIG Only use the box containing the UPS dispatch note addressed to the unit INSERM UMR -S 1147 After sending this box, the box needed at inclusion of the next patient , or for the next sample, will be sent by CRB EPIGENETEC. In case of questions or logistic pro blems, contact CRB EPIGENETEC, Claire MULOT at +33 (0)1 42 86 38 61, claire.mulot@parisdescartes.fr or FFCD at +33 (0)3 80 39 34 86 - Tumor block fixed in paraffin: Sending the pre -filled letter to your anatomopathologist : - The anatomopatologist has to fax to the FFCD the sample sheet at the +33 (0)3 80 38 18 41"
36,page_36,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 37 de 123 - FFCD sends a max letter for sending tumor blocks Tumor block will be sent to : Centre de Ressources Biologiques EPIGENETEC Unité UMR -S 1147 45, rue des Saints -Pères - 75006 PARIS (France) Headed by Pr. Pierre LAURENT -PUIG In case of questions or logistic problems, contact CRB EPIGEN ETEC , Claire MULOT at +33 (0)1 42 86 38 61, claire.mulot@parisdescartes.fr or FFCD at +33 (0)3 80 39 34 86 - Stool sample A document explaining in detail the sampling and shipping procedure will be provided to the patient at inclusion in the study and specific and validated material will be provided to the patient for the stool sampling and shipment. Stool samples will be h arvested: - 1 stool sample at W0 (in the 5 days preceding the first course of treatment) - 1 stool sample at W8 (in the 5 days preceding the first evaluation of treatment efficacy ) Sending stools , via the box su pplied at opening of the center : Laboratoire d’analyse des microbiotes, Microbiote intestinal et immunité Pr Harry Sokol INSERM U1157 / UMR CNRS 7203 Université Pierre et Marie Curie 27 rue de Chaligny, 75012 Paris, France Once received in the laboratory responsible for the analysis, the stool will be aliquoted and stored at -80°C until processing. 9. PATIENT MONITORING 9.1. During treatment 9.1.1. Before each administration of treatment Clinical examination - Vital signs: BP, pulse, temperature - Weight, height and body surface area - ECOG performance status - Safety evaluation (toxicity precedent cycle according to NCI -CT v4.0) Laboratory assessment: - CBC , platelets - Serum electrolytes (sodium, potassium, calcium, magnesium) , TSH*, urea, creatinine and creatinine clearance (MDRD formula) - Lipase, glucose - Liver panel comprising GGT, ALP, AST, ALT, total and conjugated bilirubin - Pregnancy test each month for women with childbearing potential"
37,page_37,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 38 de 123 * Measure s of free T3, T4 will be done if there is an abnormal TSH level or if there is a clinical suspicion of an AE related to the endocrine system. 9.1.2. Evaluation every 8 weeks until radiological progression Patients will be evaluated every 8 weeks (regardless of the number of cycles received) for: Clinical examination - Vital signs: BP, pulse, temperature - Weight, body Area - ECOG performance status - Safety evaluation (toxicity precedent cycle according to NCI -CT v4.0) - QLQ -C30 v3.0 and STO -22 questionn aires (phase II only) Laboratory assessment: - CBC , platelets - Serum electrolytes (sodium, potassium, calcium, magnesium) , TSH *, urea, creatinine and creatinine clearance (MDRD formula) - Lipase, glucose - Liver panel comprising GGT, ALP, AST, ALT, total and conjugated bilirubin , LDH - Blood protein, albumin and prealbumin - CEA, CA 19.9 - Urinalysis (protein level) * Measure s of free T3, T4 will be done if there is an abnormal TSH level or if there is a clinical suspicion of an AE related to the endocrine system. Morphological assessment : - Thoracic -abdominal -pelvic CT (or thoracic CT and abdominal -pelvic MRI if IV contrast -enhanced CT is contraindicated) measuring tumor targets according to RECIST criteria (version 1.1, Appendix 6). Use same technique in each imaging examination as that of the initial evaluation. - Imaging of brain lesion(s) if present at baseline by CT -scan (or brain MRI) Phase II only: For radiological progression assessments, at the physician’s discretion, it is p ossible to continue treatment and perform a new CT -scan 4 to 8 weeks later in order to confirm progression. Send an anonymized copy of images in CD -ROM format to FFCD, 7 bd Jeanne d’Arc, BP 87900, 21079 DIJON cedex ( centralized review for the secondary end point and the ancillary study) 9.2. After treatment discontinuation 9.2.1. Within 30 days for evaluating the toxicity of the last treatment Laboratory asses sment: - CBC , platelets, - Serum electrolytes (sodium, potassium, magnesium, calcium), TSH *, serum creatini ne, creatinine clearance (MDRD) - Lipase , glucose - Liver panel comprising GGT, PAL, ASAT, ALAT, bilirubin (total and conjugated), LDH - Serum albumin - Evaluation of toxicities from the preceding cycle * Measures of free T3, T4 will be done if there is an abnormal TSH level or if there is a clinical suspicion of an AE related to the endocrine system."
38,page_38,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 39 de 123 9.2.2. After premature discontinuation of treatment other than for radiological progression * Patients will be monitored in the same way every 8 weeks until radiological progression: Clinical exam (identical as 10.2.1 paragraph) Laboratory test assessment (identical as 10.2.1 paragraph) Evaluation of persistent toxicities (including neuropathy) up to disease progression CT-scan: TAP (or MRI scan of abdomen -pelvis + CT -scan of thorax) and imaging of brain lesion(s) if present at baseline (CT -scan or MRI) with measurement of tumour targets according to RECIST v1.1 criteria Phase II only: Send an anonymized copy of images in CD -ROM format to FFCD, 7 bd Jeanne d’Arc, BP 87900, 21079 DIJON cedex (centralized review for the secondary end point and the ancillary study) * Clinical progression, toxicity, withdrawal of consent, patient refusal, medical d ecision, pregnancy or suspected pregnancy 9.2.3. After treatment discontinuation because of radiological progression Patients will be monitored every 2 to 3 months during 1 year after treatment end or until death : - Evaluation of persistent toxicities until 12 months after the end of treatment - TAP -CT scan (or MRI) and imaging of brain lesion(s) if present at baseline (CT -scan or MRI) 10. SUBS EQUENT TREATMENTS The 1st line treatments and subsequent treatments will be collected in the CRF. For each line, the following information will be collected: - Type of chemotherapy, - Number of cycles , - Start date of chemotherapy of first chemotherapy cycle , - End date of last chemotherapy cycle , - Progression date . 11. MANAGEMENT OF SERIOU S ADVERSE EVENTS Parameters for assessing safety Safety will be assessed by evaluating the clinical and biological health status of patients during visits and by recording events that occur betwee n visits. Toxicities will be evaluated using the NCI -CTCAE toxicity scale (version 4.0) ( Appendix 8 ). In case of emergency, the patient, the patient's family or the patient's physician must call the investigator to make it known that an event has occurred. Definitions Adverse event (AE) An AE is an untoward medical occurrence in a person enrolled in a clinical trial , whether this occurrence is related or not to the trial itself or to the study product. All AEs will be recorded in the CRF in the pages provided. Serious adverse event (SAE) An SAE is any event that meets at least one of the following criteria: - results in death"
39,page_39,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 40 de 123 - is life -threatening - results in hospitalization or prolongs hospitalization - causes permanent disability or serious temporary incapacity - causes a congenital anomaly, fetal malformation or an abortion - is medically significant The terms disability and incapacity mean any temporary or permanent physical or mental disability that is clinically significant and that impacts the physic al activity and/or quality of life of the patient. A significant medical event is any clinical event or laboratory result considered to be serious by the investigator that does not meet the seriousness criteria defined above. It may put the patient at ris k and require medical intervention to prevent an outcome such as one of the criteria for seriousness previously mentioned. Examples include overdose, second cancers, pregnancy and new facts that may be considered to be medically significant. The following AE, observed with durvalumab ± tremelimumab , represent a specific interest and must be declared as SAE : - Grade ≥ 3 diarrhea and colitis, intestinal perforation - Pneumonitis and Interstitial Lung Disease (ILD) - Grade ≥ 3 hepatitis and transaminase increase - Grade ≥ 3 endocrinopathies ( i.e. events of hypophysitis/hypopituitarism, adrenal insufficiency, hyper - and hypothyroidism and type I diabetes mellitus) - Grade ≥ 3 rash and dermatitis - Grade ≥ 3 nephritis and blood creatinine increases - Grade ≥ 3 pancreatitis and serum lipase and amylase increases - Myocarditis - Myositis / Polymyositis - Peripheral or central neurotoxicity / neuromuscular toxicity ( e.g. Guillain -Barré, and myasthenia gravis) - Other inflammatory responses that are rare / less frequen t with a potential immune -mediated etiology includ ing pericarditis, sarcoidosis, uveitis and other events involving the eye, hematological events. Pregnancy is a non -inclusion criterion in this trial and a highly effective method of birth control must be used during the treatment and 6 months after for patients of childbearing potential . However, if a pregnancy occurs after a female patient’s enrollment, this patient must discontinue the trial. The sponsor should be noticed of this pregnancy with the SAE report form (no seriousness criteria must be filled). The patient will be followed until the end of the pregnancy and the outcome of the pregnancy must be reported to the sponsor. If a pregnancy occurs in partner of male pati ent enrolled on the trial, the sponsor should be noticed and will try, as possible, to follow the pregnancy. Adverse reaction Any harmful, undesired reaction to a study drug regardless of the dose administered or to any investigational element. It is ser ious if it meets at least one of the seriousness criteria. Unexpected SAE An unexpected SAE is an event that is not mentioned in, or that differs in nature, intensity , frequency or outcome from the reference safety information . New fact Any new safety da ta that could lead to: • a re -evaluation of the risk -benefit ratio for the research or investigational medicinal product, • changes in the administration of the investigational medicinal product, in the conduct of the research or in documents relating to the research, • or suspend or interrupt or modify the research protocol or similar researches. Severity (or intensity) Severity must not be confused with seriousness, which serves as a guide defining reporting obligations."
40,page_40,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 41 de 123 The severity of an event will be assessed according to the extract of the CTCAE classifi cation (version 4.0) (Appendix 8 ). The severity of adverse event s not listed in this classification will be assessed using the following terms: - Mild (grade 1): asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated - Moderate (grade 2): moderate; minimal, local or noninvasive intervention indicated; limiting age - appropriate instrumental activities of daily living - Severe (grade 3): severe or medically significant but not immediately life -threatening; hospitalization or prolongation of existing hospitalization indicated; disabli ng; limiting self care activities of daily living - Very severe (grade 4): life-threatening consequences; urgent intervention indicated - Death (grade 5) Causal relationship Related: an event is said to be ""related"" when a causal relationship between the event and the product being studied may reasonably be suspected Unrelated: an event is said to be ""unrelated"" when a causal relationship between the event and the product being studied cannot reasonably be suspected Doubtful : the causal relationship is sai d to be "" doubtful "" if there are doubts about the causal relationship between the event and the product being studied. The relationship cannot be positively ruled out or confirmed. A doubtful relationship will be considered as “related” for the purpose of r eporting to the authorities. Sponsor's responsibilities As soon as the sponsor receives the SAE report made by the investigator, he has to assess the causal relationship between the SAE and the study product (s). If the investigator and/or sponsor consider the SAE as related to one of the study products, it is therefore a serious adverse reaction , and the sponsor must determine whether the reaction is expected or unexpected. If it is an unexpected serious adverse reaction the sponsor drafts an initial report which is sent to the ANSM and EMA (via EudraVigilance) with out delay in the event of death or of a life -threatening situation or within 15 days in other cases. The sponsor declares in the form of a follow -up report the relevant additional informatio n within 8 days of the initial declaration. If it is an expected serious adverse reaction , it is compiled for the purpose of drafting the annual safety reports. New facts will be sent without delay to ANSM and IRB. Events that must not be considered serious Disease progression must not be considered as a SAE. Events that may be related to progression but may also have been caused by the treatment still need to be reported, for example thromboembolic events, hemorrhage, or perforation. Because of the s eriousness of the disease in this study, certain conditions defined as SAEs will be excluded from the SAE reporting procedure. It includes : - Hospitalization or surgery that is specifically connected with treating the disease. However, hospitalization or the prolonging of hospitalization due to one of the study products must be reported as SAEs. - Hospitalization to simplify the study treatments or procedures. The reference safety information in this trial will be: For 5 -FU: FLUOROURACILE TEVA ® SmPC For Folinic acid: ELVORINE® S mPC For Irinotecan : CAMPTO® S mPC For Durvalumab : section Reference Safety Information of Investigator’s Brochure For Tremelimumab : section Reference Safety Information of Investigator’s Brochure The versions of the S mPCs and Investigator’s Brochure that we will use to define expectedness will be those in effect at the time of analysis. Procedure"
41,page_41,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 42 de 123 The investigator reports all SAEs to the sponsor, whether expected or unexpected, and whether related to the trial or not, that occur during the study or within 90 days of the last administration of treatment. Any late SAEs (occurring after this 90-days period) that are reasonably related to the study drugs or to the trial must be reported regardless of when they occu r. The report is filed by faxing the ""Serious Adverse Event Report"" form ( Appendix 11 ), dated, signed and documented as soon as possible, within 24 working hours of the event being observed to the FFCD data center on +33 (0)3 80 38 18 41. The investigator must follow the patient until the event resolves or stabilizes or until the patient dies. It may sometimes require a follow -up of the patient after the trial discontinuation . The investigator sends additional information to the sponsor using the SAE report form, ticking the ""follow -up"" box and increasing the number of the report to highlight that it is a follow -up report and not an initial report. These follow -up reports must be sent within 24 hours of receiving the information. The investigator also sends the last follow -up report when the SAE has resolved or stabilized. The investigator handles requests for additional information to document the initial observation. 12. STATISTICAL ANALYSIS 12.1. Safety analyses (safety run -in phase) For safety run -in phases, patients will be treated in 5 expert centers with a huge experience in the use of immune checkpoints inhibitors. 1st step: In order to check the good tolerability of FOLFIRI plus durvalumab combination, 5 patients will be treated by FOLFIRI (irinotecan 180mg/m²) plus durvalumab (1500 mg) in 5 expert centers. The inclusion will be stopped at 5 patients. When the 5th patient wi ll have received 2 cycles of treatment, the safety analysis will be done with all the safety data available at this date. The review will be done by an Independent Data Monitoring Committee (IDMC). The decision of IDMC and the data available will be sent t o ANSM. We will wait the ANSM approval to re - open the inclusion of patients. 2nd step: 3 patients per arm will be randomized to receive either FOLFIRI (irinotecan 180 mg/m²) plus durvalumab (1500 mg) or FOLFIRI ( irinotecan 150 mg/m² ) plus durvalumab (1500 mg) plus tremelimumab (75 mg). These 6 patients will be treated in the same 5 expert centers. When the 6th patient will have received 2 cycles of treatment, the safety analysis will be done with all the safety data available at this date (for the 11 patien ts included in these safety run -in phase s). The review will be done by an Independent Data Monitoring Committee (IDMC). The decision of IDMC and the data available will be sent to ANSM. We will wait the ANSM approval to open the phase II trial. 12.2. Endpoint s for phase II study 12.2.1. Primary efficacy endpoint The primary endpoint is the percentage of patients alive and without radiological progression (according to RECIST 1.1) at 4 months after randomization according to investigator . 12.2.2. Secondary endpoints The secondary endpoints are: Progression free survival ( PFS) median : Is defined as the time between date of randomization and date of the first radiological progression (according to RECIST 1.1) or death ( from any cause), whichever occurs first. Patients alive without progression will be censored at date of last news."
42,page_42,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 43 de 123 Overall Survival ( OS): Is defined as the time between date of randomization and date of death ( from any cause). Patients alive will be censored at date of last news. Time to progression ( TTP ): Is defined as the time between date of randomization and the date of first radiological progression (according to RECIST v1.1). Patients without progression will be censored at date of last news or date of death. The death will not be considered as an event . Best Objective Response rate ( BRR): Is defined as complete or partial response at the best response evaluation during the treatment according to RECIST v1.1. Disease control rate ( DCR ) at each timepoint : Is defined as complete or partial response or stable disease at the best response evaluation according to RECIST v1.1. Time to strategy failure : Is defined as the time between randomization date and date of death (from any cause) or the date of first radiological progression in the FOLFIRI + durvalumab arm or date of the second radiological progression after re-introduction of tremelimumab in the FOLFIRI plus durvalumab plus tremelimumab arm or date of definitive discontinuation . In case a treatment i s stopped for toxicity reason but re -introduced later for progression, then this progression will not be considered for this endpoint. Safety profile Toxicities will be graded according to the NCI -CTCAE v4.0 classifications. Quality of life (QoL) Is evaluated using EORTC QLQ -C30 and the STO22 questionnaires. Centralized evaluation of PD -L1 expression All efficacy endpoints (OS, PFS, TTP, BRR and DCR) will be evaluated according to the expression of PD -L1. Centralized radiological assessments of RECIST v1.1 response and iRECIST response according Seymour et al. criteria (22 ). For exploration, secondary endpoints (OS, PFS, TTP, BRR and DCR) will be analysed according to this centralized review. 12.3. Sample size justification , statistical hypothesis There is n o statistical hypothes is for the safety run -in phase . A total of 11 patients will be included in the 2 steps of the safety run -in phase before the randomized phase II study will begin. Median PFS with FOLFIRI as second -line chemotherapy in gastric and GEJ adenocarcinoma is b etween 2 to 4 months (10, 13, 23 -25). We expect at least a 5 months median PFS with FOLFIRI + durvalumab ± tremelimumab which is clinically significant. The hypotheses for the randomized phase II are: - H0: 50% of patients alive and without progression at 4 months is not acceptable. - H1: 70% of patients alive and without progression at 4 months is expected."
43,page_43,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 44 de 123 With a risk α (one -sided) of 5%, a power of 85% and according to the b inomial exact method (A’Hern) (26), 44 evaluable patients (i.e. patients randomized and with at least one dose of products taken) are needed by arm. Assuming 5% of non -evaluable or lost to follow -up patients, 47 patients will be included by arm (94 patients in total). Taking into accou nt the 11 patients included in the safety run -in phase, 105 patients will be included in the trial. Rules for selection to be applied to both experimental arms (on the 44 evaluable patients): if 28 or more patients are alive without progression at 4 month s then the arm will be considered as efficient. In case both arms will conclude to efficacy, safety data will be analyzed (both Adverse events and Serious Adverse events) in order to see if one has a better safety profile. One or both arms could be compared to a control arm (FOLFIRI) in a phase III study. 12.4. Statistical analysis for phase II study A detailed Statistical Analysis Plan (SAP) will be written before the database lock. 12.4.1. Population definition Intent -to-treat (ITT) population: all randomized patients, whatever their eligibility and whatever treatment they have received. Patients will be analyzed in the treatment arm allocated at randomization. Modified Intent -to-treat (mITT) population: ITT patients who have taken at least one dose of product s (whatever the dose is and whatever the treatment is). Safety population (SP): ITT patients who have received at least one dose of treatment. The patients will be analysed in the treatment arm really received. 12.4.2. Endpoint evaluation Evaluation of baseline characteristics (ITT) All b aseline characteristics will be described using descriptive statistics and will be presented by treatment arm and on the overall population. The continuous variables are described by the usual statistics as mean (with standard deviation), median (with interval Inter -quartiles) and min -max. The categorical variables will be described using patient numbers and percentages. Evaluation of the primary endpoint (m ITT) For the primary endpoint, frequencies and percentage will be given for each treatment arms. A one -sided 95% confidence interval of each percentage will also be given. Evaluation of secondary endpoints (ITT) For Survival analyses ( OS, PFS , TTP and Time to strategy failure ), the Kaplan -Meier method (27) will be used to estimate median and curve s will be plotted. The median and the rates at different times will be described with their 95% confidence interval. The median follow -up time will be calculated using the ""reverse Kaplan -Meier"" method (28). Evaluation of safety (SP) A safety analysis will be performed on the first 10 patient s included in the study. Patient enrolment will be stopped and toxicities data on these 10 first patients will be harvested ."
44,page_44,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 45 de 123 Adverse events (toxicity events) will be described for each treatment arm, by number of patients by preferred term (PT) within each SOCs (System Organ Classes) . Each toxicity will be analyzed with on the maximum grade according to the NCI -CTC v4 during the treatment phase . They will also be described by grouping the maximum grade 1 -2 versus 3 -4-5. A Serious Adverse Event (SAE) report will be provided by pharmacovigilance. Evaluation of quality of life (ITT) Quality of life will be evaluated using the EORTC QLQ -C30 + STO -22 questionnaire s. The scores will be described at baseline by treatment arms. The time to definitive deterioration of the global health score will be calculated: it is defined as the time between the date of randomization and the date of first deterioration by more than five points on the global health scale in comparison with the score at baseline (without any subsequent improvement). Patients alive or who died without deterioration will be censored at date of la st news. 13. STUDY COMMITTEES 13.1. Independent data monitoring committee An independent data monitoring committee (IDMC) will be established that comprises at least two digestive oncologists , a statistician or methodologist, and an expert in pharmacovigilance. IDMC members will be selected by the Sponsor and will be independent from the study . The IDMC will be convened at the end of each step of safety run -in phase as described in the protocol . Then, throughout the duration of the study the IDMC will meet at lea st once a year, or more often if the sponsor deems it is necessary in light of pharmacovigilance signal . The IDMC may also be convened at any time during the trial whenever the sponsor considers there to be a need to do so. The committee will issue decisio ns on all safety data sent to the sponsor by the centers (AEs and/or SAEs). It will evaluate all patients included in the trial in the 2 months preceding the date of its meeting. The IDMC can recommend that the clinical study be stopped early if there is s trong evidence that the investigational medicinal products are harming patients . The committee can make recommendations regarding modification of the study if there is strong evidence that such change would substantially contribute to the well - being of pat ients. 13.2. Steering committee A steering committee will be set up. The chairperson of the steering committee will be the study coordinator. This committee will also comprise the co -coordinators, the FFCD study project manager, an FFCD statistician, and the chair man of the biological research committee. Its functions will include, among other things, issuing decisions on the management of the research, such as amendments or, if needed, early trial closure. The steering committee will meet as often as required throughout the study. It will make the necessary decisions concerning substantial protocol amendments, trial closure or trial extension. 13.3. Medical review A medical review committee will be set up to improve the quality of clinical data collected. If there is a discrepancy between the data provided by the investigator and those provided by the medical review committee, data management will seek clarification from the investigator . 13.4. Biological research committee A biological research committee will be establi shed whose role is to answer questions about sample -taking and storage as well as the organization of sample analysis. The committee will meet regularly and report its proposals to the steering committee. This committee will comprise, among others, the stu dy coordinator and a biologist. The committee chairman will be Pr Pierre Laurent -Puig."
45,page_45,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 46 de 123 14. BACKGROUND INFORMATI ON AND RATIONALE FOR THE TRIAL Gastric adenocarcinoma is the fourth most frequent cancer and the second leading cause of cancer mortality (1). Advanced gastric adenocarcinoma has a poor prognosis with short overall survival (ranging from 10% to 15% at 5 -years) even after surgical complete resection and despite the progress in therapeutic approaches. Most of the patients have metastatic, locally a dvanced or recurrent unresectable disease. So, systemic treatment remains an important issue especially since chemotherapy improve s survival and quality of life (compared to best supportive care alone). First -line chemotherapy depends on HER2 status , which also influenced overall survival (14 months for HER2 positive versus 10 months for HER2 negative tumors). In HER2 negative tumors standard first -line regimen is a doublet of fluoropyrimidine (5 -fluorouracil or capecitabine) plus a platinum salt (cisplatin or oxaliplatin) (2). 5 -fluorouracil (5 -FU) and capecitabine as also cisplatin and oxaliplatin have similar efficacy but different toxicities (3, 4). In patients whose tumor overexpresses the HER2 receptor adding trastuzumab to fluoropyrimidine/cisplatin regimen increased overall survival compared to chemotherapy alone (5). In HER2 negative tumors the addition of docetaxel to cisplatin/fluoropyrimidine regimen increased overall survival (6) but its use remains limited in clinical practice because of its h igh toxicity. Preliminary results demonstrated a high efficacy with less toxicities of docetaxel -oxaliplatin -fluoropyrimidine combination, also called TFOX/FLOT regimen (7). Indeed, in France a large phase III trial comparing TFOX versus FOLFOX in first -line treatment of patients with advanced gastric or gastro -oesophageal junction adenocarcinoma is ongoing (GASTFOX , trial NCT03006432). Primary endpoint is progression -free survival (PFS) and 506 patients are planned between 2017 and 2020 (actually at the da te of January 30, 2018, 65 patients are included ). Second -line chemotherapy improves overall survival (OS) as compared to best supportive care alone in patients with an acceptable general condition (performance status 0 -2). Indeed, with docetaxel monothera py there was a significant difference in overall survival for the chemotherapy arm with a median of 5.2 versus 3.6 months in best supportive care alone arm (HR=0.67, p=0.01) (8). Weekly paclitaxel monotherapy is also used because of its good efficacy -toxic ity ratio (9). Irinotecan monotherapy also significantly improves overall survival compared to supportive care alone in a phase III study (4.0 versus 2.4 months; HR=0.48, 95%CI 0.25 - 0.92; p=0.012) (10). Recently ramucirumab monotherapy demonstrated its eff icacy on overall survival in a randomized, placebo -controlled second -line metastatic study (11). In a randomized phase 3 trial ramucirumab also showed its efficacy in combination with paclitaxel versus paclitaxel monotherapy with a median overall survival of 9.6 versus 7.4 months, respectively (p=0.017; HR=0.81) (12). However, the “amelioration du service medical rendu” (ASMR) assessed by the French “Haute Autorité de Santé” (HAS) consider an insufficient benefit to a reimbursement of ramucirumab in France . The HAS gave a moderate ASMR opinion (ASMR IV). Docetaxel is more and more frequently used in first -line chemotherapy then in this setting taxane (alone or combined with others drugs) cannot be used as second -line regimen. Indeed, based on a phase III trial FOLFIRI (5-FU plus irinotecan) is one most use d regimen in second -line in European countries, especially in France (13). FFCD 0307 trial, a phase III comparing FOLFIRI -ECX (epirubicin -cisplatin -capecitabine) to the reverse sequence (ECX -FOLFIRI) , showed that both sequence s are possible. Human tumors tend to activate the immune system regulatory checkpoints as a means of escaping immunosurveillance. For instance, interaction between PD1 (Program Death 1) and PD -L1 (Program Death 1 ligand) will lead the activated T cell to a state of anergy . PD-L1 is u p regulated on a wide range of cancers. Anti-PD1 and anti -PD-L1 monoclonal antibodies (mAbs), called immune checkpoint inhibitors (ICIs), have consequently been designed to restore T cell activity. Others ICIs are investigated, notably cytotoxic T - lymphocy te-associated protein 4 (CTLA -4) inhibitors. CTLA -4 transmits an inhibitory signal to T cells to prevent early excessive T cell activation. CTLA4 blockade may stimulate a more robust antitumor response by sustaining activation and proliferation of T lympho cytes and may overcome immune suppression mediated by"
46,page_46,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 47 de 123 regulatory T cells. ICIs have been recently tested in many cancers with promising results, especially in tumors with microsatellite instability (MSI) and/or PD -L1 overexpression. Preliminary results in metastatic gastric cancer with anti -PD1 mAbs are highly promising. In a trial with pembrolizumab, only PD -L1 positive tumors were eligible to the treatment with a cut off at 1% (14). Thirty -nine patients were enrolled and 67% had received at least two p rior chemotherapy regimens. The overall response rate was 22%. The median PFS and OS were 1.9 months and 11.4 months, respectively. KEYNOTE -059 Phase 2 multicohort study with pembrolizumab monotherapy in advanced gastric cancer treatment has been presented at ASCO 2017 meeting (15). Among 259 patients included in the tr ial response rate was 11.6%. OS was 5.6 months. Response rates were 15.5% in PDL1+ tumors versus 6.4% in PDL1 - tumors and 57.1% in MSI tumors versus 9% in MSS tumors. Up until now, overlap be tween microsatellite instability and PD -L1 expression is unknown in gastric cancer. An anti -PD-L1 mAb (avelumab) was evaluated in a phase Ib expansion study (n=20, Japanese patients), with 15% of objective response rate and 11.9 weeks for progression -free survival. A second cohort with avelumab included 55 patients for maintenance therapy after first -line chemotherapy, with 7.3% of objective response rate and 14 week s of PFS (16). Phase I/II CheckMate -032 evaluated nivolumab (anti -PD-1) ± ipilimumab (anti -CTLA4) at different doses in advanced gastric cancer (17). The overall response rate was between 8% to 24% and the median OS between 4.8 to 6.9 months according to treatment arm. Others anti -PD1/anti -PD-L1/anti -CTLA4 mAbs are also currently under investig ation in gastric cancer alone or in combination with chemotherapy. Nevertheless, up until now there is no published data concerning ICI plus chemotherapy in gastric cancer. Finally, immunogenic cell death induced by chemotherapy may enhance efficacy of ICI s (18). Durvalumab (MEDI4736) is a human monoclonal antibody directed against PD - L1 in development for the treatment of many cancers (19). A phase I study included 16 patients with advanced gastric cancer and the objective response rate was 25% (20). Treme limumab is a fully human monoclonal antibody against CTLA -4. Durvalumab plus tremelimumab combination showed a manageable tolerability profile, with antitumour activity irrespective of PD -L1 status in non -small cell lung cancer (NSCLC) (21). Durvalumab alo ne or combined with tremelimumab is evaluated in phase III studies in NSCLC (e.g NEPTUNE and MYSTIC), small cell lung cancer (CASPIAN), hepatocellular carcinoma (HIMALAYA), bladder cancer (DANUBE) and head and neck cancer (EAGLE and KESTREL). Concerning s afety of anti-PD1 plus anti -CTLA4 combination, i n the randomized phase I/II CheckMate -032 study , that included 160 patients , there was no unexpected toxicity signal. Grade 3 and 4 treatment -related adverse events were 17%, 47%, and 27%, respectively ( 17). These rates of g rade 3 and 4 treatment -related adverse events are those usually found with the anti -PD1 plus anti -CTLA4 combination in other tumors, observed approximately in 40% of patients . Up until now, there is no published data concerning combination of ICIs plus irinotecan. Nevertheless, in all trial combining chemotherapy plus anti-PD1 and/or anti-CTLA4 chemotherapy drugs were used at full -dose (5FU, oxaliplatin, cisplatin…). A n Italian trial just started and combin ed full-dose FOLFOXIRI (5 -FU 3200 mg/m2 plus irinotecan 165 mg/m2 and oxaliplatin 85 mg/m2) with bevacizumab (5 mg/ kg) and at ezolizumab (anti -PD-L1, 840 mg) in metastatic colorectal cancers as first -line treatment. FOLFOXIRI is a tri plet chemotherapy more ""t oxic"" than FOLFIRI doublet chemotherapy and this trial is a randomized phase II (FOLFOXIRI plus bevacizumab and at ezolizumab versus FOLFOXIRI plus bevacizumab). There is, however, a preliminary safety phase in 6 patients, once they have all received at lea st 2 cycles of treatment, the latter being administered at full dose (AtezoTRIBE trial, NCT03721653). The present randomized multicentric non -comparative phase II study aimed to assess the rate of patients alive and without progression at 4 months with a dvanced gastric or gastro -oesophageal junction (GEJ) adenocarcinoma, pre -treated with fluoropyrimidine + platinum +/ - taxane, with two arms Folfiri plus durvalumab versus Folfiri plus durvalumab plus tremelimumab. Indeed, most patients in the French multic entric first-line GASTFOX trial ( 506 patients planned between 2017 and 202 0) can be included in the second -line setting in the DURIGAST trial. Due to the lack of data concerning Folfiri plus durvalumab plus tremelimumab combination, a safety run -in phase w ill be performed at the beginning of the DURIGAST trial."
47,page_47,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 48 de 123 15. REFERENCES 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69 -90. 2. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al. Capecitabine/cisplatin versus 5 - fluorouracil/cisplatin as first -line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666 -73. 3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36 -46. 4. Al -Batran SE, Hartmann JT, Probst S, Sch malenberg H, Hollerbach S, Hofheinz R et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin. J Clin Oncol 2008;26:1435 -42. 5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 -positive advanced gastric or gastro - oesophageal junction cancer (ToGA) : a phase 3, openlabel, randomised controlled trial. Lancet 2010;37 6:687 - 97. 6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first -line therapy for advanced gastric c ancer. J Clin Oncol 2006;24:4991 -7. 7. Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. Ann Oncol 2015;26:149 - 56. 8. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR -02): an openlabel, phase 3 randomised controlled trial. Lancet Oncol 2014 ;15:78 -86. 9. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al. Randomized, open -label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prio r combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:4438 -44. 10. Thuss -Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K et al. Survival advantage for irinotecan versus best supportive c are as second -line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft internistische onkologie (AIO). Eur J Cancer 2011;47:2306 -14. 11. Fuchs CS, Tomasek J, Yang CJ, Dumitru F, Passalacqua R, Goswami C et al. Ramuciruma b monotherapy for previously treated advanced gastric or gastro -oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo -controlled, phase 3 trial. Lancet 2014;383:31 -9. 12. Wilke H, K Muro, Van Cutsem E, Oh SC, Bodo ky G, Shimada Y et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel I patients with previously treated advanced gastric or gastro -oesophageal junction adenocarcinoma (RAINBOW): a double -blind, randomized phase 3 trial. Lancet Oncol 2014;15:12 24-35. 13. Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma : a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520 -6. 14. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE -012): a multicentre, open -label, phase 1b trial. Lancet Oncol 2016;17:717 -26. 15. Fuchs CS, Doi T, Woo -Jun Jang R, Muro K, Satoh T, Mach ado M et al. KEYNOTE -059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 2017;35 (suppl; abstr 4003)."
48,page_48,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 49 de 123 16. Yamada Y, Nishina T, Iwasa S, Shitara K, Muro K, Esaki T et al. A phase I dose expansion trial of avelumab (MSB0010718C), an anti -PD-L1 antibody, in Japanese patients with advanced gastric cancer. J Clin Oncol 2015;33 (suppl; abstr 4047). 17. Janjigian YY, Ott PA, Calvo E, Kim JW, Ascierto PA, Sharma P et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy -refractory (CTx -R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study . J Clin Oncol 2017;35 (suppl; abstr 4014). 18. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti -Programmed Cell Death Ligand -1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Blad der Cancer. J Clin Oncol 2016;34:3119 -25. 19. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exp osure pathway. Clin Cancer Res 2010;16:3100 -4. 20. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake -Haskins A, Li X et al. Preliminary data from a multi - arm expansion study of MEDI4736, an anti -PD-L1 antibody. J Clin Oncol 2014;32 (suppl; abstr 3002). 21. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non -small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299 -308. 22. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143 -e152. 23. Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R et al. Efficacy of irinotecan in combination with 5 -fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clin Res Hepatol Gastroenterol 2011;35:48 -54. 24. Maugeri -Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S et al. FOLFI RI as a second -line therapy in patients with docetaxel -pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32:67. 25. Kim SH, Lee GW, Go SI, Cho SH, Kim HJ, Kim HG et al. A phase II study of irinotecan, continuous 5 - fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine -based regimen. Am J Clin Oncol 2010;33:572 -6. 26. A'Hern R. P., Sample size tables for exact single -stage ph ase II designs. Statistics in medicine 2001; 20:859 - 866 27. Kaplan EL and Meier P. Nonparametric Estimation from Incomplete Observation. Journal of the American Statistical Association 1958;53:457 -481 28. Schemper M and Smith TL. ""A Note on Quantifying F ollow -up in Studies of Failure Time"". Control Clin Trials 1996;17:343 -6. 16. ADMINISTRATIVE CONSIDERATIONS TRIAL SPONSOR The trial sponsor is the FFCD. The trial is registered under the EudraCT number 2018 -002014 -13. REMINDER CONCERNING A PPLICABLE REGULATIONS This trial will be conducted in accordance with current French law, with the ethical principles of the Helsinki Declaration of 1964 and its subsequent revisions, with Good Clinical Practice of the International Conference on Harmonization (ICH –E6, 17/07/96), with European directive 2001/20/EC on the conduct of clinical trials, with the Huriet Act as amended (20/12/88) on the protection of persons participating in biomedical research, and with the provisions laid down by the CNIL, the French dat a protection agency (Act no. 94-548 of 01/07/94 completing Act no. 78-17 of 06/01/78). PUBLIC LIABILITY INSU RANCE An insurance policy was taken out by the sponsor on 29/11 /2018 under the number 137.681, in accordance with article L 1121 -10 of the French Public Health Code (Appendix 13 )."
49,page_49,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 50 de 123 APPLICATION FOR APPRO VAL FROM THE IRB AND ANSM This protocol received approval from IRB CPP NORD OUEST II on 16/04/2019 (Appendix 14 ). This protocol received authorization from the ANSM on 27/11/2018 (Appendix 15 ). COLLECTING PATIENT CO NSENT The investigator undertakes to provide the patient with information and to collect written clinical and biological consent from the patient (using the information sheets and consent forms in appendices 1 and 2) before registerin g the patient in the study. A copy of these consent forms must be retained by the investigator for 15 years so that they may be shown to the regulatory authorities in the event of inspection. The originals must be given back to the patient. In accordance with the recommendations of the French cancer action plan (measure 5.1), this document was submitted to the Patient Advisory Board for Clinical Research of the French League Against Cancer. NOTIFICATION OF HOSPI TAL SENIOR MANAGEMEN T AND CLINICAL TRIAL AGR EEMENT Before the trial is launched, the sponsor will inform the senior management of the hospitals of the utility for the investigator of taking part in this trial. A clinical trial agreement (which includes no additional costs) will be drawn up between the administrator of the investigator center and the sponsor. IMMUNOTHERAPY PATIENT CARD The investigator can give an “immunotherapy patient card ” once the patient randomization performed. This card will inform that the patient is being treated by immunotherapy and will follow the patient throughout the clinical study. This is useful especially if the patient must be treated urgently in another center. DATA ARCHIVING Files will remain confidential and may be consulted only under the authority of t he physicians treating the patients. The sponsor and health authorities will have direct access to these documents in the event of an inspection. The investigator will retain the study documents for 15 years after the end of the trial. COMPUTERIZED ARCHIVING In accordance with the provisions of French Data Protection Act no. 78-17 of January 6, 1978, as amended by the Act of August 9, 2004, trial data will be recorded in a computerized database of the Randomization, Management and Analysis Center of the FFCD, with the exception of items relating to patient identity. DATA PROCESSING The Randomization, Management and Analysis Center of the FFCD will be responsible for managing and analyzing data. MONITORING , QUALITY ASSURANCE AN D INSPECTIONS BY THE AUTHORITIES The investigator hereby accepts that the files of patients enrolled may be consulted by any person appointed by the sponsor and/or by the health authorities to carry out an audit. Visits to inspect the files on site, which are scheduled with t he investigator's agreement, may be made during or after the trial inclusion period. This protocol will be monitored by traveling CRAs of the FFCD."
50,page_50,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 51 de 123 17. RULES FOR PUBLICATION They will comply with those laid down by the PRODIGE research group (Appendix 12). 18. APPENDICES
51,page_51,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 52 de 123 APPENDIX 1 : CLINICAL AND BIOLOGICAL INFORMED CONSENT NOTICE D’INFORMATION ET CONSENTEMENT DE L’ETUDE CLINIQUE PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE1 EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TREMELIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GASTRIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE PHASE DE TOLERANCE N° EudraCT : 2018 -002014 -13 Promoteur : Fédération Francophone de Cancérologie Digestive (FFCD) : Faculté de Médecine, 7 Boulevard Jeanne d’Arc, BP 87900 21079 Dijon Cedex, France Tel : + 33 (0)3 80 66 80 13 – Fax : + 33 (0)3 80 38 18 41 Investigateur coordonnateur : Pr. David Tougeron, CHU de Poitiers (Fait en 2 exemplaires : Un remis au patient, l’autre conservé par le médecin investigateur.) Madame, Monsieur, Vous êtes actuellement suivi(e) pour un cancer de l’estomac et votre médecin vous a proposé de participe r à l’étude PRODIGE 59 - (FFCD 1707) - DURIGAST dont le but est de comparer l’efficacité de 2 nouveaux traitements. Ces traitements combinent la chimiothérapie classiquement utilisée dans le cadre de votre maladie (FOLFIRI) avec une nouvelle méthode de tra itement appelée l’immunothérapie. L’immunothérapie a pour but de stimuler votre système immunitaire (les cellules de votre corps qui vous protège de certaines maladies) afin de pouvoir lutter contre la tumeur. Les associations de médicaments présentées c i-dessous n’ont été testées que dans quelques études cliniques. C’est pourquoi dans le cadre de cette recherche, deux étapes préliminaires sont prévues et ont pour but dans d’évaluer la tolérance des traitements au sein d’une population restreinte de patients. Lors de ces 2 étapes, les informations uniquement relatives à la toxicité de ces associations seront transmises à l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) et à des médecins experts indépendants. Si ces avis con cluent que la toxicité des traitements étudiés n’est pas supérieure à d’autres traitements utilisés pour le traitement de votre maladie alors une étude à plus grande échelle sera lancée. Par ailleurs, au moindre signal de toxicité lors des étapes prélimina ires, le médecin investigateur2 pourra vous faire reprendre le traitement de référence (FOLFIRI). Les traitements de cette phase de tolérance sont les suivants : - La première étape a pour but d’évaluer la tolérance du traitement FOLFIRI (Irinotécan + 5 -fluorouracile (5-FU) + acide folinique (LV)) couplé à une immunothérapie (durvalumab) et ce, sur seulement 5 patients. C’est donc la chimiothérapie standard (FOLFIRI) plus un traitement d’immunothérapie . - La seconde étape a pour but de confirmer que le traite ment FOLFIRI plus durvalumab est bien toléré et d’évaluer la tolérance de la combinaison du FOLFIRI couplé à 2 traitements d’immunothérapie (durvalumab + trémélimumab). Cette seconde étape sera effectuée via un tirage au hasard sur 6 patients : 3 patients qui recevront du FOLFIRI plus durvalumab et 3 patients qui recevront du FOLFIRI plus durvalumab plus trémélimumab. C’est donc la chimiothérapie standard (FOLFIRI) plus un ou deux traitements d’immunothérapie. 1 Etude randomisée : étude au cours de laquelle les participants sont répartis de façon aléatoire dans différents groupes de traitement (dans DURIGAST il y a ainsi 2 groupes de traitement différent). 2 Médecin investigateur : médecin participant à la recherche clinique présentée et qui vous suivra tout au long de votre traitement"
52,page_52,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 53 de 123 Votre médecin investigateur vous informera à q uelle étape de cette étude préliminaire de tolérances se situe l’étude et quel(s) traitement(s) vous pourrez potentiellement recevoir. Votre participation à cette étude est strictement volontaire, vous êtes donc entièrement libre de décider si vous souhait ez ou non y participer. Avant de faire votre choix, prenez tout le temps qu’il vous faudra pour lire attentivement ce document. Son but est de vous informer sur l’intérêt de cette recherche, son déroulement, les bénéfices attendus, mais aussi les contraint es et les risques prévisibles. Vous pouvez lire ce document et en discuter avec une ou plusieurs personnes de votre entourage, une association de patients, votre médecin traitant si vous le souhaitez et bien sûr votre cancérologue. Votre médecin traitant, sauf avis contraire de votre part, sera informé par votre médecin cancérologue de votre participation à cette étude avec un traitement combiné par chimiothérapie et immunothérapie Si vous acceptez de participer à cette étude : - vous devez être affilié(e) à un régime de sécurité sociale ou être bénéficiaire d’un tel régime, - vous ne recevrez pas de rémunération, - vous ne pourrez pas participer en même temps à une autre étude s’intéressant au traitement de votre cancer. Si vous décidez de ne pas particip er à cette étude : - cette décision vous appartient et vous ne serez nullement obligé de vous justifier, - cela n’affectera en rien la qualité de votre prise en charge, de même que vos relations avec l’équipe soignante, - vous aurez les mêmes examens de su rveillance et d’évaluation, avec une fréquence identique. 1. L’OBJECTIF PRINCIPAL DE L’ETUDE : Si vous receviez un traitement en dehors de cette étude, votre médecin vous proposerait du FOLFIRI seul, qui est une combinaison de 2 molécules de chimiothérapie standard (5 -fluorouracile et irinotécan). Dans cette étude, le traitement est une combinaison de FOLFIRI (chimiothérapie classique utilisée dans le traitement de votre maladie) et de traitements d’immunothérapie3 : durvalumab avec ou sans trémélimumab . Ces molécules d’immunothérapie ont récemment été développées et permettent de stimuler votre système immunitaire (vos cellules qui agissent contre les maladies comme les infections et les cancers, notamment les lymphocytes T) pour lutter contre la tumeur. De s résultats récents montrent l’intérêt et l’efficacité importante de l’immunothérapie dans certains cancers de la peau (mélanome) et du poumon. En effet, l’immunothérapie stimule les cellules immunitaires que la tumeur avait réussi à inactiver. Les premie rs résultats dans le cancer de l’estomac et de l’œsophage montrent une certaine efficacité de ces molécules utilisées seules, c’est pourquoi dans cette étude nous testons des molécules d’immunothérapie innovantes en combinaison à la chimiothérapie classiqu e pour être encore plus efficace pour détruire votre tumeur. Nous allons comparer deux traitements combinés : chimiothérapie standard plus une immunothérapie (durvalumab) et chimiothérapie standard plus deux immunothérapies (durvalumab et trémélimumab). Ce sont deux immunothérapies avec des mécanismes d’action différents, et dans certains cancers deux immunothérapies sont plus efficaces qu’une seule mais cela n’est pas encore démontré dans les cancers de l’estomac et de l’œsophage. 2. LE DEROULEMENT DE L’ETU DE : 2.1. Durée de l’étude Au total onze (11) patients seront traités dans cette phase de tolérance (5 à la première étape et 6 à la deuxième étape). A l’issue de la première étape, les données de tolérance du traitement seront analysées. Si elles sont bonnes à la deuxième étape débutera. Cinq centres experts investigateurs en France participeront. La période pendant laquelle les patients seront inclus dans cette étude est d’environ 1 an (durée estimée nécessaire pour identifier les 11 patients compatibles 3 Immunothérapie : traitement qui stimule les cellules responsables de l’immunité pour combattre la tumeur"
53,page_53,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 54 de 123 avec cette étude et évaluer la tolérance du traitement). Si le traitement est suffisamment bien toléré par les patients alors la phase, de plus gran de envergure, pourra être lancée sur quatre -vingt -quatorze (94) patients. Les résultats de l’étude de plus grande envergure devraient être connu en 2024. 2.2. Examens préalables : Si vous acceptez de participer à cette étude, le médecin investigateur s’assurer a que vous ne présentez pas de contre -indication au traitement proposé. Pour cela, il vous examinera et fera le bilan de votre maladie (examen clinique, prise de sang pour un bilan biologique complet, électrocardiogramme (ECG), scanner du thorax (poitrine) , de l’abdomen (ventre) et du bassin pour évaluer l’extension de votre maladie). Ces examens sont standards dans le cadre de votre prise en charge et non spécifiques à l’étude. 2.3. Traitement(s) administré(s) dans le cadre de l’étude : Première étape de tolér ance (5 patients) : Si vous acceptez de participer à cette étude, vous recevrez le traitement suivant :  Une chimiothérapie FOLFIRI, toutes les 2 semaines, combinée à une seule immunothérapie (durvalumab), toutes les 4 semaines. Seconde étape de toléran ce (3 + 3 patients) : Le choix du traitement reçu se fera par tirage au hasard. Si vous acceptez de participer à cette étude, vous recevrez un des traitements suivants :  soit la chimiothérapie FOLFIRI, toutes les 2 semaines, combinée à une immunothérapie (durvalumab), toutes les 4 semaines.  soit la chimiothérapie FOLFIRI, toutes les 2 semaines, combinée à deux immunothérapies (durvalumab + trémélimumab), toutes les 4 semaines. Cette séquence sera réalisée pendant 4 mois, puis vous recevrez un traitement par FOLFIRI plus durvalumab (arrêt du trémélimumab). En vue d’évaluer la tolérance de la combinaison de deux immunothérapies plus FOLFIRI et de limiter l’apparition de toxicités éventuelles, vous recevrez d’emblée une dose réduite d e FOLFIRI (irinotécan à 150 mg/m ² au lieu de 180 mg/m ²). Ensuite, si les données de tolérance de ce traitement sont bonnes, vous aurez alors la possibilité de recevoir du FOLFIRI à une dose standard (180 mg/m ²) selon l’avis de votre médecin investigateur."
54,page_54,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 55 de 123 L’attribution du traitement sera faite par tirage au hasard informatique (appelé également « randomisation »). Cette procédure est habituelle au cours des essais cliniques. Elle permet de constituer deux groupes de patients comparables et ainsi de pouvo ir comparer de façon rigoureuse les effets des différents traitements entre ces deux groupes. A l’issue du tirage au hasard, votre médecin investigateur vous dira quel traitement vous a été attribué. 2.3.1. Administration de votre traitement Votre traitement se déroulera à raison d’une cure tous les 14 jours, comme dans la pratique standard avec le FOLFIRI, mais avec de l’immunothérapie en plus. Les médicaments de votre traitement vous seront tous administrés le même jour à l’hôpital. Vous recevrez votre traitem ent tous les 14 jours tant qu’il sera efficace sur votre maladie et que vous le supportez bien. Le cas échéant celui -ci sera adapté pour que vous puissiez le tolérer convenablement (diminution de la dose de traitement). Voici le déroulement des cures de traitement : Vous arriverez à l’hôpital et serez installé(e) soit dans un fauteuil soit dans un lit en fonction des habitudes de votre hôpital et votre état de santé. Le système d’injection qui vous aura été installé sous la peau préalablement à l’étude (chambre implantable ou cathéter), sera désinfecté. Une prémédication sera effectuée afin de vous permettre de mieux tolérer les traitements qui vous seront administrés et éviter les réactions allergiques. Si vous participez à la 1ère étape d’étude de tol érance : Vous recevrez du FOLFIRI plus durvalumab : L’infirmière fixera à votre chambre implantable, la perfusion qui délivrera le durvalumab (1500 mg) pendant 1 heure. Vous recevrez ce traitement 1 fois tous les 28 jours. Vous recevrez également tous le s 14 jours, l’irinotécan (180 mg/m²) plus une perfusion d’acide folinique (400 mg/m²) pendant 2 heures, enfin du 5 -FU (400 mg/m²) pendant 10 minutes. Pour finir un diffuseur sera branché à votre chambre implantable. Ce diffuseur contient une dose de 2400 m g/m² de 5 -FU qui sera diffusé pendant environ 46 heures. Si vous vous portez bien, vous pourrez sortir de l’hôpital avec votre diffuseur et une infirmière viendra le débrancher à votre domicile dès que la perfusion sera terminée. L’équipe soignante vous donnera toutes les instructions nécessaires. Si vous participez à la seconde étape de l’étude de tolérance, - Si vous êtes dans le groupe de patients qui recevront le FOLFIRI plus durvalumab : La procédure sera exactement la même que décrite précédemment (c f. première étape de tolérance). - Si vous êtes dans le groupe de patients qui recevront le FOLFIRI plus durvalumab plus trémélimumab : L’infirmière fixera à votre chambre implantable, la perfusion qui délivrera le trémélimumab (75 mg) pendant 1 heure, sui vi par le durvalumab (1500 mg) pendant 1 heure. Vous recevrez ce traitement 1 fois tous les 28 jours. Vous recevrez également tous les 14 jours, l’irinotécan (150 mg/m²) plus une perfusion d’acide folinique (400 mg/m²) pendant 2 heures, enfin du 5 -FU (400 mg/m²) pendant 10 minutes. Pour finir un diffuseur sera branché à votre chambre implantable. Ce diffuseur contient une dose de 2400 mg/m² de 5 -FU qui sera diffusé pendant"
55,page_55,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 56 de 123 environ 46 heures. Si vous vous portez bien, vous pourrez sortir de l’hôpital avec v otre diffuseur et une infirmière viendra le débrancher à votre domicile dès que la perfusion sera terminée. L’équipe soignante vous donnera toutes les instructions nécessaires. 2.3.2. Calendrier de suivi Vous serez suivi(e) tout au long de votre traitement avec des examens biologiques avant chaque cure de chimiothérapie et éventuellement entre les cures si nécessaires, qui permettront d’évaluer la tolérance des traitements. De même un scanner sera réalisé tous les 2 mois afin d’évaluer l’efficacité du traitement . Après arrêt du traitement proposé dans le cadre de ce protocole, vous continuerez d’être suivi(e) par votre médecin et vous pourrez, si votre médecin le juge nécessaire, recevoir un autre traitement. Vous continuerez donc à être suivi(e) au minimum tou s les 3 mois en consultation et avec un scanner si votre médecin le juge nécessaire. Les résultats des examens médicaux préalables à l’entrée à l’étude vous seront communiqués directement ou indirectement par le médecin investigateur (conformément à l’article L, 1121 -11 CSP). CALENDRIER DES EXAMENS ET DU SUIVI * ces évaluations vous seront expliquées et réalisées par votre médecin 3. LES BENEFICES ATTENDUS : Même si le médecin investigateur pense que ces traitements vont agir sur votre maladie, les effets sont variables d’un patient à l’autre, et par conséquent nous ne pouvons pas vous garantir un bénéfice pour votre santé. Suite aux précédentes études, l’association de ce médicament de la même famille a donné de bons résultats et nous espérons que ce protocole permettra de stabiliser votre maladie plus longtemps tout en limitant les toxicités liées au traitement. Quoiqu’il en soit le traitement réalisé dans cette étude (FOLFIRI plus immunothérapie) ne pourra en aucun cas être moins efficace que le traitement standard habituellement proposé en dehors de cette étude (FOL FIRI seul). 4. LES RISQUES PREVISIBLES : Il est important de savoir que tout traitement quel qu’il soit, peut engendrer des effets indésirables. C’est également le cas des thérapies testées ici. AVANT TRAITEMENT PENDANT TRAITEMENT APRES ARRET DU TRAITEMENT Pendant les 14 jours précédant le début du traitement Avant chaque cure de traitement Toute les 8 semaines Tous les 2 à 3 mois Signature du consentement éclairé clinique et biologique X EXAMEN CLINIQUE Évaluation de la toxicité du traitement* X X (et 30 jours après la fin du traitement) X (jusqu’à 12 mois après la fin du traitement) TESTS BIOLOGIQUES Examen biologique standard X X X Dépistage hépatite B, C et VIH X Test de grossesse X X (et 30 jours après la fin du traitement) Marqueurs tumoraux X X EXAMEN PARACLINIQUE Scanner X X X Electrocardiogramme (ECG) X"
56,page_56,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 57 de 123 Les traitements de chimiothérapies et d’immunothérapies de ce p rotocole présentent des effets indésirables liés aux molécules utilisées. Ces effets sont inconstants et variables dans leur survenue et dans leur sévérité d’une personne à l’autre. Vous pouvez au cours de cette étude ressentir un ou plusieurs des effets i ndésirables décrits ci-dessous. Ils sont le plus souvent réversibles. Il peut exister des effets indésirables qui ne peuvent pas être prédits. Si vous présentez ces effets, ils seront pris en charge par votre médecin investigateur (le numéro de téléphone o ù vous pourrez le contacter sera noté en dernière page lors de la signature du consentement) qui pourra vous prescrire des médicaments adaptés pour diminuer ces effets indésirables et éventuellement diminuera les doses de chimiothérapies lors de votre proc hain traitement. N’essayez pas de traiter tout seul ces effets car certains médicaments peuvent être incompatibles avec les traitements que vous prenez dans le cadre de cette étude. Dans tous les cas, il est important que vous préveniez le médecin investigateur immédiatement si vous ressentez un effet qui vous semble anormal. N’oubliez pas de signaler également au médecin investigateur les traitements additionnels que vous auriez pu prendre. En cas d’urgence, contacter les services d’urgence médical e en téléphonant au 15. Compte tenu des informations disponibles, les effets indésirables les plus fréquents décrits liés aux différentes molécules de chimiothérapie et d’immunothérapie utilisées dans le cadre de ce protocole sont décrits ci -dessous. La ch imiothérapie est celle que vous recevriez (FOLFIRI, c’est -à-dire de l’irinotécan et du 5 -FU) si vous ne participez pas au protocole. Concernant l’immunothérapie elle donne essentiellement des manifestions auto -immunes4 qui sont d’évolution favorable sous traitements médicamenteux et souvent signe d’efficacité du traitement (forte stimulation du système immunitaire contre la tumeur). Traitement expérimental : Pour l’irinotécan : Les toxicités les plus fréquentes (≥ 1/10) sont :  Modification des résultats sanguins avec : une baisse des globules blancs (leucopénie et neutropénie), baisse des globules rouges (anémie), diminution des plaquettes (thrombopénie)  Troubles du métabolisme et de la nutrition : déficit de calcium (hypocalcémie), déficit en magnésium (hypomagnésémie), déshydratation, baisse de l’appétit, perte de poids  Vertiges  Diarrhée, nausées, vomissements, douleurs abdominales, inflammation des muqueuses buccales (stomatites)  Fatigue (asthénie)  Perte des cheveux (alopécie) Pour le 5-FU (5-fluorouracile) : Les toxicités les plus fréquentes (≥ 1/10) sont : - Stomatite (inflammation de la bouche), mucite (type d’aphtes), diarrhée - Baisse de l’appétit, nausées - Modification des résultats sanguins avec : diminution des plaquettes (thrombop énie), diminution des globules blancs (leucopénie et neutropénie) Pour le durvalumab et le trémélimumab : Les toxicités les plus fréquentes (≥ 1/10) sont : - Modification des résultats sanguins avec : baisse de l’hémoglobine dans le sang (anémie) - Troubles d u métabolisme et de la nutrition : déficit de sodium (hyponatrémie) - Fièvre, gonflement des pieds/chevilles/jambes (œdème périphérique), douleurs articulaires (arthralgie), fatigue (asthénie) - Diarrhée, constipation, nausées, vomissements, douleurs abdominal es - Hypothyroïdie 4 Manifestation au to-immune : maladie impliquant le système immunitaire de l'organisme qui est trop actif et peut alors provoquer une réaction inflammatoire dans certains organes (thyroïde, intestin…)."
57,page_57,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 58 de 123 - Démangeaisons (prurit), éruption cutanée (rash) - Toux 5. LES CONDITIONS D’ARRET DE TRAITEMENT Votre participation à cette recherche est strictement volontaire. Cela signifie que vous êtes libre de vous retirer de l’étude à tout moment, sans avoir d’explication à donner. Dans ce cas, vous devrez simplement en informer le médecin investigateur. Cela ne gênera en rien votre relation avec ce dernier et vous continuerez de bénéficier des meilleurs soins actuellement disponibles pour votre maladie. Le médecin investigateur en charge de votre suivi dans cette étude pourra également décider d’interrompre le traitement s’il en estime la nécessité : - en cas d’évolution de votre maladie - en cas d’altération de votre état général, - en cas de toxicité majeure qui ne permet plus de continuer le traitement, - en cas d’évènement grave ou imprévu nécessitant l’arrêt du traitement. 6. CONTRACEPTION Si vous êtes un homme ou une femme en âge de procréer, vous devrez utiliser deux moyens de contraception (i.e. c'est à dire une méthode de contraception pour vous et une pour votre partenaire) efficace durant toute la durée du traitement et pendant au moins 6 mois après la dernière dose du traitement. Il faut éviter toute grossesse pendant le traitement au vu du d anger potentiel pour le fœtus. Dans le cas où une grossesse inattendue survient, vous devez prévenir au plus vite votre médecin investigateur afin qu’il puisse prendre les précautions nécessaires pour le fœtus. 7. ALTERNATIVES MEDICALES Si vous décidez de ne pas participer à cet essai, la prise en charge standard vous sera proposée, et cela ne nuira pas à la qualité des soins qui vous seront délivrés. La prise en charge standard consiste à administrer en général une chimiothérapie par FOLFIRI seul (irinotéca n, 5-FU et acide folinique). D'autres produits qui ont montré une efficacité du même ordre dans cette situation peuvent dans certains cas être proposés à la discrétion de votre médecin. De plus, si vous participez à l'essai, vous pouvez à tout moment déc ider d'arrêter. Dans ce cas, la chimiothérapie standard la plus adaptée à votre cas vous sera proposée. 8. ASPECTS REGLEMENTAIRES ET ADMINISTRATIFS Protection des personnes Le promoteur de cette étude, la FFCD, a pris toutes les dispositions prévues par la loi sur la protection des participants (Code de la Santé Publique, titre II, livre 1er, relatif aux recherches médicales) et a souscrit une assurance en responsabilité civi le pour cette étude auprès de la société hospitalière d’assurances mutuelles (SHAM) sous le numéro de 137.681. Si vous estimez avoir subi un préjudice du fait de votre participation à l’étude, vous devez contacter votre médecin investigateur. Les modalité s de ce protocole ont été soumises à l’examen du Comité de Protection des Personnes (CPP) Nord - Ouest II, qui a pour mission de vérifier si les conditions requises pour votre protection et l’ensemble de vos droits ont été respectées. Ce comité a donné son a vis favorable le 16/04/2019. Les modalités de ce protocole ont été soumises à l’examen de l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) qui nous a donné l’autorisation le 27/11/2018. Du fait des contraintes liées au protocole, le Comité de Protection des Personnes a requis votre inscription auprès du fichier national des « Volontaires de Recherche Biomédicale » (VRB) en application de l’article L. 1121 -16 du code de la santé publique. Seul le médecin investigateur ser a habilité à vous inscrire dans ce fichier électronique dont l’accès est protégé par mot de passe électronique. Conformément aux recommandations du Plan Cancer (Mesure 5.1), ce document a été soumis pour relecture, avis et conseil au Comité de Patients pour la Recherche Clinique (CPRC) de la Ligue Nationale Contre le Cancer."
58,page_58,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 59 de 123 En cas d’arrêt prématuré de l’étude, le médecin investigateur vous en informera et vous communiquera les raisons éventuelles d’un tel arrêt. Toute information nouvelle survenant pendan t votre participation vous sera communiquée et un formulaire de consentement vous sera remis pour confirmer votre participation à l’étude. A l’issue de l’étude, vous pourrez, si vous le souhaitez, être informé(e) par le médecin investigateur, des résultats globaux de cette recherche lorsqu’ils seront disponibles. Les modalités d’informations sont décrites au bas de la page 8. 9. CONFIDENTIALITE Vos données personnelles recueillies au cours de la recherche clinique seront traitées de sorte que les résultats de la recherche soient analysés pour l'objectif de l'étude, et ce, à des fins de recherche scientifique. Le traitement informatisé des données nominatives est conforme au règlement européen 2016/679 du 27 avril 2016 et aux dispositions de la loi n 0 2004 -801 du 6 août 2004 relative à la protection des personnes physiques à l’égard des traitements de données à caractère personnel modifiant la loi n o 78-17 du 6 janvier 1978 relative à l'informatique , aux fichiers et aux libertés. Le Promoteur – la FFCD (7 boulevard jeanne d’Arc, 21000 Dijon) - est le responsable du traitement des données recueillies au cours de l'étude, qu’il traite de manière légale, équitable et transparente. La confidentialité sera garantie par le fait que seul le numéro attribué à votre r andomisation, figurera dans les analyses et les documents écrits et que votre nom n’apparaîtra jamais. Les informations pourront être contrôlées selon la réglementation en vigueur. Votre dossier médical et les données recueillies resteront strictement conf identiels et ne pourra être consulté que sous la responsabilité du médecin investigateur s’occupant de votre traitement ainsi que par les Autorités de Santé et par les personnes autorisées par le promoteur de la recherche (FFCD – Fédération Francophone de Cancérologie Digestive, Dijon). Les personnes mandatées par le promoteur sont soumises au secret professionnel. 10. UTILISATION DES DONNEES DE LA RECHERCHE Les résultats peuvent conduire à l’obtention de droits exclusifs reposant sur des découvertes liées à la recherche scientifique. Si vous acceptez de participer à cette recherche, vous ne recevrez aucune contrepartie financière. Dans l’éventualité où la FFC D (Fédération Francophone de Cancérologie Digestive), promoteur de l’étude, bénéficierait d’un financement lié à la valorisation de la recherche, il serait réinvesti dans la recherche contre le cancer dans le seul but d’en améliorer le traitement. Vos don nées cliniques seront conservées au minimum 15 ans après la fin de l’étude (sauf opposition de votre part en cas de retrait de consentement). Vos données personnelles seront transmises au Promoteur de l'étude ou à des personnes ou sociétés travaillant pour le Promoteur, en France ou à l'étranger. Ces données peuvent également être transmises aux Autorités de Santé et à d'autres entités que le Promoteur, dans des conditions assurant leur confidentialité. Vos données personnelles peuvent être transférées ver s un pays tiers ou une organisation internationale (i) où la Commission européenne a adopté une décision d'adéquation reconnaissant qu'elles garantissent un niveau de protection adéquat (ii) ou lorsque le Promoteur a mis en place des garanties appropriées vous permettant de disposer de droits opposables et de voies de droit effectives. 11. VOS DROITS Vous êtes libre d’accepter ou non de participer à cette étude. Si vous acceptez, vous pourrez vous en retirer quand vous le souhaiterez et sans avoir à vous justi fier. Conformément aux dispositions du règlement applicable, vous avez : - le droit d'accéder à vos données personnelles ou de demander leur rectification ou leur effacement garanti par l’article 39 et 40 en s’adressant à l’investigateur principal qui fera remonter l’information auprès du promoteur (droit à l’oubli). Ce retrait n’a pas d’incidence sur les activités menées et sur l’utilisation des données obtenues sur la base du consentement éclairé exprimé avant que celui -ci ne soit retiré. - le droit de faire une réclamation auprès d'une autorité de surveillance (CNIL) - le droit de demander la restriction dans le traitement de vos données ou de s'opposer à leur traitement, si ce dernier ne compromet pas gravement ou ne rends pas impossible la réalisation des ob jectifs de la recherche. Ces droits s’exercent auprès de l’investigateur ou de son représentant désigné qui vous suit dans le cadre de la recherche et qui connaît votre identité."
59,page_59,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 60 de 123 - le droit de récupérer l’ensemble des données vous concernant en vue de les tr ansmettre à un autre responsable de traitement (droit à la portabilité) Vous pouvez également contacter la Déléguée à la Protection des Données désignée par le Promoteur en la contactant par mail (marie.moreau@u -bourgogne.fr) ou par voie postale (FFCD, 7 boulevard Jeanne d’arc, 21000 Dijon). Votre refus de participer à cette étude n’aura aucun effet sur vos relations avec le médecin investigateur, ni sur la qualité des soins que vous aurez. De même, vos relations avec l’équipe médicale ne seront aucunement modifiées quelle que soit votre décision. Vous êtes invité(e) à discuter de votre éventuelle participation à cette étude avec vos proches et votre médecin traitant si vous le souhaitez. Votre acceptation et votre consentement écrit sont indispensables ava nt de décider du traitement qui vous sera donné. Vous pourrez, si vous le souhaitez, demander au médecin investigateur les résultats globaux à la fin de l’étude. Vous aurez la liberté de contacter le médecin investigateur pour connaitre les résultats de l’étude, par des modalités que vous aurez l’occasion d’évoquer ensemble lors de consultations prévues dans le cadre de cette étude, ou via les coordonnées présentes ci-dessous. Si vous avez des questions concernant cette étude, avant ou bien pendant l’étude, n’hésitez pas à les poser à votre médecin investigateur par téléphone quand vous le souhaitez ou bien lors de consultations ultérieures : Nom, prénom, service d e la personne à contacter dans le centre* : ................................ ................................ ................................ .. ................................ ................................ ................................ .. Téléphone : ................................ ................................ ...................... *à compléter par le médecin investigateur ayant recueilli le consentement du patient En cas d’urgence, contacter les services d’urgence médicale en téléphonant au 15. DATE DE REMISE DE L’INFORMATION PATIENT :  (Format : JJ/MM/AAAA) à …………………… MEDECIN INVESTIGATEUR QUI A PRESENTE LE CONSENTEMENT (Nom et Prénom) :……………… Signature"
60,page_60,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 61 de 123 FORMULAIRE DE RECUEIL DE CONSENTEMENT ECLAIRE POUR L ’ETUDE CLINIQUE (Fait en 2 exemplaires : un exemplaire est remis à la personne, l'autre est conservé par l’investigateur) PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TRÉMÉLIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GASTRIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE PHASE DE TOLERANCE N° EudraCT : 2018 -002014 -13 Le Docteur ……………… m’a proposé de participer au protocole de recherche sus -cité, promue par la Fédération Francophone de Cancérologie Digestive (FFCD) situé au 7 boulevard Jeanne d’arc, 21000 Dijon. J’ai reçu et j’ai lu la notice d’information. J’ai pu poser toutes les questions qui me se mblaient nécessaires et j’ai obtenu des réponses satisfaisantes. Le médecin investigateur m’a proposé de prendre le temps d’y réfléchir et tous mes droits m’ont été clairement expliqués. Je donne librement mon consentement pour participer à cette étude cl inique. Le protocole a obtenu l’avis favorable du Comité de Protection des Personnes Nord -Ouest II, le 16/04/2019 et l’autorisation de l’ANSM le 27/11/2018. J’accepte que les données enregistrées à l’occasion de cette étude puissent faire l’objet d’un tra itement informatisé de façon strictement anonyme selon les dispositions du Règlement européen 2016/679 du 27 avril 2016 et aux dispositions de la loi n 0 2004 -801 du 6 août 2004 relative à la protection des personnes physiques à l’égard des traitements de données à caractère personnel modifiant la loi n o 78-17 du 6 janvier 1978 relative à l'informatique , aux fichiers et aux libertés (article 40). J'ai noté les droits que j'ai sur mes données personnelles informatisées et décrits dans les exigences réglem entaires. Je peux exercer mes droits à tout moment auprès du médecin d'étude qui me suit dans le cadre de la recherche et qui est la seule personne qui connaît mon identité et qui contactera le promoteur de l'étude J'ai compris que les données médicales me concernant resteront confidentielles et ne pourront être consultées que par l'investigateur et ses collaborateurs par des personnes mandatées par le promoteur et astreintes au secret professionnel et par des personnes mandatées par les autorités sanitai res et judiciaires J’accepte que mes données soient partagées ou cédées en cas de collaboration de la FFCD avec un tiers (autre institution/organisme universitaire ou compagnie pharmaceutique). J’accepte que toutes recherches futures sur le cancer puissent être réalisées sur mes données. Je suis libre d’accepter ou de refuser ce traitement à tout moment sans avoir à me justifier et sans conséquence sur la suite de mon suivi médical. Je pourrai être pris(e) en charge si je le souhaite par la même éq uipe médicale. Tout autre traitement ou option thérapeutique pourra m’être proposé. J’ai également été informé(e) des risques et bénéfices éventuels de cette recherche et des autres traitements disponibles pour ma maladie. Mon consentement ne décharge en rien les organisateurs de la recherche et les investigateurs de leurs responsabilités et je conserve tous mes droits garantis par la loi. J'autorise le transfert de mes données de manière anonyme en dehors de l'Union européenne."
61,page_61,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 62 de 123 Je déclare avoir répondu à toutes les questions qui m'ont été posées à propos de mes antécédents médicaux et je m'engage à suivre toutes les consignes et instructions qui me seront données par l'équipe médicale et qui sont détaillées dans la notice d'information. Je suis bien af filié(e) à un régime de sécurité sociale ou à une assurance maladie. En l'absence d'autonomie de lecture et d'écriture de M, Mme (rayer la mention inutile) …………………………… la personne de confiance ci -dessous identifiée, atteste avoir personnellement et fidèlem ent lu au sujet la notice d'information et le présent formulaire de consentement, et recueilli son consentement et recueilli son accord pour signer ici en son nom. PATIENT OU PERSONNE DE CONFIANCE (nom et prénom du patient) :……………………………… à_______________ date de signature _________________ date de naissance du patient  (Format : MM/AAAA) Signature MEDECIN INVESTIGATEUR QUI A RECUEILLI LE CONSENTEMENT (nom et prénom) :……………… à________________ date de signature _________________ Signature NOTICE D’INFORMATION ET CONSENTEMENT DE L’ETUDE CLINIQUE PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE1 EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TREMELIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GASTRIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE N° EudraCT : 2018 -002014 -13 Promoteur : Fédération Francophone de Cancérologie Digestive (FFCD) : Faculté de Médecine, 7 Boulevard Jeanne d’Arc, BP 87900 21079 Dijon Cedex, France Tel: + 33 (0)3 80 66 80 13 - Fax: + 33 (0)3 80 38 18 41 Investigateur coordonnateur : Pr. David Tougeron, CHU de Poitiers (Fait en 2 exemplaires : Un remis au patient, l’autre conservé par l’investigateur.) Madame, Monsieur, Vous êtes actuellement suivi(e) pour un cancer de l’estomac et votre médecin vous a proposé de participer à l’étude PRODIGE 59 - (FFCD 1707) - DURIGAST dont le but est de comparer l’efficacité de 2 nouveaux traitements. Ces traitements combinent la chimiothérapie classiquement utilisée dans le cadre de votre maladie (FOLFIRI) avec une nouvelle méthode de traitement appelée l’immu nothérapie. L’immunothérapie a pour but de stimuler votre système immunitaire (les cellules de votre corps qui vous protège de certaines maladies) afin de pouvoir lutter contre la tumeur. Nous vous expliquerons ci -dessous les 2 schémas de traitements pré sents dans cette étude : - chimiothérapie par FOLFIRI (Irinotécan + 5 -fluorouracile (5 -FU) + acide folinique (LV)) et une immunothérapie (durvalumab) - chimiothérapie par FOLFIRI (Irinotécan + 5 -fluorouracile (5 -FU) + acide folinique (LV)) et une combina ison de 2 traitements d’immunothérapie (durvalumab + trémélimumab) Le but est de voir si 2 molécules différentes d’immunothérapie sont plus efficaces qu’une seule. Les associations de médicaments présentées ci -dessus ont été testés sur 11 patients lors d’ une étape préliminaire d’évaluation de la toxicité. Lors de cette étape, les informations relatives à la toxicité ont été transmises à l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) et à des médecins experts indépendants. Ceci a permis de conclure que les combinaisons de traitement utilisées dans l’étude 1 Etude randomisée : étude au cours de laquelle les participants sont répartis de façon aléatoire dans différents des groupes (dans DURIGAST il y a ainsi 2 groupes de traitement différent)."
62,page_62,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 63 de 123 ne présentent pas de toxicité significativement plus importante que d’autres associations déjà décrites pour le traitement de votre maladie. Votre participation à cette étude est strictement volontaire, vous êtes donc entièrement libre de décider si vous souhaitez ou non y participer. Avant de faire votre choix, prenez tout le temps qu’il vous faudra pour lire attentivement ce document. Son but est de vous informer sur l’intérê t de cette recherche, son déroulement, les bénéfices attendus, mais aussi les contraintes et les risques prévisibles. Vous pouvez lire ce document et en discuter avec une ou plusieurs personnes de votre entourage, une association de patients, votre médecin traitant si vous le souhaitez et bien sûr votre cancérologue. Votre médecin traitant, sera informé par votre médecin cancérologue de votre participation à cette étude avec un traitement combiné par chimiothérapie et immunothérapie. Si vous acceptez de pa rticiper à cette étude : - vous devez être affilié(e) à un régime de sécurité sociale ou être bénéficiaire d’un tel régime, - vous ne recevrez pas de rémunération, - vous ne pourrez pas participer en même temps à une autre étude s’intéressant au traitement de votre cancer. Si vous décidez de ne pas participer à cette étude : - cette décision vous appartient et vous ne serez nullement obligé de vous justifier, - cela n’affectera en rien la qualité de votre prise en charge, de même que vos relations avec l’é quipe soignante, - vous aurez les mêmes examens de surveillance et d’évaluation, avec une fréquence identique. OBJECTIF PRINCIPAL DE L’ETUDE : Si vous receviez un traitement en dehors de cette étude, votre médecin vous proposerait du FOLFIRI seul, qui est une combinaison de 2 molécules de chimiothérapie standard (5 -fluorouracile et irinotécan). Dans cette étude, le traitement est une combinaison de FOLFIRI (chimiothérapie classique utilisée dans le traitement de votre maladie) et de traitements d’immunoth érapie : durvalumab avec ou sans trémélimumab. Ces molécules d’immunothérapie2 ont récemment été développées et permettent de stimuler votre système immunitaire (vos cellules qui agissent contre les maladies comme les infections et les cancers, notamment l es lymphocytes T) pour lutter contre la tumeur. Des résultats récents montrent l’intérêt et l’efficacité importante de l’immunothérapie dans certains cancers de la peau (mélanome) et du poumon. En effet, l’immunothérapie stimule les cellules immunitaires q ue la tumeur avait réussi à inactiver. Les premiers résultats dans le cancer de l’estomac et de l’œsophage montrent une certaine efficacité de ces molécules utilisées seules, c’est pourquoi dans cette étude nous testons des molécules d’immunothérapie innovantes en combinaison à la chimiothérapie classique pour être encore plus efficace pour détruite votre tumeur. Nous allons comparer deux traitements combinés : chimiothérapie plus une immunothérapie (durvalumab) et chimiothérapie plus deux immunothérapies (durvalumab et trémélimumab). Ce sont deux immunothérapies avec des mécanismes d’action différents, et dans certains cancers deux immunothérapies sont plus efficaces qu’une seule mais cela n’est pas encore démontré dans les cancers de l’estomac et de l’œso phage. DEROULEMENT DE L’ETUDE : Examens préalables : Si vous acceptez de participer à cette étude, le médecin investigateur3 s’assurera que vous ne présentez pas de contre -indication au traitement proposé. Pour cela, il vous examinera et fera le bilan de votre maladie (examen clinique, prise de sang pour un bilan biologique complet, électrocardiogramme (ECG), scanner du thorax (poitrine), de l’abdomen (ventre) et du bassin pour évaluer l’extension de votre maladie). Ces examens sont standards dans le cadre de votre prise en charge et non spécifiques à l’étude. Déroulement de la stratégie de traitement dans le cadre de l’étude : Tirage au hasard du traitement Si vous acceptez de participer à cette étude, vous recevrez un des traitements suivants : 2 Immunothérapie : traitement qui stimule les cellules responsables de l’immunité pour combattre la tumeur 3 Médecin investigateur : méd ecin participant à la recherche clinique présentée et qui vous suivra tout au long de votre traitement"
63,page_63,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 64 de 123  Pour le bras4 A : la chimiothérapie FOLFIRI, toutes les 2 semaines, combinée à l’immunothérapie simple (durvalumab), toutes les 4 sema ines  Pour le bras4 B : la chimiothérapie FOLFIRI, toutes les 2 semaines, combinée à une bi -immunothérapie (durvalumab + trémélimumab), toutes les 4 semaines. Cette séquence sera réalisée pendant 4 mois, puis vous recevrez le même traitement que le bras A (FOLFIRI plus durvalumab) L’attribution du traitement sera faite par tirage au hasard informatique. Le tirage au hasard (appelé également « randomisation ») est une procédure habituelle au cours des essais cliniques. Il permet de constituer deux groupes de patients comparables et ainsi de pouvoir comparer de façon rigoureuse les effets des différents traitements entre ces deux groupes (bras A et B). A l’issue du tirage au hasard, votre médecin vous dira quel traitement vous a été attribué. Traitement de votre maladie Votre traitement se déroulera à raison d’une cure tous les 14 jours, comme dans la pratique standard avec le FOLFIRI, mais avec de l’immunothérapie en plus. Les médicaments de votre traitement vous seront tous administrés le même jour à l ’hôpital. Vous recevrez votre traitement tous les 14 jours tant qu’il sera efficace sur votre maladie et que vous le supportez bien. Le cas échéant celui -ci sera adapté pour que vous puissiez le tolérer convenablement (diminution de la dose de traitement) . Voici le déroulement des cures de traitement : Vous arriverez à l’hôpital et serez installé(e) soit dans un fauteuil soit dans un lit en fonction des habitudes de votre hôpital. Le système d’injection qui vous aura été installé sous la peau préalablem ent à l’étude (chambre implantable ou cathéter), sera désinfecté. Une prémédication sera effectuée afin de vous permettre de mieux tolérer les traitements qui vous seront administrés et éviter les réactions allergiques. Si vous êtes dans le groupe de pati ents qui recevront le traitement expérimental du bras A : L’infirmière fixera à votre chambre implantable, la perfusion qui délivrera le durvalumab (1500 mg) pendant 1 heure. Vous recevrez ce traitement 1 fois tous les 28 jours. Vous recevrez également t ous les 14 jours, l’irinotécan (180 mg/m²) en 2 heures, suivi par une perfusion d’acide folinique (400 mg/m²) pendant 2 heures, enfin du 5 -FU (400 mg/m²) pendant 10 minutes. Pour finir un diffuseur sera branché à votre chambre implantable. Ce diffuseur con tient une dose de 2400 mg/m² de 5 -FU qui sera diffusé pendant environ 46 heures. Si vous vous portez bien, vous pourrez sortir de l’hôpital avec votre diffuseur et une infirmière viendra le débrancher à votre domicile dès que la perfusion sera terminée. L’ équipe soignante vous donnera toutes les instructions nécessaires. Si vous êtes dans le groupe de patients qui recevront le traitement expérimental du bras B : L’infirmière fixera à votre chambre implantable, la perfusion qui délivrera le durvalumab (150 0 mg) pendant 1 heure, suivi par le trémélimumab (75 mg) pendant 1 heure. Vous recevrez ce traitement 1 fois tous les 28 jours. Vous recevrez également tous les 14 jours, l’irinotécan (180 mg/m²) en 2 heures, suivi par une perfusion d’acide folinique (400 mg/m²) pendant 2 heures, enfin du 5 -FU (400 mg/m²) pendant 10 minutes. Pour finir un diffuseur sera branché à votre chambre implantable. Ce diffuseur contient une dose de 2400 mg/m² de 5 -FU qui sera diffusé pendant environ 46 heures. Si vous vous portez b ien, vous pourrez sortir de l’hôpital avec votre diffuseur et une infirmière viendra le débrancher à votre domicile dès que la perfusion sera terminée. L’équipe soignante vous donnera toutes les instructions nécessaires. DUREE DE L’ETUDE Quatre -vingt -quatorze (94) patients devront être traités dans le cadre de cette étude. Cinquante centres investigateurs en France participeront. La période pendant laquelle les patients seront inclus dans cette étude est d’environ 2 ans (durée estimée néce ssaire pour identifier 94 patients compatibles avec cette étude) et l’étude durera environ 3 ans dans sa totalité (délai entre 1er patient inclus et le résultat attendu de l’étude). 4 Bras : c’est un groupe de patients participant à l’étude qui vont tous recevoir le même traitement"
64,page_64,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 65 de 123 Vous serez suivi(e) tout au long de votre traitement avec des examens biologiques avant chaque cure de chimiothérapie et éventuellement entre les cures si nécessaires, qui permettront d’évaluer la tolérance des traitements. De même un scanner sera réalisé tous les 2 mois afin d’évaluer l’efficacité du traitement. Nous vous demanderons également de compléter un questionnaire de qualité de vie (durée de remplissage environ 10 minutes) tous les 2 mois pendant toute la durée de votre participation à l’étude. Après arrêt du traitement proposé dans le cadre de ce protocole, vous continuerez d’être suivi(e) par votre médecin et vous pourrez, si votre médecin le juge nécessaire, recevoir un autre traitement. Vous continuerez donc à être suivi(e) au minimum tous les 3 mois en consultation et avec un scanner si votre médecin le juge nécessaire. CALENDRIER DES EXAMENS ET DU SUIVI Les résultats des examens médicaux préalables à l’entrée à l’étude vous seront communiqués directement ou indirectement par le médecin i nvestigateur (conforméme nt à l’article L, 1121 -11 CSP). * ces évaluations vous seront expliquées et réalisées par votre médecin ** ces questionnaires - très courts – portant sur votre mobilité et votre alimentation/appétit seront à remplir par vos soins LES BENEFICES ATTENDUS : Même si le médecin investigateur pense que ces traitements vont agir sur votre maladie, les effets sont variables d’un patient à l’autre, et par conséquent nous ne pouvons pas vous garantir un bénéfice pour votre santé. Suite aux précédentes études, l’association de ces médicaments a donné de bons résultats et nous espérons que ce protocole permettra de stabiliser votre maladie plus longtemps tout en limitant les toxicités liées au traitement. Quoiqu’il en soit le traitement réalisé dans cette étude ( FOLFIRI plus immunothérapie) ne pourra en aucun cas être moins efficace que le traitement standard habituellement proposé en dehors de cette étude (FOLFIRI seul). LES RISQUES PREVISIBLES : Il est important de savoir que tout traitement quel qu’il soit, peut engendrer des effets indésirables. C’est également le cas des thérapies testées ici. Les traitements de chimiothérapies et d’immunothérapies de ce protocole présentent des effets indésirables liés aux molécules utilisées. Ces effets sont inconstants e t variables dans leur survenue et dans leur sévérité d’une personne à l’autre. Vous pouvez au cours de cette étude ressentir un ou plusieurs des effets indésirables décrits AVANT TRAITEMENT PENDANT TRAITEMENT APRES ARRET DU TRAITEMENT Pendant les 14 jours précédant le début du traitement Avant chaque cure de traitement Toute les 8 semaines Tous les 2 à 3 mois Signature du consentement éclairé clinique et biologique X EXAMEN CLINIQUE Évaluation de la toxicité du traitement* X X (et 30 jours après la fin du traitement) X (jusqu’à 12 mois après la fin du traitement) 2 questionnaires de qualité de vie** X X X TESTS BIOLOGIQUES Examen biologique standard X X X Dépistage hépatite B, C et VIH X Test de grossesse X X (et 30 jours après la fin du traitement) Marqueurs tumoraux X X EXAMEN PARACLINIQUE Scanner X X X Electrocardiogramme (ECG) X"
65,page_65,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 66 de 123 ci-dessous. Ils sont le plus souvent réversibles. Il peut exister des effets indési rables qui ne peuvent pas être prédits. Si vous présentez ces effets, ils seront pris en charge par votre médecin investigateur (le numéro de téléphone où vous pourrez le contacter sera noté en dernière page lors de la signature du consentement) qui pourra vous prescrire des médicaments adaptés pour diminuer ces effets indésirables et éventuellement diminuera les doses de chimiothérapies lors de votre prochain traitement. N’essayez pas de traiter tout seul ces effets car certains médicaments peuvent être in compatibles avec les traitements que vous prenez dans le cadre de cette étude. Dans tous les cas, il est important que vous préveniez le médecin investigateur immédiatement si vous ressentez un effet qui vous semble anormal. N’oubliez pas de signaler éga lement au médecin investigateur les traitements additionnels que vous auriez pu prendre. En cas d’urgence, contactez les services d’urgence médicale en téléphonant au 15. Compte tenu des informations disponibles, les effets indésirables les plus fréquents décrits liés aux différentes molécules de chimiothérapie et d’immunothérapie utilisées dans le cadre de ce protocole sont décrits ci -dessous. La chimiothérapie est celle que vous recevriez (FOLFIRI, c’est -à-dire de l’irinotécan et du 5 -FU) si vous ne participez pas au protocole. Concernant l’immunothérapie elle donne essentiellement des manifestions auto -immunes5 qui sont d’évolution favorable sous traitements médicamenteux et souvent signe d’efficacité du traitement (forte stimulation du système immunitai re contre la tumeur). Traitement expérimental : Pour l’irinotécan : Les toxicités les plus fréquentes (≥ 1/10) sont :  Modification des résultats sanguins avec : une baisse des globules blancs (leucopénie et neutropénie), baisse des globules rouges (aném ie), diminution des plaquettes (thrombopénie)  Troubles du métabolisme et de la nutrition : déficit de calcium (hypocalcémie), déficit en magnésium (hypomagnèsémie), déshydratation, baisse de l’appétit, perte de poids  Vertiges  Diarrhée, nausées, vomissement s, douleurs abdominales, inflammation des muqueuses buccales (stomatites)  Fatigue (asthénie)  Perte des cheveux (alopécie) Pour le 5 -FU (5-fluorouracile) : Les toxicités les plus fréquentes (≥ 1/10) sont : - Stomatite (inflammation de la bouche), mucite (type d’aphtes), diarrhée - Baisse de l’appétit, nausées - Modification des résultats sanguins avec : diminution des plaquettes (thrombopénie), diminution des globules blancs (leucopénie et neutropénie) Pour le durvalumab et le trémélimumab : Les toxicités les plus fréquentes (≥ 1/10) sont : - Modification des résultats sanguins avec : baisse de l’hémoglobine dans le sang (anémie) - Troubles du métabolisme et de la nutrition : déficit de sodium (hyponatrémie) - Fièvre, gonflement des pieds/chevilles/jambes (œdème périphérique), douleurs articulaires (arthralgie), fatigue (asthénie) - Diarrhée, constipation, nausées, vomissements, douleurs abdominales - Hypothyroïdie - Démangeaisons (prurit), éruption cutanée (rash) - Toux LES CONDITIONS D’ARRET DE TRAITEMENT 5 Manifestation auto -immune : maladie impliquant le système immunitaire de l'organisme qui est trop actif et peut alors provoquer une réaction inflammatoire dans certains organes (thyroïde, intestin…)."
66,page_66,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 67 de 123 Votre partic ipation à cette recherche est strictement volontaire. Cela signifie que vous êtes libre de vous retirer de l’étude à tout moment, sans avoir d’explication à donner. Dans ce cas, vous devrez simplement en informer le médecin investigateur. Cela ne gênera en rien votre relation avec ce dernier et vous continuerez de bénéficier des meilleurs soins actuellement disponibles pour votre maladie. Le médecin investigateur en charge de votre suivi dans cette étude pourra également décider d’interrompre le traitement s’il en estime la nécessité : - en cas d’évolution de votre maladie - en cas d’altération de votre état général, - en cas de toxicité majeure qui ne permet plus de continuer le traitement, - en cas d’évènement grave ou imprévu nécessitant l’arrêt du traitement. CONTRACEPTION Si vous êtes un homme ou une femme en âge de procréer, vous devrez utiliser deux moyens de contraception (i.e. c'est à dire une méthode de contraception pour vous et une pour votre partenaire) efficace durant toute la durée du traitement et pendant au moins 6 mois après la dernière dose du traitement. Il faut éviter toute grossesse pendant le traitement au vu du danger potentiel pour le fœtus. Dans le cas où une grosse sse inattendue survient, vous devez prévenir au plus vite votre médecin investigateur afin qu’il puisse prendre les précautions nécessaires pour le fœtus. ALTERNATIVES MEDICALES Si vous décidez de ne pas participer à cet essai, la prise en charge standard vous sera proposée, et cela ne nuira pas à la qualité des soins qui vous seront délivrés. La prise en charge standard consiste à administrer en général une chimiothérapie par FOLFIRI seul (irinotécan, 5-FU et acide folinique). D'autres produits qui ont montré une efficacité du même ordre dans cette situation peuvent dans certains cas être proposés à la discrétion de votre médecin. De plus, si vous participez à l'essai, vous pouvez à tout moment décider d'arrêter. Dans ce cas, la chimiothérapie standard la plus adaptée à votre cas vous sera proposée. ASPECTS REGLEMENTAIRES ET ADMINISTRATIFS Protection des personnes Le promoteur de cette étude, la FFCD, a pris toutes les dispositions prévues par la loi sur la protection des participants (Code de la Sa nté Publique, titre II, livre 1er, relatif aux recherches médicales) et a souscrit une assurance en responsabilité civile pour cette étude auprès de la société hospitalière d’assurances mutuelles (SHAM) sous le numéro de 137.681. Si vous estimez avoir subi un préjudice du fait de votre participation à l’étude, vous devez contacter votre médecin investigateur. Les modalités de ce protocole ont été soumises à l’examen du Comité de Protection des Personnes (CPP) Nord - Ouest II, qui a pour mission de vérifier s i les conditions requises pour votre protection et l’ensemble de vos droits ont été respectées. Ce comité a donné son avis favorable le 16/04/2019. Du fait des contraintes liées au protocole, le Comité de Protection des Personnes a requis votre inscription auprès du fichier national des « Volontaires de Recherche Biomédicale » (VRB) en application de l’article L. 1121 -16 du code de la santé publique. Seul le médecin investigateur sera habilité à vous inscrire dans ce fichier électronique dont l’accès est pr otégé par mot de passe électronique. Conformément aux recommandations du Plan Cancer (Mesure 5.1), ce document a été soumis pour relecture, avis et conseil au Comité de Patients pour la Recherche Clinique (CPRC) de la Ligue Nationale Contre le Cancer. En c as d’arrêt prématuré de l’étude, le médecin investigateur vous en informera et vous communiquera les raisons éventuelles d’un tel arrêt. Toute information nouvelle survenant pendant votre participation vous sera communiquée et un formulaire de consentement vous sera remis pour confirmer votre participation à l’étude. A l’issue de l’étude, vous pourrez, si vous le souhaitez, être informé(e) par le médecin investigateur, des résultats globaux de cette recherche lorsqu’ils seront disponibles. Les modalités d’i nformations sont décrites au bas de la page 7. CONFIDENTIALITE Vos données personnelles recueillies au cours de la recherche clinique seront traitées de sorte que les résultats de la recherche soient analysés pour l'objectif de l'étude, et ce, à des fins de recherche scientifique. Le traitement"
67,page_67,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 68 de 123 informatisé des données nominatives est conforme au règlement européen 2016/679 du 27 avril 2016 et aux dispositions de la loi n 0 2004 -801 du 6 août 2004 relative à la protection des personnes physiques à l’égard des traitements de données à caractère personnel modifiant la loi n o 78-17 du 6 janvier 1978 relative à l'informatique , aux fichiers et aux libertés. Le Promoteur – la FFCD (7 boulevard jeanne d’Arc, 21000 Dijon) - est le responsable du traitement des données recueillies au cours de l'étude, qu’il traite de manière lég ale, équitable et transparente. La confidentialité sera garantie par le fait que seul le numéro attribué à votre randomisation, figurera dans les analyses et les documents écrits et que votre nom n’apparaîtra jamais. Les informations pourront être contrô lées selon la réglementation en vigueur. Votre dossier médical et les données recueillies resteront strictement confidentiels et ne pourront être consultés que sous la responsabilité du médecin investigateur s’occupant de votre traitement ainsi que par le s Autorités de Santé et par les personnes autorisées par le promoteur de la recherche (FFCD – Fédération Francophone de Cancérologie Digestive, Dijon). Les personnes mandatées par le promoteur sont soumises au secret professionnel. UTILISATION DES DONNEES DE LA RECHERCHE Les résultats peuvent conduire à l’obtention de droits exclusifs reposant sur des découvertes liées à la recherche scientifique. Si vous acceptez de participer à cette recherche, vous ne recevrez aucune contrepartie financière. Dans l’éven tualité où la FFCD (Fédération Francophone de Cancérologie Digestive), promoteur de l’étude, bénéficierait d’un financement lié à la valorisation de la recherche, il serait réinvesti dans la recherche contre le cancer dans le seul but d’en améliorer le tra itement. Vos données cliniques seront conservées au minimum 15 ans après la fin de l’étude (sauf opposition de votre part en cas de retrait de consentement). Vos données personnelles seront transmises au Promoteur de l'étude ou à des personnes ou société s travaillant pour le Promoteur, en France ou à l'étranger. Ces données peuvent également être transmises aux Autorités de Santé et à d'autres entités que le Promoteur, dans des conditions assurant leur confidentialité. Vos données personnelles peuvent êtr e transférées vers un pays tiers ou une organisation internationale (i) où la Commission européenne a adopté une décision d'adéquation reconnaissant qu'elles garantissent un niveau de protection adéquat (ii) ou lorsque le Promoteur a mis en place des garan ties appropriées vous permettant de disposer de droits opposables et de voies de droit effectives. VOS DROITS Vous êtes libre d’accepter ou non de participer à cette étude. Si vous acceptez, vous pourrez vous en retirer quand vous le souhaiterez et sans avoir à vous justifier. Conformément aux dispositions du règlement applicable, vous avez : - le droit d'accéder à vos données personnelles ou de demander leur rectification ou leur effacement garanti par l’article 39 et 40 en s’adressant à l’investigateur principal qui fera remonter l’information auprès du promoteur (droit à l’oubli). Ce retrait n’a pas d’incidence sur les activités menées et sur l’utilisation des données obtenues sur la base du consentement éclairé exprimé avant que celui -ci ne soit retiré . - le droit de faire une réclamation auprès d'une autorité de surveillance (CNIL) - le droit de demander la restriction dans le traitement de vos données ou de s'opposer à leur traitement, si ce dernier ne compromets pas gravement ou ne rends pas impossible l a réalisation des objectifs de la recherche. Ces droits s’exercent auprès de l’investigateur ou de son représentant désigné qui vous suit dans le cadre de la recherche et qui connaît votre identité. - le droit de récupérer l’ensemble des données vous concern ant en vue de les transmettre à un autre responsable de traitement (droit à la portabilité) Vous pouvez également contacter la Déléguée à la Protection des Données désignée par le Promoteur en la contactant par mail (marie.moreau@u -bourgogne.fr) ou par voie postale (FFCD, 7 boulevard Jeanne d’arc, 21000 Dijon). Votre refus de participer à cette étude n’aura aucun effet sur vos relations avec le médecin investigateur, ni sur la qualité des soins que vous aurez. De même, vos relations avec l’équipe médical e ne seront aucunement modifiées quelle que soit votre décision. Vous êtes invité(e) à discuter de votre éventuelle participation à cette étude avec vos proches et votre médecin traitant si vous le souhaitez."
68,page_68,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 69 de 123 Votre acceptation et votre consentement écrit s ont indispensables avant de décider du traitement qui vous sera donné. Vous pourrez, si vous le souhaitez, demander au médecin investigateur les résultats globaux à la fin de l’étude. Vous aurez la liberté de contacter le médecin investigateur pour connait re les résultats de l’étude, par des modalités que vous aurez l’occasion d’évoquer ensemble lors de consultations prévues dans le cadre de cette étude, ou via les coordonnées présentes ci -dessous. Si vous avez des questions concernant cette étude, avant ou bien pendant l’étude, n’hésitez pas à les poser à votre médecin investigateur par téléphone quand vous le souhaitez ou bien lors de consultations ultérieures : Nom, prénom, service de la personne à contacter dans le centre* : ................................ ................................ ................................ .. ................................ ................................ ................................ .. Téléphone : ................................ ................................ ...................... *à compl éter par la personne ayant recueilli le consentement du patient En cas d’urgence, contacter les services d’urgence médicale en téléphonant au 15. REMISE DE L’INFORMATION PATIENT : Date : (Format : JJ/MM/AAAA) à……….……………………. MEDECIN INVEST IGATEUR QUI A PRESENTE LE CONSENTEMENT (Nom et Prénom) :……………………..…… Signature FORMULAIRE DE RECUEIL DE CONSENTEMENT ECLAIRE POUR L ’ETUDE CLINIQUE (Fait en 2 exemplaires : un exemplaire est remis à la personne, l'autre est conservé par l’investigateur) PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TRÉMÉLIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GAST RIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE N° EudraCT : 2018 -002014 -13 Le Docteur ……………… m’a proposé de participer au protocole de recherche sus -cité, promue par la Fédération Francophone de Cancérologie Digestive (FFCD) situé au 7 boulevard Jeanne d’arc, 21000 Dijon. J’ai reçu et j’ai lu la notice d’information. J’ai pu poser toutes les questions qui me semblaient nécessaires et j’ai obtenu des réponses satisfaisantes. Le médecin investigateur m’a proposé de prendre le temps d’y réfléchir et tous m es droits m’ont été clairement expliqués Je donne librement mon consentement pour participer à cette étude clinique. Le protocole a obtenu l’avis favorable du Comité de Protection des Personnes Nord -Ouest II, le 16/04/2019 et l’autorisation de l’ANSM le 2 7/11/2018. J’accepte que les données enregistrées à l’occasion de cette étude puissent faire l’objet d’un traitement informatisé de faço n strictement anonyme selon les dispositions du Règlement européen 2016/679 du 27 avril 2016 et aux dispositions de la loi n° 2004 -801 du 6 août 2004 relative à la protection des personnes physiques à l’égard des traitements de données à caractère personnel modifiant la loi n o 78-17 du 6 janvier 1978 relative à l'informatique , aux fichiers et aux libertés (article 40). J'ai noté les droits que j'ai sur mes données personnelles informatisées et décrits dans les exigences réglementaires. Je peu x exercer mes droits à tout moment auprès du médecin d'étude qui me suit dans le cadre de la recherche et qui est la seule personne qui connaît mon identité et qui contactera le promoteur de l'étude. J'ai compris que les données médicales me concernant resteront confidentielles et ne pourront être consultées que par l'investigateur et ses collaborateurs par des personnes mandatées pa r le promoteur et astreintes au secret professionnel et par des personnes mandatées par les autorités sanitaires et judiciaires."
69,page_69,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 70 de 123 J’accepte que mes données soient partagées ou cédées en cas de collaboration de la FFCD avec un tiers (autre institution/organ isme universitaire ou compagnie pharmaceutique). J’accepte que toutes recherches futures sur le cancer puissent être réalisées sur mes données. Je suis libre d’accepter ou de refuser ce traitement à tout moment sans avoir à me justifier et sans conséque nce sur la suite de mon suivi médical. Je pourrai être pris(e) en charge si je le souhaite par la même équipe médicale. Tout autre traitement ou option thérapeutique pourra m’être proposé. J’ai également été informé(e) des risques et bénéfices éventuels d e cette recherche et des autres traitements disponibles pour ma maladie. Mon consentement ne décharge en rien les organisateurs de la recherche et les investigateurs de leurs responsabilités et je conserve tous mes droits garantis par la loi. J'autorise le transfert de mes données de manière anonyme en dehors de l'Union européenne. Je déclare avoir répondu à toutes les questions qui m'ont été posées à propos de mes antécédents médicaux et je m'engage à suivre toutes les consignes et instructions qui me s eront données par l'équipe médicale et qui sont détaillées dans la notice d'information. Je suis bien affilié(e) à un régime de sécurité sociale ou à une assurance maladie. En l'absence d'autonomie de lecture et d'écriture de M, Mme (rayer la mention inu tile) …………………………… la personne de confiance ci -dessous identifiée, atteste avoir personnellement et fidèlement lu au sujet la notice d'information et le présent formulaire de consentement, et recueilli son consentement et recueilli son accord pour signer ici en son nom. PATIENT OU PERSONNE DE CONFIANCE (nom et prénom) :……………………………… à_______________ date de signature_________________ date de naissance du patient  (Format : MM/AAAA) Signature MEDECIN INVESTIGATEUR QUI A RECUEILLI LE CONSENTEMENT (nom et prénom) :……………… à________________ date de signature _________________ Signature"
70,page_70,"PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 71 de 123 NOTICE D’INFORMATION ET CONSENTEMENT DE L’ETUDE BIOLOGIQUE PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE10 EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TREMELIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GASTRIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE N° EudraCT : 2018 -002014 -13 Promoteur : Fédération Francophone de Cancérologie Digestive (FFCD) : Faculté de Médecine, 7 Boulevard Jeanne d’Arc, BP 87900 21079 Dijon Cedex, France Tel: + 33 (0)3 80 66 80 13 - Fax: + 33 (0)3 80 38 18 41 Investigateur coordonnateur : Pr. David T ougeron, CHU de Poitiers (Fait en 2 exemplaires : Un remis au patient, l’autre conservé par l’investigateur.) Une étude biologique11 associée est mise en place en parallèle de l’étude clinique PRODIGE 59 - (FFCD 1707) - DURIGAST. Cette étude biologique est optionnelle et elle vous est décrite dans même document. Vous pouvez avoir recours à l’avis de vos proches, une personne de confia nce ou de votre médecin traitant pour lire cette note d’information et vous aider dans votre prise de décision. DESCRIPTION DE LA RECHERCHE BIOLOGIQUE COMPLEMENTAIRE SUR ECHANTILLONS DE SANG, DE TUMEUR ET DE SELLES Actuellement, les facteurs permettant de prédire l’efficacité de l’immunothérapie sont peu connus dans les cancers de l’estomac ou l’œsophage. La détermination de certaines caractéristiques de votre maladie qui peuvent être détectée dans la tumeur ou dans votre sang est d’un intérêt scientifique important pour mieux comprendre comment fonctionnent ces traitements et permettre d’identifier à l’avance les patients chez qui ces traitements vont le mieux fonctionner. Cette étude est non invasive12 puisqu’elle s’effectue sur des échantillons sanguins d éjà demandés dans le cadre du suivi de votre maladie, de même que les prélèvements initiaux de votre tumeur (pas de nouvelle biopsie13 nécessaire). Ainsi, certains facteurs seront recherchés au niveau de l’ADN tumoral présent dans votre sang circulant (les tumeurs libèrent de l’ADN que l’on peut analyser) et également directement sur l’ADN des cellules de votre tumeur. Par ailleurs, des études scientifiques suggèrent que le microbiote intestinal14 pourrait être impliqué également dans la manière dont votre o rganisme réagit au traitement. Ceci pouvant modifier l’efficacité et la toxicité du traitement. C’est pourquoi une analyse de vos selles est également prévue dans le cadre de ce protocole, et ce, afin de comprendre comment prédire et améliorer l’efficacité du traitement de votre maladie. Les échantillons biologiques qui vous seront prélevés : Si vous acceptez de participer à cette recherche biologique, et afin d’effectuer les différentes analyses prévues, des prélèvements seront effectués : - Les échantillo ns de sang seront récoltés dans le cadre de votre suivi par l’équipe médicale : 10 Etude randomisée : étude au cours de laquelle les participants sont répartis de façon aléatoire dans différents des groupes (dans DURIGAST il y a ainsi 2 groupes de traitement différent). 11 Etude biologique : étude avec pour but d’étudier les caractéristiques de la maladie par le prélèvement d’échantillons de sang ou bien de tumeur avec le plus souvent po ur objectif de trouver des facteurs qui permettraient de prédire si le traitement va fonctionner ou pas 12 Etude non -invasive : une étude non -invasive ne nécessite pas d’effraction de la peau autre que pour prélever du sang comme dans la prise en charge sta ndard. Aucune hospitalisation supplémentaire n’est donc à prévoir. 13 Biopsie : prélèvement d'un fragment de tumeur. 14 Microbiote intestinal : ce sont les bactéries présentent dans votre intestin."
71,page_71,"PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 72 de 123 o Une prise de sang avant le début de votre traitement. Ce prélèvement sera réalisé en même temps que les prises de sang réalisées pour le bilan avant votre inclusion dans l’étu de clinique (pas de prélèvement supplémentaire), et sera d’un volume de 17 mL (2 tubes de 8.5 mL). o Une prise de sang à 4 semaines (juste avant la 3ème cure de FOLFIRI) (ce prélèvement peut être fait au moment du branchement de votre chimiothérapie sur vot re chambre implantable pour éviter une prise de sang supplémentaire), et sera d’un volume de 17 mL (2 tubes de 8.5 mL) o Une prise de sang avant le début de votre prochain traitement, et sera d’un volume de 17 mL (2 tubes de 8.5 mL), dans le cas où le traite ment prévu dans le cadre de cette étude n’est plus adapté à votre situation. - Les échantillons de tumeurs o Un échantillon de votre tumeur, qui, a soit été prélevé par le chirurgien lors de la chirurgie initiale de votre cancer, soit lors d’une biopsie au moment où votre maladie a été diagnostiquée, sera également récupéré auprès du laboratoire pour analyse. - Les échantillons de selles seront à prélever par vos soins. Toute la procédure de recueil des échantillons de selles vous sera expliquée et détaillée d ans un kit fourni par votre médecin. Vous pourrez le réaliser tranquillement chez vous. L’envoi des selles pourra se réaliser par la poste via une enveloppe préaffranchie. o Un prélèvement de selle à réaliser dans les 5 jours avant le début du traitement. o Un prélèvement de selle à réaliser dans les 5 jours précédant l’évaluation de la réponse de votre traitement (à 8 semaines après le début du traitement). CALENDRIER DE PRELEVEMENT D’ECHANTILLONS BIOLOGIQUE * les échantillons de selles pourront être prélevés à la maison à l’aide d’une notice explicative qui sera donnée par votre médecin. Recueil des échantillons biologiques et gestion des données des analyses et des échantillons : Les échantillons sanguins et de tumeur seront manipulés et conservés dans une institution appelée Centre de Ressources Biologiques (CRB) - EPIGENETEC, en accord avec toutes les lois en vigueur. Ce CRB est situé à Paris (Laboratoire de toxicologie moléculai re – 45, rue des Saints Pères – 75006 PARIS), actuellement sous la responsabilité du Pr Pierre Laurent -Puig. Les échantillons de selles seront manipulés et conservés au Laboratoire d'analyse des microbiotes, Equipe microbiote intestinal et immunité, INSE RM U1157 / UMR CNRS 7203, Université Pierre et Marie Curie, 27 rue de Chaligny, 75012 Paris, France sous la responsabilité du Pr Harry Sokol. Les prélèvements ne seront utilisés que dans le cadre de cette étude et ensuite détruits après analyses. Particip ation volontaire Votre participation au projet de recherche sur les matériels biologiques est entièrement volontaire et vous aurez suffisamment de temps pour décider si vous voulez y participer ou non. Vous êtes libre de décider à AVANT TRAITEMENT PENDANT TRAITEMENT Pendant les 14 jours précédant le début du traitement Avant chaque cure de traitement A 8 semaines Signature du consentement biologique X Échantillons de sang (2 tubes par échantillon) X X Échantillon de selles* X (dans les 5 jours avant la première cure) X (dans les 5 jours avant la première évaluation)"
72,page_72,"PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 73 de 123 tout moment de ne plus participer au projet de recherche sur les matériels biologiques sans donner aucune raison. Votre retrait de ce projet n’affectera aucunement votre participation à l’essai clinique principal, ni vos relations avec votre médecin ou le personnel hospitalier. En cas de retrait, vos données ne seront pas (ou plus) utilisées dans quelque analyse que ce soit, à moins que celle -ci n’ait déjà été terminée avant votre retrait. Seules les données accumulées jusqu’à ce moment -là seront conservées pour la recherche et l’analyse. Tous les matériels non utilisés seront détruits. Au terme de l’étude biologique, vous pourrez demander à votre médecin les résultats globaux de cette recherche biologique si vous le souhaitez ASPECTS REGLEMENTAIRES ET ADMINISTRATIFS Protection des personnes Le promoteur de cette étude, la FFCD, a pris toutes les dispositions prévues par la loi sur la protection des participants (Code de la Santé Publique, titre II, livre 1er, relatif aux recherches médicales) et a souscrit une assuran ce en responsabilité civile pour cette étude auprès de la société hospitalière d’assurances mutuelles (SHAM) sous le numéro de 137.681. Si vous estimez avoir subi un préjudice du fait de votre participation à l’étude, vous devez contacter votre médecin inv estigateur. Les modalités de prises d’informations sont décrites en page 4 du présent document. Les modalités de cette recherche biologique ont été soumises à l’examen du Comité de Protection des Personnes (CPP) Nord -Ouest II, qui a pour mission de vérifi er si les conditions requises pour votre protection et l’ensemble de vos droits ont été respectées. Ce comité a donné son avis favorable le 16/04/2018. Du fait des contraintes liées au protocole, le Comité de Protection des Personnes a requis votre inscrip tion auprès du fichier national des « Volontaires de Recherche Biomédicale » (VRB) en application de l’article L. 1121 -16 du code de la santé publique. Seul le médecin investigateur sera habilité à vous inscrire dans ce fichier électronique dont l’accès es t protégé par mot de passe électronique. CONFIDENTIALITE Vos données personnelles recueillies au cours de la recherche clinique seront traitées de sorte que les résultats de la recherche soient analysés pour l'objectif de l'étude, et ce, à des fins de rec herche scientifique. Le traitement informatisé des données nominatives est conforme au règlement européen 2016/679 du 27 avril 2016 et aux dispositions de la loi n 0 2004 -801 du 6 août 2004 relative à la protection des personnes physiques à l’égard des traitements de données à caractère personnel modifiant la loi n o 78-17 du 6 janvier 1978 relative à l'informatique , aux fichiers et aux libertés. Le Promoteur – la FFCD (7 boulevard jeanne d’Arc, 21000 Dijon) - est le responsable du traitement des données recueillies au cours de l'étude, qu’il traite de manière légale, équitable et transparente. La confidentialité sera garantie par le fait que seul le numéro attribué à votre randomisation, figurera dans les analyses et les documents écrits et que votre nom n’apparaîtra jamais. Les informations pourront être contrôlées selon la réglementation en vigueur. Votre dossier médical et les données recueillies resteront stricte ment confidentiels et ne pourra être consulté que sous la responsabilité du médecin investigateur s’occupant de votre traitement ainsi que par les Autorités de Santé et par les personnes autorisées par le promoteur de la recherche (FFCD – Fédération Franco phone de Cancérologie Digestive, Dijon). Les personnes mandatées par le promoteur sont soumises au secret professionnel. VOS DROITS Vous êtes libre d’accepter ou non de participer à cette étude biologique. Si vous acceptez, vous pourrez vous en retirer q uand vous le souhaiterez et sans avoir à vous justifier. Conformément aux dispositions du règlement applicable, vous avez : - le droit d'accéder à vos données personnelles ou de demander leur rectification ou leur effacement garanti par l’article 39 et 40 en s’adressant à l’investigateur principal qui fera remonter l’information auprès du promoteur (droit à l’oubli). Ce retrait n’a pas d’incidence sur les activités menées et sur l’utilisation des données obtenues sur la base du consentement éclairé exprimé av ant que celui -ci ne soit retiré. - le droit de faire une réclamation auprès d'une autorité de surveillance (CNIL)"
73,page_73,"PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 74 de 123 - le droit de demander la restriction dans le traitement de vos données ou de s'opposer à leur traitement, si ce dernier ne compromets pas graveme nt ou ne rends pas impossible la réalisation des objectifs de la recherche. Ces droits s’exercent auprès de l’investigateur ou de son représentant désigné qui vous suit dans le cadre de la recherche et qui connaît votre identité. - le droit de récupérer l’ensemble des données vous concernant en vue de les transmettre à un autre responsable de traitement (droit à la portabilité) Vous pouvez également contacter la Déléguée à la Protection des Données désignée par le Promoteur en la contactant par mail (mar ie.moreau@u -bourgogne.fr) ou par voie postale (FFCD, 7 boulevard Jeanne d’arc, 21000 Dijon). Votre refus de participer à cette étude biologique n’aura aucun effet sur vos relations avec le médecin investigateur, ni sur la qualité des soins que vous aurez. De même, vos relations avec l’équipe médicale ne seront aucunement modifiées quelle que soit votre décision. Vous êtes invité(e) à discuter de votre éventuelle participation à cette étude avec vos proches et votre médecin traitant si vous le souhaitez. Votre acceptation et votre consentement écrit sont indispensables avant de procéder à des prélèvements biologiques. Vous pourrez, si vous le souhaitez, demander au médecin investigateur les résultats globaux à la fin de l’étude. Vous aurez la liberté de co ntacter le médecin investigateur pour connaitre les résultats de l’étude, par des modalités que vous aurez l’occasion d’évoquer ensemble lors de consultations prévues dans le cadre de cette étude, ou via les coordonnées présentes ci -dessous. Si vous avez des questions concernant cette étude, avant ou bien pendant l’étude, n’hésitez pas à les poser à votre médecin investigateur par téléphone quand vous le souhaitez ou bien lors de consultations ultérieures : Nom, prénom, service de la personne à contacter dans le centre* : ................................ ................................ ................................ .. ................................ ................................ ................................ .. Téléphone : ................................ ................................ ...................... *à compléter par la personne ayant recueilli le consentement du patient En cas d’urgence, contacter les services d’urgence médicale en téléphonant au 15. DATE DE REMISE DE L’INFORMATION PATIENT :  (Format : JJ/MM/AAAA) à……….………… MEDECIN INVESTIGATEUR QUI A PRESENTE LE CONSENTEMENT (Nom et Prénom) :……………… Signature"
74,page_74,"PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 75 de 123 FORMULAIRE DE RECUEIL DE CONSENTEMENT ECLAIRE POUR L ’ETUDE BIOLOGIQUE (Fait en 2 exemplaires : un exemplaire est remis à la personne, l'autre est conservé par l’investigateur) PRODIGE 59 – (FFCD 1707) – ETUDE DURIGAST ETUDE DE PHASE II RANDOMISEE EVALUANT L’EFFICACITE DU FOLFIRI + DURVALUMAB VS FOLFIRI + DURVALUMAB + TRÉMÉLIMUMAB EN DEUXIEME LIGNE DE TRAITEMENT CHEZ DES PATIENTS PRESENTANT UN ADENOCARCINOME GASTRIQUE OU DE LA JONCTION OESO -GASTRIQUE AVANCE N° EudraCT : 2018 -002014 -13 Le Docteur ……………… m’a proposé de participer à l’étude biologique sus -cité, adossée à l’étude clinique promue par la Fédération Fr ancophone de Cancérologie Digestive (FFCD) situé au 7 boulevard Jeanne d’arc, 21000 Dijon. J’ai reçu des informations claires et adaptées sur l'étude biologique optionnelle à l'essai PRODIGE 59 - DURIGAST, et j’ai eu suffisamment de temps pour réfléchir à ma participation J’ai reçu et j’ai lu l a notice d’information. J’ai pu poser toutes les questions qui me semblaient nécessaires et j’ai obtenu des réponses satisfaisantes. Le médecin investigateur m’a proposé de prendre le temps d’y réfléchir et tous mes droits m’ont été clairement expliqués Je donne librement mon consentement pour participer à cette étude biologique. J’accepte la collecte, la conservation et la recherche sur mes prélèvements. Les prélèvements ne seront utilisés que dans le cadre de cette étude et détruits après analyse. Je participe de mon plein gré et j’ai la possibilité de retirer mon consentement à tout moment sans donner d’explication. Cela n’affectera pas ma participation à l’étude clinique, ni mes relations avec mon médecin o u le personnel hospitalier. Les données me concernant seront strictement confidentielles. J’ai bien noté que mon droit d’accès à mes données, prévu par la loi française du 6 janvier 1978 relative à l’informatique aux fichiers et aux libertés et le Règlem ent européen 2016/679 du 27 avril 2016, s’exerce à tout moment auprès de l’investigateur ou de son représentant désigné qui me suit dans le cadre de la recherche et qui connaît mon identité. Je pourrai exercer les droits que j’ai sur mes données personnell es et décrits dans les exigences règlementaires auprès de l’investigateur ou de son représentant désigné. J'ai compris que les données médicales me concernant resteront confidentielles et ne pourront être consultées que par l'investigateur et ses collabor ateurs par des personnes mandatées par le promoteur et astreintes au secret professionnel et par des personnes mandatées par les autorités sanitaires et judiciaires J’accepte que toutes recherches futures sur le cancer puissent être réalisées sur mes don nées. Mon consentement ne décharge en rien les organisateurs de la recherche et les investigateurs de leurs responsabilités et je conserve tous mes droits garantis par la loi. J’accepte, en cas de collaboration de la FFCD avec un tiers, que mes matériel s biologiques soient utilisés par ce tiers (autre institution/organisme universitaire ou compagnie pharmaceutique) En l'absence d'autonomie de lecture et d'écriture de M, Mme (rayer la mention inutile) …………………………… la personne de confiance ci -dessous iden tifiée, atteste avoir personnellement et fidèlement lu au sujet la notice d'information et le présent formulaire de consentement, et recueilli son consentement et recueilli son accord pour signer ici en son nom. PATIENT OU PERSONNE DE CONFIANCE (nom et pr énom) :……………………………… à_______________ date de signature_________________ date de naissance du patient  (Format : MM/AAAA) Signature MEDECIN INVESTIGATEUR QUI A RECUEILLI LE CONSENTEMENT (nom et prénom) :……………… à________________ date de signature _________________"
75,page_75,PRODIGE 59 – DURIGAST – Version 1.1 – 15.09.2019 ENG Page 76 de 123 Signature
76,page_76,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 77 de 123 APPENDIX 2: BIOLOGICAL STUDIES An ancillary study of biological samples (blood) , tumour samples (primary tumours) and stools has been set up in order to look for factors predictive of treatment response and prognostic factors. The principal objective is to generate hypotheses enabling to determine future biomarkers predictive of response to immune checkpoint inhibitors, in particular levels of circulating tumour DNA, immunohistochemistry (IHC) o n the tumour (PD -L1, PD -L2, CD8 an d others immune markers ), mutational load , gastric molecular sub -group and intestinal microbiota . Molecular and IHC analyses planned have been defined based on current knowledge and may change over time depending on new findings. This will be decided by t he DURIGAST biological study steering committee. 1/ RATIONALE Circulating tumour DNA Up until now, molecular analysis of tumour cells was performed using samples of cancerous tissue. Improvement in molecular biology techniques now makes it possible to d etect, to extract and to analyse circulating DNA. Circulating free DNA exists in healthy subjects at concentrations of approximately 0 to 100 ng/ml (1). In cancer patients, concentrations range from 0 to 5,000 ng/ml. Existence of free DNA in the blood of cancer patients that is a carrier of specific alterations, in fact has been demonstrated in many studies. This tumour DNA, which presents the same molecular signature as the tumour, is released by tumour cells when they enter into apoptosis or undergo necro sis (1,2) . It is possible to detect cancer -specific mutations in the peripheral blood of patients with metastatic cancer. This then specifically involves circulating tumour DNA (ctDNA). The kinetic follow -up study of ctDNA may make it possible to monitor the evolution of the tumour, determine the efficacy of treatment and detect possible recurrences, as well as the emergence of tumour subclones of resistance to targeted treatments (3,4) . Furthermore, preliminary data suggest that ctDNA may predict non -response to treatment even before radiological progressi on. To date, there are no data on the dynamic evolution of ctDNA in patients treated with an immune checkpoint inhibitor in gastric cancer . Therefore, ctDNA represents a marker of tumour burden which is easily detectable and relevant to analyse in the DURI GAST trial. Factors predictive of response to immune checkpoint inhibitors Currently, molecular biology technical laboratories have high output sequencing techniques enabling to analyse a mutational panel prognostic and/or predictive of response to treat ment, as example RAS and BRAF mutations for metastatic colorectal cancer . In the DURIGAST study, blocks of tumour tissue collected enable analysis of a large mutational panel determined based on advances in knowledge on the carcinogenesis of gastric cancer (MSI, HER2 , PIK3CA …) as well as gastric molecular sub -group . Gastric cancer s were divided into four subtypes: tumours positive for Epstein –Barr virus (PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, PD -L1 and PD -L2); microsatellite unstable tumours (elevated mutation rates); genomically stable tumours (e nriched for the diffuse histological variant); and tumours with chromosomal instability (aneuploidy and focal amplification of receptor tyrosine kinases). The expression of PD -1 or of PD -L1 has been studied to predict efficacy of immune checkpoint inhibito rs (ICI), but remains controversial with thresholds for positivity that have not been precisely determined. Even if expression of PD -L1 seems to be correlated with clinical efficacy, objective responses have been observed in PD -L1 negative tumours. Further more, a uniform definition of a PD -L1 positive tumour is needed, in fact the threshold for a positive response ranges between 1 and 50% depending on studies and the expression of PD -L1 can be analysed either in tumour cells or in immune cell infiltration o f tumours (5). The predictive value of expression of PD -L1 and of other biomarkers remains to be evaluated in gastric cancer treated with ICI, in particular with durvalumab and tremelimumab . Furthermore, recently other markers (PD -1, PD -L2) or T - lymphocyte populations (CD8, CD4, CD3, FoxP3) separately or in the setting of a combined immunoscore may influence response to ICI. Different immune scores and immune markers will be evaluated in the DURIGAST study in order to compare them alone or in combination wi th each other. Recent studies suggest that mutational load, which is related to the number of potentially immunogenic tumour antigens, affects the efficacy of ICI (6). Therefore, a high mutational load is an essential prior condition for efficacy of ICI. New technics of molecular biology now make it possible to determine precisely this mutational load and represent a potentially major biomarker of efficacy of ICI and will be performed in the DURIGAST trial. Rational for Microbiome Analysis"
77,page_77,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 78 de 123 Some studies suggest that the gut microbiota might be involved in the efficacy and toxicity of chemotherapies and immunotherapies (7-9). A study lead in Gustave Roussy hospital showed intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Indeed, cyclophosphamide alters the microbiota composition and induces translocation of a type of Gram+ bacteria into secondary lymphoid organs. There, these bacteri a stimulate immune response by generation of pTh17 antitumoral cells. Experience on mice’s microbiota without these bacteria showed a reduction of pTh17 generation and resistance to cyclophosphamide, whereas transfer of these bacteria into mices lead to cy clophosphamide efficacy. Besides, nivolumab and ipilimumab can increase immune response and can also induce immune -related adverse effects as diarrheas or enterocolitis. The inflammatory mechanism of these effects suggests an important role of the gut micr obiota (10). The main objective of this part of the study is to evaluate the influence of gut microbiota composition on toxicity and efficacy of Folfiri plus durvalumab ± tremelimumab in patients included in this clinical trial. For this purpose, fecal mic robiota composition will be analyzed before initiating the treatment (W0) and at week 8 (W8, first evaluation) and will be correlated to treatment toxicity and efficacy. A document explaining in detail the sampling and shipping procedure will be provided t o the patient at inclusion in the study and specific and validated material will be provided to the patient for the stool sampling and shipment. The patient will be contacted (phone, email, text message) few days before the planned sampling to remind him w hat should be done. The sampling day (W0 and W8), the patient will have to fill a simple clinical information file that will be sent with the stool sample. Once received in the laboratory responsible (Laboratory for microbiota analysis, Gut Microbiota and Immunity lab (Pr Harry Sokol), INSERM U1157 / UMR CNRS 7203, Université Pierre et Marie Curie, 27 rue de Chaligny, 75012 Paris, France) for the analysis, the stool will be aliquoted and stored at -80°C until processing. The fecal microbiota composition w ill be assessed by sequencing the small -subunit (16S) ribosomal RNA gene of bacterial communities. Indeed, all the bacteria have the 16S rRNA gene, which is characterized by enough sequence conservation allowing accurate alignment and enough variation allo wing phylogenetic analyses. The recent advances and decrease cost of deep sequencing offers the possibility to characterize the complete gut microbiota, in our case using MiSeq Illumina technology. Following DNA extraction with a validated method (11) and sequencing, sequences will be analyzed as described previously (12, 13). Briefly, the sequences will be processed in a data curation pipeline, which remove sequences from the analysis if they are less than 200 nucleotides or greater than 600 nucleotides, have a low read quality score, contain ambiguous characters, or have a non -exact barcode match. Remaining sequences will be assigned to samples based on barcode matches, and barcode and primer sequences will be then trimmed. Chimeric sequences will be iden tified and removed, and reads classified using Greengenes ribosomal RNA database. Sequences will be also aligned and clustered (Qiime, http://qiime.org/). Microbiota data will be analyzed by a combination of supervised and unsupervised modeling strategies. Briefly, this will include: implementation of ecology -derived diversity and similarity indices to derive correlation models with studied genotype or clinical status. Linear discriminant analysis effect size (LEfSe) and multivariate analysis by linear mode ls (MaAsLin) will be used to identify components of the microbiota associated with clinical status. Hierarchical clustering and Principal Component Analysis will be also performed. All the comparisons between groups of interest will be performed at Phylum, class, order, family, genus and species level. The analysis will particularly focus on: (1) looking for microbiota factors associated with treatment toxicity and (2) efficacy. 2/ PRACTICAL MODALITIES Necessary samples For patients who signed the biolo gical study informed consent form, the following samples will be collected: - Blood samples : test tubes will be used for extraction of DNA from plasma (circulating tumour DNA) and will be sent to EPIGENETEC .  For measurement of ctDNA: 2 test tubes of cell free DNA blood will be collected before the 1st course of CT, the 3rd course and at disease progression (before the 1st course of L3 ). - Tumour block fixed in paraffin: tumour block will be used to detect several molecular markers and will be sent to EPI GENTEC ."
78,page_78,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 79 de 123 - Stool sample: stool sample s will be used for 16S rRNA detection of microbiota bacteria and will be sent to the Laboratory for microbiota analysis, Gut Microbiota and Immunity lab (Pr Harry Sokol), INSERM U1157 / UMR CNRS 7203, Université Pierre et Marie Curie, 27 rue de Chaligny, 75012 Paris, France . Conduct of analyses : 1/ Blood samples : - Measurement of ctDNA: * total concentration of circulating DNA * ctDNA concentration (Garrigou et al. Clin Chem 2016, Pecuchet Clin Chem 2016) 2/ A block of tumour tissue embedded in paraffin: - Extraction of DNA for: * microsatellite instability * gastric molecular subgroup * tumour mutation load - Construction of the Tissue Micro Array block for immunohistochemistry: * expression of immune checkpoints (PD-L1, PD-L2) * immune response/immune scores 3/ Stool samples : - Extraction of 16S rRNA: * identification of bacteria composing the intestinal microbiota of patients Bibliography: 1. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426 -37 2. Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313:139 -42 3. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti - EGFR therapy in colorectal cancer. Nature. 2012;486:532 -6 4. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537 -40. 5. Granier C, Roussel H, de Guillebon E, et al. Biomarkers from the tumor microenvironment to predict clinical response to checkpoint inhibitors. J OncoPathology 2014. 6. Vogelstein B, Papadopoulos N, Velcu lescu VE et al. Cancer genome landscapes. Science 2013;339:1546 -58. 7. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971 -6. 8. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti -PD-1 immunotherapy in melanoma patients. Science 2018;359:97 -103. 9. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD -1-based immunothera py against epithelial tumors. Science 2018;359:91 -97. 10. Carbonnel F, Soularue E, Coutzac C, et al. Inflammatory bowel disease and cancer response due to anti - CTLA -4: is it in the flora? Semin Immunopathol 2017;39:327 -31. 11. Qin J, Li R, Raes J, et al. A human g ut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59 -65. 12. Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 2016 ;22:598 -605. 13. Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66 :1039 -1048"
79,page_79,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 80 de 123 APPENDIX 3: QUALITY OF LIFE – QLQ -C30 EORTC QL Q-C30 (version 3.0) – PRODIGE 59 - DURIGAST We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best applies to you. There are no ""right"" or ""wrong"" answers. The information that you provide will remain strictly confiden tial. Please fill in: The first three letters of your surname:  The first two letters of your first name:  Your date of birth:  Today's date:  Not at all A little Quite a bit Very much 1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or suitcase? 1 2 3 4 2. Do you have any trouble taking a long walk? 1 2 3 4 3. Do you have any trouble taking a short walk outside the house? 1 2 3 4 4. Do you need to stay in bed or in a chair during the day? 1 2 3 4 5 Do you need help with eating, dressing, washing yourself or using the toilet? 1 2 3 4 During the past week: For the following questions, please circle the number between 1 and 7 that best applies to you 29. How would you rate your overall health during the last week? 1 2 3 4 5 6 7 Very poor Excellent 30. How would you rate your overall quality of life during the last week? 1 2 3 4 5 6 7 Very poor Excellent © Copyright 1999 EORTC Quality of Life Study Group, version 3.0. All rights reserved. English version The data collected will be analyzed by computer. In accordance with the law ""Informatique et Liberté"" of January 6, 1978 amen ded by law 2004 -801 of August 6, 2004 relating to the automated processing of health data, you may exercise a right of access and modification through your investigat or. Not at all A little Quite a bit Very much 6. Were you limited in doing either your work or other daily activities? 1 2 3 4 7. Were you limited in pursuing your hobbies or other leisure time activities? 1 2 3 4 8. Were you short of breath? 1 2 3 4 9. Have you had pain? 1 2 3 4 10. Did you need to rest? 1 2 3 4 11. Have you had trouble sleeping? 1 2 3 4 12. Have you felt weak? 1 2 3 4 13. Have you lacked appetite? 1 2 3 4 14. Have you felt nauseated? 1 2 3 4 15. Have you vomited? 1 2 3 4 16. Have you been constipated? 1 2 3 4 17. Have you had diarrhea? 1 2 3 4 18. Were you tired? 1 2 3 4 19. Did pain interfere with your daily activities? 1 2 3 4 20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television? 1 2 3 4 21. Did you feel tense? 1 2 3 4 22. Did you worry? 1 2 3 4 23. Did you feel irritable? 1 2 3 4 24. Did you feel depressed? 1 2 3 4 25. Have you had difficulty remembering things? 1 2 3 4 26. Has your physical condition or medical treatment interfered with the family life? 1 2 3 4 27. Has your physical condition or medical treatment interfered with your social activities? 1 2 3 4 28. Has your physical condition or medical treatment caused you financial difficulties? 1 2 3 4"
80,page_80,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 81 de 123 APPENDIX 4 : QUALITY OF LIFE - STO -22 Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have experienced these symptoms or problems during the past week. Please answer by circling the number that best applies to you. ________________________________________________________________ __________ During the past week: QLQ -TO22 Copyright 1999 EORTC Group on Quality of life. All rights reserved. ENGLISH The data collected will be analyzed by computer. In accordance with the law ""Informatique et Liberté"" of January 6, 1978 amended by law 2004 -801 of August 6, 2004 relating to the automated processing of health data, you may exercise a right of access and modification through your investigat or. Not al all A little Quite a bit Very Much 31. Have you had problems eating solid foods? 1 2 3 4 32. Have you had problems eating liquidised or soft foods? 1 2 3 4 33. Have you had problems drinking liquids? 1 2 3 4 34. H ave you had discomfort when eating? 1 2 3 4 35. Have you had pain in your stomach area? 1 2 3 4 36. Have you had discomfort in your stomach area? 1 2 3 4 37. Did you have a bloated feeling in your abdomen? 1 2 3 4 38. Have you had trouble with acid or bile coming into your mouth? 1 2 3 4 39. Have you had acid indigestion or heartburn? 1 2 3 4 40. Have you had trouble with belching? 1 2 3 4 41. Have you felt full up too quickly after beginning to eat? 1 2 3 4 42. Have you had trouble enjoying your meals? 1 2 3 4 43. Has it taken you a long time to complete your meals? 1 2 3 4 44. Have you had a dry mouth? 1 2 3 4 45. Did food and drink taste different from usual? 1 2 3 4 46. Have you had trouble with eating in front of other people ? 1 2 3 4 47. H ave you been thinking about your illness? 1 2 3 4 48. Have you worried about your weight being too low? 1 2 3 4 49. Have you felt physically less attractive as a result of your disease or treatment? 1 2 3 4 50. Have you worried about your health in the future? 1 2 3 4 51. Have you lost any hair? 1 2 3 4 52. Answer this question only if you lost any hair: If so, were you upset by the loss of your hair? 1 2 3 4"
81,page_81,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 82 de 123 APPENDIX 5: ECOG PERFORMANCE STATUS – CALCULATION OF CLEAR ANCE ECOG Perfor mance Status 0= Fully ac tive, able to carry on all predisease perform ance without restriction 1= Restricted i n physically strenuous activity but ambulatory and able t o carry out work of a light or sedentary natu re 2= Am bulat ory and capable of all selfcare but unable to carry out any work activities. U p and about more than 50% of waking hours 3= Capable of only lim ited selfcare, confined to bed or chair more than 50% of waking hours 4= Com pletely disabled. Cannot carry on any selfca re. Totally confined to bed or chair 5= Dead CLEARANCE MDRD ( Modification of the Diet in Renal Disease ) formula (Levey, 2000): 186.3 × (creatinine (in mmol/L)/88.4) × 1154 age -0203 (x 0.742 if female x 1.21 if black skin)"
82,page_82,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 83 de 123 APPENDIX 6 : RECIST CRITERIA , VERSION 1.1 ""New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)"" E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij; Eur J Cancer, 4 5 ( 2 0 0 9 ) 2 2 8 –2 4 7. Lesions on inclusion: Lesions and lymph nodes are classed individually as being measurable or non -measurable. Measurable disease A lesion is measurable if i t can be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be reported). To be measurable, lesions must have a minimum size of ≥ 10 mm on CT (CT scan slice thickness no greater than 5 mm) ≥ 10 mm on clinical examination (measured using a caliper); lesions that cannot be accurately measured with calipers should be classed as non -measurable 20 mm on chest X -ray For a malignant lymph node to be considered pathological and measurable, its short axis must measure ≥ 15 mm (the short axis is the axis perpendicular to the largest dimension of the lymph node). Only the length of this short axis is reported on inclusion and during follow -up. Non-measurable disease All other lesions, including small lesions (longest diam eter < 10 mm on CT or lymph nodes with ≥ 10 mm and < 15 mm short axis) as well as truly non -measurable lesions: leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdomin al masses identified by physical examination but unconfirmed by imaging techniques, and cystic lesions. NB: bone lesions, simple cystic lesions and lesions that have received prior local treatment require special consideration (see comments below). Target lesions Target lesions are selected from the measurable lesions presented by the patient on entry into the study. A maximum of five target lesions are selected, with no more than two target lesions per organ. Target lesions will be selected so as to be representative of all involved organs. The largest lesions (in the longest dimension) that may be repeatedly and reproducibly measured throughout the trial using the initial examination method are to be chosen. Lymph nodes may be considered as target lesions if their short axis as measured on CT is ≥ 15 mm. The sum of the diameters of these target lesions (the longest diameter for lesions, and short axis for lymph nodes) is what i s followed throughout the trial for assessing response or progression. Non-target lesions All other lesions are identified as non -target lesions and are also recorded on inclusion. They are not measured but they are followed throughout the trial. Criteria for response to treatment: Target lesions: Complete response (CR) Disappearance of all lesions, and all lymph nodes (whether target or non -target) must have reduction in short axis to < 10 mm. Note: lymph nodes selected as target lesions must always be measured (in the same anatomical plane as the baseline examination) , even if they decrease in size during the study to a short axis of < 10 mm. Therefore, when lymph nodes are used as target lesions, the sum of the lesions' dimensions is not necessarily zero even if there is CR since a normal lymph node is defined as havi ng a short axis < 10 mm. To qualify for CR, every lymph node must achieve a short axis of < 10 mm. Partial response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive diseas e (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum, or nadir, in the study (this includes the baseline sum if that is the smallest in the study). In addition to the relativ e increase of 20%, the s um must also demonstrate an absolute increase of at least 5 mm. Note: the appearance of one or more new lesions is also considered progression. However, if there is progression compared with the nadir and response compared with the baseline examination, th is is considered progression."
83,page_83,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 84 de 123 Stable disease (SD) Neither PR, CR or PD. Non-target lesions CR Disappearance of all non -target lesions and normalization of tumor markers. All lymph nodes must have reached a short axis of < 10 mm. Non-CR/SD Persistence of one or more non -target lesions and/or tumor marker levels above the normal limits. PD Unequivocal increase in size of existing non -target lesions or appearance of one or more new lesions. Overall response: Target lesions Non-target lesions New lesion Overall response CR CR No = CR CR Non-CR/Non -PD No = PR CR PR Not assessed Non-PD or not all assessed No No = = PR PR SD Non-PD or not all assessed No = SD Not all assessed PD Non-PD Any No Yes or no = = Unassessable PD Any PD Yes or no = PD Any Any Yes = PD Comments on lesion measurability on entry Bone lesions: Bone scan, PET scan or plain films are not considered adequate imaging techniques to measure bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions. Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue components, can be considered as measurable lesions if they can be evaluated by cross -sectional imaging techniques such as CT or MRI and if the soft tissue comp onent meets the definition of measurability described above. Cystic lesions: Lesions that meet the criteria for radiographically defined simple cysts are not considered as malignant lesions (be it measurable or non -measurable). Cystic lesions thought to re present cystic metastases can be considered as measurable lesions if they meet the definition of measurability described above. However, if noncystic lesions are present in the same patient, these are preferred for selection as target lesions. Lesions with prior local treatment: Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco -regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion since the local thera py. Study protocols should detail the conditions under which such lesions may be considered measurable."
84,page_84,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 85 de 123 APPENDIX 7 : IRECIST CRITERIA OF IMMUNOLOGICAL RESPON SE iRECIST immunological response criteria (Bibliographical reference: Seymour and al Lancet Oncol. 2017 Mar;18(3):e143 -e152. doi: 10.1016/S1470 -2045(17)30074 -8. Epub 2017 Mar 2. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.) Identification of lesions at inclusion: Lesions and lymph nodes will be classified individually as measurable or not measurable.  Measurable disease In order for a lesion to be considered measurable, at least one of its dimensions must be able to be measured precisely (the longest dimension, in the plan of measurement, should be recorded). To be measurable, lesions should present a minimum measurement of: - ≥ 10 mm in a CT -scan (so that the width of the band of the CT -scan is at most 5 mm) - ≥ 10 mm by the clinical examination (measurable with a sliding calliper) (lesions which cannot be measured precisely should be classified as non -measurable) - 20 mm per X -ray of the chest (or of the thorax) - For a malignant lymph node to be considered as pathological and measurable, the latter should have a smallest axis ≥ 15 mm (the smallest axis being perpendicular to the largest dimension of the node). Only the length of the smallest axis will be recorded both at inclusion, as well as during follow -up.  Non-measurable disease All other lesions including small lesions (largest diameter < 10 mm in a CT -scan or lymph nodes whose smallest axis is ≥ 10 mm and < 15 mm ) as well as actually non -measurable lesions: leptomeningeal disease, ascites, pleurisy, pericarditis, inflammatory breast disease, pulmonary or cutaneous carcinomatous lymphangitis, ab dominal or pelvic masses detected by clinical examination but not confirmed by imaging and cystic lesions. NB: bone lesions, simple cystic lesions and lesions which previously underwent local treatment require special consideration (see comments below). Classification of lesions Lesions and nodes then will be classified as target or non -target lesions:  Target lesions Target lesions are selected from among measurable lesions which the patient presents at time of entry in the study. 5 target lesions at most are selected in total with a maximum of 2 target lesions per organ. Selection of target lesions will be performed in order to be representative of all organs invaded by choosing the largest lesions (in their largest dimension) wh ich, in addition, may be f ollowed throughout the trial with the method used in the initial examination. The largest lesions are not necessarily the best measurable targets to follow. The most representative lesions and moreover the easiest to find from one examination to another ar e to be preferred, but are not necessarily the largest. Lymph nodes can be considered as target lesions if their smallest axis (measured on CT -scan) is ≥ 15 mm. If possible, avoid necrotic lesions. It is the sum total of diameters of these target lesions (largest axis for lesions and smallest axis for nodes) which will be followed throughout the trial to evaluate response or progression.  Non-target lesions All other lesions are identified as non -target lesions and are also recorded at inclusion. They are not measured, but are followed throughout the trial. Comments relating to the measurability of lesions at time of admission  Bone lesions: Imaging by bone scinti -scan, PET -scan and plain X -ray films are not considered as adequate for measurement of bone lesions. However, these techniques can be used to confirm the existence or disappearance of bone lesions. Lytic or mixed lytic -osteoblastic bone lesions, wh ich contain a soft tissue identifiable component can be considered as measurable lesions in so far as they may be measured by cross -sectional techniques such as CT or MRI scan, and that the soft tissue component satisfies conditions for measurability indic ated in the above.  Cystic lesions:"
85,page_85,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 86 de 123 Lesions which correspond to the X -ray diagnosis of a simple cyst are not considered as malignant lesions (neither measurable, nor non -measurable) Malignant cystic lesions can be taken into account as a measurable lesion insofar as they satisfy criteria for measurability defined in the above. However, if the patient presents with other non -cystic lesions, the latter will be chosen preferably as the target lesion.  Lesions previously treated locally: Lesions located in a p reviously radiated area or which received another loco -regional therapy generally are not considered measurable, except for lesions which have progressed since local treatment. The study protocol should detail the specific conditions enabling to consider s uch lesions as measurable. Criteria of response to treatment: Evaluation of target lesions: Complete response (iCR: immune complete response) : Disappearance of all lesions. Furthermore, all lymph nodes (target or non-target), should have reached a dimension < 10 mm in their smallest axis. No confirmation is necessary. Warning: nodes selected as target lesions should always be measured (dimensio n of the smallest axis in the anatomical plane used for BASELINE examination), even if they decrease in size during the study and that their smallest axis becomes < 10 mm. From then, when the nodes are used as a target lesion, the “sum total” of dimensions of lesions is not necessarily nil, even in case of a complete response, since a normal lymph node is defined as having its smallest axis < 10 mm. In order to obtain a complete response, each node should have reached a dimension of < 10 mm in its smallest axis. Partial response (iPR: immune partial response) : Decrease by at least 30% in sum total of diameters of target lesions compared to initial sum total of diameters (BASELINE examination). Non-confirmed progression (iUPD: immune unconfirmed progressive disease) : Increase ≥ 20% of sum total of diameters of target lesions compared to the smallest total of diameters observed in the study (NADIR), including baseline visit. In additi on to this, relative increase of 20%, this sum total should increase by at l east 5 mm. Comment: unconfirmed progression does not result in discontinuation of treatment. Confirmed progression (iCPD: immune confirmed progressive disease) : An additional increase ≥ 5 mm of sum total of diameters of target lesions Stabilisation (i SD: immune stability of disease) : Neither iPR (or iCR), nor progression. Evaluation of non -target lesions Complete response (iCR: immune complete response) : Disappearance of all non -target lesions and normalisation of tumour markers. All lymph nodes shou ld have reached a smallest diameter < 10 mm. Incomplete response – Stabilisation (non -iCR – non-iUPD) : Persistence of at least one non -target lesion and/or one tumour marker above normal. Unconfirmed progression (iUPD: immune unconfirmed progressive dise ase): an indisputable increase in size of non -target lesions observed at the first evaluation or after an evaluation which concluded in a complete response or stabilisation of th ese non-target lesions. Comment: unconfirmed progression does not result in discontinuation of treatment Confirmed progression (iCPD: immune confirmed progressive disease): An additional indisputable increase in size of non -target lesions following an evaluation which concluded iUPD fo r these non - target lesions. Evaluation of new lesions (NL): Initial occurrence of one or more new lesions is a progression which should be confirmed 4 to 8 weeks later. The new lesion(s ) is/are to be categorised as measurable or not measurable and shou ld be followed independently of target and non -target lesions at baseline. These new lesions are to be categorised: - As measurable new lesions: at most 5 new lesions (of which maximum 2 per organ) will be measured and followed, but should not be included i n the sum total of lesions identified at the baseline examination."
86,page_86,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 87 de 123 - As non -measurable new lesions: all other new lesions are identified as non -target lesions and are followed in the following evaluations. An evaluation of these new lesions satisfies rules e stablished by RECIST 1.1 (see following table) Measurable NL Non-measurable NL Occurrence of NL Overall response NL CR CR No = CR CR Non-CR/Non -PD No = PR CR Not evaluated No = PR PR Non-PD or not all evaluated No = PR SD Non-PD or not all evaluated No = SD Not all evaluated Non-PD No = Not evaluable (NE) PD* Indifferent Yes or no = PD Indifferent PD** Yes or no = PD Indifferent Indifferent Yes = PD *For measurable new lesions, progression is observed if an increase of at least 5 mm. **For non -measurable new lesions, progression is observed if an increase is indisputable. Overall response: The overall response is the conjunction of target lesions, non -target lesions, new lesions; each type of lesion should be considere d first individually and then in a combined manner for overall response. Following observation of an unconfirmed progression (iUPD), in the following evaluation (4 to 8 weeks later), the overall response will be: - Confirmed progression (iCPD), if observat ion of a further new progression of measurable target lesions and/or of non-target lesions and/or of new lesions - Re-initialisation of response in other cases (iCR, iPR or iSD) In this case, a new cycle iUPD and then iCPD will be necessary in order to conc lude in failure of therapy because of disease progression. This rule applies for all categories of lesions followed (target lesions, non -target lesions and new lesions). This concept makes it possible to take into account typical responses in immunothera py, i.e. responses to postponement which occurred after pseudo -progression."
87,page_87,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 88 de 123 Allocation of overall response according to iRECIST criteria: If no non -target lesion is followed, the overall response is based on the result of response of target lesions, new lesions and overall response in previous evaluations. Evaluation at time t Overall response in previous evaluation (t -1) Overall response at time t Target lesion Response Non-target lesion response Overall response of New lesions iCR iCR Absence or CR Indifferent iCR iCR iCR PR or NE Indifferent iPR iCR iCR SD Indifferent iSD iCR Neither iCR – nor iUPD Absence or CR Indifferent iPR iCR Neither iCR – nor iUPD PR or NE Indifferent iPR iCR Neither iCR – nor iUPD SD Indifferent iSD iPR Neither iCR – nor iUPD Absence or CR or PR or NE Indifferent iPR iPR Neither iCR – nor iUPD SD Indifferent iSD iSD Neither iCR – nor iUPD Absence or non -PD Indifferent iSD iUPD Neither iCR – nor iUPD Absence or non -PD Neither iUPD/iCPD iUPD Neither iUPD/iCPD iUPD Absence or non -PD Neither iUPD/iCPD iUPD iUPD Neither iUPD/iCPD Absence iUPD – observed solely for target lesions iUPD Neither iUPD/iCPD iUPD Absence iUPD observed solely for non -target lesions iUPD iUPD iUPD Absence Neither iUPD/iCPD iUPD iUPD iUPD Absence iUPD – observed for target lesions and non -target lesions iUPD Non-iCPD Non-iCPD 1st occurrence Neither iUPD/iCPD iUPD indifferent indifferent 1st occurrence iUPD – observed solely for target lesions and/or non -target lesions iCPD iUPD indifferent indifferent iUPD - observed for non -target lesions and/or occurrence of new lesions iCPD indifferent iUPD indifferent iUPD - observed for target lesions and/or occurrence of new lesions iCPD indifferent indifferent PD Indifferent iCPD iCPD indifferent indifferent Indifferent iCPD indifferent iCPD indifferent Indifferent iCPD"
88,page_88,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 89 de 123 APPENDIX 8: ASSESSMENT OF TOXICI TIES ASSESSMENT OF TOXICITIES NCI -CTC V4.0 http://evs.nci.nih.gov/ftp1/CTCAE/About.html and then click « Files Data » on « CTCAE 4.03 2010 -06-14.xls » TOXICITY MANAGEMENT GUIDELINES This document describing the management of toxicity related to immunotherapy is provided hereinafter. Each new u pdated version will be provided by the sponsor to the center .
89,page_89,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 90 de 123 Dosing Modification and Toxicity Management Guidelines for Immune -Mediated, Infusion -Related, and Non-Immune –Mediated Reactions (MEDI4736 Monotherapy or Combination Therapy With Tremelimumab or Tremelimumab Monotherapy) 1 November 2017 Version General Considerations Dose Modifications Toxicity Management Drug administration modifications of study drug/study regimen will be made to manage potential immune -related AEs based on severity of treatment -emergent toxicities graded per NCI CTCAE v4.03. In addition to the criteria for permanent discontinuation of study drug/study regimen based on CTC grade/severity (table below), permanently discontinue study drug/study regimen for the following conditions:  Inability to reduce corticosteroid to a dose of ≤10 mg of prednisone per day (or equivalent) within 12 weeks after last dose of study drug/study regimen  Recurrence of a previously experienced Grade 3 treatment -related AE following resumption of dosing Grade 1 No dose modification Grade 2 Hold study drug/st udy regimen dose until Grade 2 resolution to Grade ≤1. If toxicity worsens, then treat as Grade 3 or Grade 4. Study drug/study regimen can be resumed once event stabilizes to Grade ≤1 after completion of steroid taper. Patients with endocrinopathies who ma y require prolonged or continued steroid replacement can be retreated with study drug/study regimen on the following conditions: 1. The event stabilizes and is controlled. 2. The patient is clinically stable as per Investigator or treating physician’s clinical judgement. 3. Doses of prednisone are at ≤10 mg/day or equivalent. Grade 3 Depending on the individual toxicity, study drug/study regimen may be permanently discontinued. Please refer to guidelines below. Grade 4 Permanently discontinue study drug/study regimen. Note: For Grade ≥3 asymptomatic amylase or lipase levels, hold study drug/study regimen, and if complete work up shows no evidence of pancreatitis, study drug/study regimen may be continued or resumed. Note: Study drug/study regimen should be perm anently discontinued in Grade 3 events with high likelihood for morbidity and/or mortality – e.g., myocarditis, or other similar events even if they are not currently noted in the guidelines. Similarly, consider whether study drug/study regimen should be It is recommended that management of immune -mediated adverse events (imAEs) follows the guidelines presented in this table: − It is possible that events with an inflammatory or immune mediated mechanism could occur in nearly all organs, some of them not noted specifically in these guidelines. − Whether specific immune -mediated events (and/or laboratory indicators of such events) are noted in these guidelines or not, patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression, concomitant medications, and infections) to a possible immune -mediated event. In the absence of a clear alternative etiology, all such events should be managed as if they were immune related. General recommendations follow. − Symptomatic and topical therapy should be considered for lo w-grade (Grade 1 or 2, unless otherwise specified) events. − For persistent (>3 to 5 days) low -grade (Grade 2) or severe (Grade ≥3) events, promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. − Some events with high likelihood for morbidity and/or mortality – e.g., myo -carditis, or other similar events even if they are not currently noted in the guidelines – should progress rapidly to high dose IV corticosteroids (methylprednisolone at 2 to 4 mg/kg/day) even if the event is Grade 2, and if clinical suspicion is high and/or there has been clinical confirmation. Consider, as necessary, discussing with the study physician, and promptly pursue specialist consultation. − If symptoms recur or worsen during corticosteroid tapering (28 days of taper), increas e the corticosteroid dose (prednisone dose [e.g., up to 2 to 4 mg/kg/day PO or IV equivalent]) until stabilization or improvement of symptoms, then resume corticosteroid tapering at a slower rate (>28 days of taper). − More potent immunosuppressives such as TNF inhibitors (e.g., infliximab) (also refer to the individual sections of the imAEs for specific type of immunosuppressive) should be considered for events not responding to systemic steroids. Progression to use of more potent immunosuppressives should p roceed more rapidly in events with high likelihood for morbidity and/or mortality – e.g., myocarditis, or other similar events even if they are not currently noted in the guidelines – when these events are not responding to systemic steroids. − With long -term steroid and other immunosuppressive use, consider need for Pneumocystis jirovecii pneumonia (PJP, formerly known as Pneumocystis carinii pneumonia) prophylaxis, gastrointestinal protection, and glucose monitoring. − Discontinuation of study drug/study regi men is not mandated for Grade 3/Grade 4 inflammatory reactions attributed to local tumor response (e.g., inflammatory reaction at sites of metastatic disease and lymph nodes). Continuation of study drug/study regimen in this situation should be based upon a benefit -risk analysis for that patient."
90,page_90,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 91 de 123 Dosing Modification and Toxicity Management Guidelines for Immune -Mediated, Infusion -Related, and Non-Immune –Mediated Reactions (MEDI4736 Monotherapy or Combination Therapy With Tremelimumab or Tremelimumab Monotherapy) 1 November 2017 Version General Considerations Dose Modifications Toxicity Management permanently discontinued in Grade 2 events with high likelihood for morbidity and/or mortality – e.g., myocarditis, or other similar events even if they are not currently noted in the guidelines – when they do not rapidly improve to Grade <1 upon treatment with systemic steroids and following full taper Note: There are some exceptions to permanent discontinuation of study drug for Grade 4 events (i.e., hyperthyroidism, hypothyroidism, Type 1 diabetes mellitus). AE Adverse event; CTC Common Toxicity Criteria; CTCAE Common Terminology Criteria for Adverse Events; imAE immune -mediated adverse event; IV intravenous; NCI National Cancer Institute; PO By mouth. Pediatric Considerations Dose Modifications Toxicity Management The criteria for permanent discontinuation of study drug/study regimen based on CTC grade/severity is the same for pediatric patients as it is for adult patients, as well as to permanently discontinue study drug/study regimen if unable to reduce corticoste roid ≤ a dose equivalent to that required for corticosteroid replacement therapy within 12 weeks after last dose of study drug/study regimen − All recommendations for specialist consultation should occur with a pediatric specialist in the specialty recommend ed. − The recommendations for dosing of steroids (i.e., mg/kg/day) and for IV IG and plasmapheresis that are provided for adult patients should also be used for pediatric patients. − The infliximab 5 mg/kg IV dose recommended for adults is the same as recommen ded for pediatric patients ≥ 6 years old. For dosing in children younger than 6 years old, consult with a pediatric specialist. − For pediatric dosing of mycophenolate mofetil, consult with a pediatric specialist. − With long -term steroid and other immunosuppressive use, consider need for PJP prophylaxis, gastrointestinal protection, and glucose monitoring."
91,page_91,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 92 de 123 Specific Immune -Mediated Reactions Adverse Events Severity Grade of the Event (NCI CTCAE version 4.03) Dose Modifications Toxicity Management Pneumonitis/Interstitial Lung Disease (ILD) Any Grade General Guidance For Any Grade: − Monitor patients for signs and symptoms of pneumonitis or ILD (new onset or worsening shortness of breath or cough). Patients should be evaluated with imaging and pulmonary function tests, including other diagnostic procedures as described below. − Initial work -up may include clinical evaluation, monitoring of oxygenation via pulse oximetry (resting and exertion), laboratory work - up, and high - resolution CT scan. Grade 1 (asymptomatic, clinical or diagnostic observations only; intervention not indicated) No dose modifications required. However, consider holding study drug/study regimen dose as clinically appropriate and during diagnostic work -up for other etiologies. For Grade 1 (radiographic changes only): − Monitor and closely follow up in 2 to 4 days for clinical symptoms, pulse oximetry (resting and exertion), and laboratory work -up and then as clinically indicated. − Consider Pulmonary and Infectious disease consult. Grade 2 (symptomatic; medical intervention indicated; limiting instrumental ADL) Hold study drug/study regimen dose until Grade 2 resolution to Grade ≤1.  If toxicity worsens, then treat as Grade 3 or Grade 4.  If toxicity improves to Grade ≤1, then the decision to reinitiate study drug/study regimen will be based upon treating physician’s clinical judgment and after completion of steroid taper. For Grade 2 (mild to moderate new symptoms): − Monitor symptoms daily and consider hospitalization. − Promptly star t systemic steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV equivalent). − Reimage as clinically indicated. − If no improvement within 3 to 5 days, additional workup should be considered and prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day star ted − If still no improvement within 3 to 5 days despite IV methylprednisolone at 2 to 4 mg/kg/day, promptly start immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general guidance before using infliximab. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -PJP treatment (refer to current NCCN guidelines for tre atment of cancer -related infections [Category 2B recommendation])a − Consider pulmonary and infectious disease consult. − Consider, as necessary, discussing with study physician."
92,page_92,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 93 de 123 Grade 3 or 4 (Grade 3: severe symptoms; limiting self-care ADL; oxygen indicated) (Grade 4: life - threatening respiratory compromise; urgent intervention indicated [e.g., tracheostomy or intubation]) Permanently discontinue study drug/study regimen. For Grade 3 or 4 (severe or new symptoms, new/worsening hypoxia, life - threate ning): − Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day or equivalent. − Obtain Pulmonary and Infectious disease consult; consider, as necessary, discussing with study physician. − Hospitalize the patient. − Supportive care (e.g., oxygen). − If no improvement within 3 to 5 days, additional workup should be considered and prompt treatment with additional immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks’ dose) started. Caution: rule out sepsis and refer to in fliximab label for general guidance before using infliximab. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and, in particular, anti-PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a Diarrhea/Colitis Any Grade General Guidance For Any Grade: − Monitor for symptoms that may be related to diarrhea/enterocolitis (abdominal pain, cramping, or changes in bowel habits such as increased frequency over baseline or blood in stool) or related to bowel perforation (such as sepsis, peritoneal signs, and ileus). − Patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression, other medic ations, or infections), including testing for clostridium difficile toxin, etc. − Steroids should be considered in the absence of clear alternative etiology, even for low -grade events, in order to prevent potential progression to higher grade event. − Use anal gesics carefully; they can mask symptoms of perforation and peritonitis. Grade 1 (Diarrhea: stool frequency of <4 over baseline per day) (Colitis: a symptomatic; clinical or diagnostic observations only) No dose modifications. For Grade 1: − Monitor closely for worsening symptoms. − Consider symptomatic treatment, including hydration, electrolyte replacement, dietary changes (e.g., American Dietetic Association colitis diet), and loperamide. Use probiotics as per treating physician’s clinical judgment. Grade 2 Hold study drug/study regimen until For Grade 2:"
93,page_93,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 94 de 123 (Diarrhea: stool frequency of 4 to 6 over baseline per day) (Colitis: a bdominal pain; mucus or blood in stool) resolution to Grade ≤1  If toxicity worsens, then treat as Grade 3 or Grade 4.  If toxicity improves to Grade ≤1, then study drug/study regimen can be resumed after completion of steroid taper. − Consider symptomatic treatment, including hydration, electrolyte replacement, dietary changes (e.g., American Dietetic Association colitis diet), and lop eramide and/or budesonide. − Promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. − If event is not responsive within 3 to 5 days or worsens despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, GI consult should be obtained for consideration of further workup, such as imaging and/or colonoscopy, to confirm colitis and rule out perforation, and prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day started. − If still no improvement within 3 to 5 days despite 2 to 4 mg/kg IV methylprednisol one, promptly start immunosuppressives such as infliximab at 5 mg/kg once every 2 weeksa. Caution: it is important to rule out bowel perforation and refer to infliximab label for general guidance before using infliximab. − Consider, as necessary, discussing with study physician if no resolution to Grade ≤1 in 3 to 4 days. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatme nt of cancer - related infections [Category 2B recommendation]).a Grade 3 or 4 (Grade 3 diarrhea: stool frequency of ≥7 over baseline per day; Grade 4 diarrhea: life threatening consequences) (Grade 3 colitis: s evere abdominal pain, change in bowel habits, medi - cal intervention indi - cated, peritoneal signs; Grade 4 colitis: l ife- threatening consequences, urgent intervention indicated) Grade 3 Permanently discontinue study drug/study regimen for Grade 3 if toxicity does not improve to Grade ≤1 within 14 days; study drug/study regimen can be resumed after completion of steroid taper. Grade 4 Permanently discontinue study drug/study regimen. For Grade 3 or 4: − Promptly initiate empiric IV methylprednisolone 2 to 4 mg/kg/day or equivalent. − Monitor stool frequency and volume and maintain hydration. − Urgent GI consult and imaging and/or colonoscopy as appropriate. − If still no improvement within 3 to 5 days of IV methylprednisolone 2 to 4 mg/kg/day or equivalent, promptly start further immunosuppressives (e.g., infliximab at 5 mg/kg once every 2 weeks). Caution : Ensure GI consult to rule out bowel perforation and refer to infliximab label for general guidance before using infliximab. − Once the patient is improving, gradually taper steroids over ≥28 days and con sider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a Hepatitis Any Grade General Guidance For Any Grade:"
94,page_94,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 95 de 123 (elevated LFTs) Infliximab should not be used for management of immune -related hepatitis. − Monitor and evaluate liver function test: AST, ALT, ALP, and TB. − Evaluate for alternative etiologies (e.g., viral hepatitis, disease progression, concomitant medications). Grade 1 (AST or ALT >ULN and ≤3.0×ULN and/or TB > ULN and ≤1.5×ULN)  No dose modifications.  If it worsens, then treat as Grade 2 event. For Grade 1: − Continue LFT monitoring per protocol. Grade 2 (AST or ALT >3.0×ULN and ≤5.0×ULN and/or TB >1.5×ULN and ≤3.0×ULN)  Hold study drug/study regimen dose until Grade 2 resolution to Grade ≤1.  If toxicity worsens, then treat as Grade 3 or Grade 4.  If toxicity improves to Grade ≤1 or baseline, resume study drug/study regimen after completion of steroid taper. For Grade 2: − Regular and frequent checking of LFTs (e.g., every 1 to 2 days) until elevations of these are improving or resolved. − If no resolution to Grade ≤1 in 1 to 2 days, consider, as necessary, discussing with study physician. − If event is persistent (>3 to 5 days) or worsens, promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. − If still no improvement within 3 to 5 days despite 1 to 2 mg/kg/day of prednisone PO or IV equivalent, consider additional work up and start prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day. − If still no improvement within 3 to 5 days despite 2 to 4 mg/kg/day of IV methylprednisolone, pr omptly start immunosuppressives (i.e., mycophenolate mofetil).a Discuss with study physician if mycophenolate mofetil is not available. Infliximab should NOT be used. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophy lactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a Grade 3 or 4 (Grade 3: AST or ALT >5.0×ULN and ≤20.0×ULN and/or TB >3.0×ULN and ≤10.0×ULN) (Grade 4: AST or ALT >20×ULN and/or TB >10×ULN) For Grade 3: For elevations in transaminases ≤8 × ULN, or elevations in bilirubin ≤5 × ULN:  Hold study drug/study regimen dose until resolution to Grade ≤1 or baseline  Resume study drug/study regimen if elevations downgrade to Grade ≤1 or baseline within 14 days and after completion of steroid taper.  Permanently discontinue study For Grade 3 or 4: − Promptly initiate empiric IV methylprednisolone at 1 to 4 mg/kg/day or equivalent. − If still no improvement within 3 to 5 days despite 1 to 4 mg/kg/day methylprednisolone IV or equivalent, promptly start treatment with immunosuppressive therapy (i.e., mycophenolate mofetil). Discuss with study physician if mycophenolate is not available. Infliximab should NOT be used. − Perform hepatology consult, abdominal workup, and imaging as appropriate. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -PLEASE SEE shaded area immediately below this se ction to find guidance for management of “Hepatitis (elevated LFTS)” in HCC patients"
95,page_95,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 96 de 123 drug/study regimen if the elevations do not downgrade to Grade ≤1 or baseline within 14 days For elevations in trans aminases >8 × ULN or elevations in bilirubin >5 × ULN, discontinue study drug/study regimen. Permanently discontinue study drug/study regimen for any case meeting Hy’s law criteria (AST and/or ALT >3 × ULN + bilirubin >2 × ULN without initial findings of c holestasis (i.e., elevated alkaline P04) and in the absence of any alternative cause.b For Grade 4: Permanently discontinue study drug/study regimen. related infections [Category 2B recommendation]).a Hepatitis (elevated LFTs) Infliximab should not be used for management of immune -related hepatitis. See instructions at bottom of shaded area if transaminase rise is not isolated but (at any time) occurs in setting of either increasing bilirubin or signs of DILI/liver decompensation Any Grade General Guidance For Any Grade: − Monitor and evaluate liver function test: AST, ALT, ALP, and TB. − Evaluate for alternative etiologies (e.g., viral hepatitis, disease progression, concomitant medications, worsening of liver cirrhosis [e.g., portal vein thrombosis]). − For HBV+ patients: evaluate quantitative HBV viral load, quantitative HBsAg, or HBeAg − For HCV+ patients: evaluate quantitative HCV viral load − Consider consulting hepatologist/Infectious disease specialist regarding change/implementation in/of antiviral medications for any patient with an elevated HBV viral load >2000 IU/ml − Consider consulting hepatologist/Infectious disease specialist regarding change/implementation in/of antiviral HCV medications if HCV viral load increased by ≥2 -fold − For HCV+ with HBcAB+: Evaluate for both HBV and HCV as above Grade 1 (Isolated AST or ALT  No dose modifications.  If ALT/AST elevations represents significant worsening based on THIS shaded area is guidance only for management of “Hepatitis (elevated LFTs)” in HCC patients"
96,page_96,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 97 de 123 >ULN and ≤5.0×ULN, whether normal or elevated at baseline) investigator assessment, then treat as Grade 2 event. For all grades, see instructions at bottom of shaded area if transaminase rise is not isolated but (at any time) occurs in setting of either increasing bilirubin or signs of DILI/liver decompensation Grade 2 (Isolated AST or ALT >5.0×ULN and ≤8.0×ULN, if normal at baseline) (Isolated AST or ALT >2.0×baseline and ≤12.5×ULN, if elevated >ULN at baseline)  Hold study drug/study regimen dose until Grade 2 resolution to Grade ≤1 or baseline.  If toxicity worsens, then treat as Grade 3 or Grade 4. If toxicity improves to Grade ≤1 or baseline, resume study drug/study regimen after completion of steroid taper. For Grade 2: − Regular and frequent checking of LFTs (e.g., every 1 to 3 days) until elevations of these are improving or resolved. − Recommend consult hepatologist; consider abdominal ultrasound, including Doppler assessment of liver perfusion. − Consider, as necessary, discussing with study physician. − If event is persistent (>3 to 5 days) or worsens, and investigat or suspects toxicity to be immune -mediated AE, recommend to start prednisone 1 to 2 mg/kg/day PO or IV equivalent. − If still no improvement within 3 to 5 days despite 1 to 2 mg/kg/day of prednisone PO or IV equivalent, consider additional workup and treatme nt with IV methylprednisolone 2 to 4 mg/kg/day. − If still no improvement within 3 to 5 days despite 2 to 4 mg/kg/day of IV methylprednisolone, consider additional abdominal workup (including liver biopsy) and imaging (i.e., liver ultrasound), and consider s tarting immunosuppressives (i.e., mycophenolate mofetil).a Discuss with study physician if mycophenolate mofetil is not available. Infliximab should NOT be used. Grade 3 (Isolated AST or ALT >8.0×ULN and ≤20.0×ULN, if normal at baseline) (Isolated AST or ALT >12.5×ULN and ≤20.0×ULN, if elevated >ULN at  Hold study drug/study regimen dose until resolution to Grade ≤1 or baseline  Resume study drug/study regimen if elevations downgrade to Grade ≤1 or baseline within 14 days and after completion o f steroid taper.  Permanently discontinue study drug/study regimen if the elevations do not downgrade to Grade ≤1 or baseline within 14 days Permanently discontinue study drug/study regimen for any case meeting Hy’s law For Grade 3: − Regular and frequent checking of LFTs (e.g., every 1 -2 days) until elevations of these are improving or resolved. − Consult hepatologist (unless investigator is hepatologist); obtain abdominal ultrasound, including Doppler as sessment of liver perfusion; and consider liver biopsy. − Consider, as necessary, discussing with study physician. − If investigator suspects toxicity to be immune -mediated, promptly initiate empiric IV methylprednisolone at 1 to 4 mg/kg/day or equivalent. − If no improvement within 3 to 5 days despite 1 to 4 mg/kg/day methylprednisolone IV or equivalent, obtain liver biopsy (if it has not been done already) and promptly start treatment with"
97,page_97,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 98 de 123 baseline) criteria, in the absence of any alternative cause.b immunosuppressive therapy (mycophenolate mofetil). Discuss with study ph ysician if mycophenolate is not available. Infliximab should NOT be used. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PCP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a Grade 4 (Isolated AST or ALT >20×ULN, whether normal or elevated at baseline) Permanently discontinue study drug/study regimen. For Grade 4: Same as above (except would recommend obtaining liver biopsy early) If transaminase rise is not isolated but (at any time) occurs in setting of either increasing total/direct bilirubin (≥1.5×UL N, if normal at baseline; or 2×baseline, if >ULN at baseline) or signs of DILI/liver decompensation (e.g., fever, elevated INR): - Manage dosing for Grade 1 transaminase rise as instructed for Grade 2 transaminase rise - Manage dosing for Grade 2 transaminase rise as instructed for Grade 3 transaminase rise - Grade 3 -4: Permanently discontinue s tudy drug/study regimen Nephritis or renal dysfunction (elevated serum creatinine) Any Grade General Guidance For Any Grade: − Consult with nephrologist. − Monitor for signs and symptoms that may be related to changes in renal function (e.g., routine urinalysis, elevated serum BUN and creatinine, decreased creatinine clearance, electrolyte imbalance, decrease in urine output, or proteinuria). − Patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression or infections). − Steroids should be considered in the absence of clear alternative etiology even for low -grade events (Grade 2), in order to prevent potential progression to higher grade event. Grade 1 (Serum creatinine > 1 No dose modifications. For Grade 1: − Monitor serum creatinine weekly and any accompanying symptoms.  If creatinine returns to baseline, resume its regular monitoring"
98,page_98,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 99 de 123 to 1.5 × baseline; > ULN to 1.5 × ULN) per study protocol.  If creatinine worsens, depending on the severity, treat as Grade 2, 3, or 4. − Consider symptomatic treatment, including hydration, electrolyte replacement, and diuretics. Grade 2 (serum creatinine >1.5 to 3.0 × baseline; >1.5 to 3.0 × ULN) Hold study drug/study regimen until resolution to Grade ≤1 or baseline.  If toxicity worsens, then treat as Grade 3 or 4.  If toxicity improves to Grade ≤1 or baseline, then resume study drug/study regimen after completion of steroid taper. For Grade 2: − Consider symptomatic treatment, including hydration, electrolyte replacement, a nd diuretics. − Carefully monitor serum creatinine every 2 to 3 days and as clinically warranted. − Consult nephrologist and consider renal biopsy if clinically indicated. − If event is persistent (>3 to 5 days) or worsens, promptly start prednisone 1 to 2 mg/kg /day PO or IV equivalent. − If event is not responsive within 3 to 5 days or worsens despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional workup should be considered and prompt treatment with IV methylprednisolone at 2 to 4 mg/kg/day starte d. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a − When event returns to baseline, resume study drug/study regimen and routine serum creatinine monitoring per study protocol. Grade 3 or 4 (Grade 3: serum creatinine >3.0 × baseline; >3.0 to 6.0 × ULN; Grade 4: serum creatinine >6.0 × ULN) Permanently discontinue study drug/study regimen. For Grade 3 or 4: − Carefully monitor serum creatinine on daily basis. − Consult nephrologist and consider renal biopsy if clinically indicated. − Promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent. − If event is not responsive within 3 to 5 days or worsens despite prednisone at 1 to 2 mg/kg/day PO or IV equivalent, additional workup should be considered and prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day started. − Once the patient is improving, gradual ly taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [Category 2B recommendation]).a Rash (excluding bullous skin formatio ns) Any Grade (refer to NCI CTCAE v 4.03 for definition of General Guidance For Any Grade: − Monitor for signs and symptoms of dermatitis (rash and pruritus). − IF THERE IS ANY BULLOUS FORMATION, THE STUDY"
99,page_99,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 100 de 123 severity/grade depending on type of skin rash) PHYSICIAN SHOULD BE CONTACTED AND STUDY DRUG DISCONTINUED. Grade 1 No dose modifications. For Grade 1: − Consider symptomatic treatment, including oral antipruritics (e.g., diphenhydramine or hydroxyzine) and topical therapy (e.g., urea cream). Grade 2 For persistent (>1 to 2 weeks) Grade 2 events, hold scheduled study drug/study regimen until resolution to Grade ≤1 or baseline.  If toxicity worsens, then treat as Grade 3.  If toxicity improves to Grade ≤1 or baseline, then resume drug/study regimen after completion of steroid taper. For Grade 2: − Obtain dermatology consult. − Consider symptomatic treatment, including oral antipruritics (e.g., diphenhydramine or hydroxyzine) and topical therapy (e.g., urea cream). − Consider moderate -strength topical steroid. − If no improvement of rash/skin lesions occurs within 3 to 5 days or is worsening despite symptomatic treatment and/or use of moderate strength topical steroid, consider, as necessary, discussing with study physi cian and promptly start systemic steroids such as prednisone 1 to 2 mg/kg/day PO or IV equivalent. − Consider skin biopsy if the event is persistent for >1 to 2 weeks or recurs. Grade 3 or 4 For Grade 3: Hold study drug/study regimen until resolution to Grade ≤1 or baseline. If temporarily holding the study drug/study regimen does not provide improvement of the Grade 3 skin rash to Grade ≤1 or baseline within 30 days, then permanently discontinue study drug/study regimen. For Grade 4: Permanently discont inue study drug/study regimen. For Grade 3 or 4: − Consult dermatology. − Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day or equivalent. − Consider hospitalization. − Monitor extent of rash [Rule of Nines]. − Consider skin biopsy (preferably more than 1) as clinically feasible. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer - related infections [C ategory 2B recommendation]).a − Consider, as necessary, discussing with study physician."
100,page_100,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 101 de 123 Endocrinopathy (e.g., hyperthyroidism, hypothyroidism, Type 1 diabetes mellitus, hypophysitis, hypopituitarism, and adrenal insufficiency; exocrine event of amylase/lipase increased also included in this section) Any Grade (depending on the type of endocrinopathy, refer to NCI CTCAE v4.03 for defining the CTC grade/severity) General Guidance For Any Grade: − Consider consulting an endocrinologist for endocrine events. − Consider, as necessary, discussing with study physician. − Monitor patients for signs and symptoms of endocrinopathies. Non - specific symptoms include headache, fatigue, behavior changes, changed mental status, vertigo, abdominal pain, unusual bowel h abits, polydipsia, polyuria, hypotension, and weakness. − Patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression including brain metastases, or infections). − Depending on the suspected endocrinopathy, monitor a nd evaluate thyroid function tests: TSH, free T3 and free T4 and other relevant endocrine and related labs (e.g., blood glucose and ketone levels, HgA1c). − For modest asymptomatic elevations in serum amylase and lipase, corticosteroid treatment is not indic ated as long as there are no other signs or symptoms of pancreatic inflammation. − If a patient experiences an AE that is thought to be possibly of autoimmune nature (e.g., thyroiditis, pancreatitis, hypophysitis, or diabetes insipidus), the investigator sho uld send a blood sample for appropriate autoimmune antibody testing. Grade 1 No dose modifications. For Grade 1 (including those with asymptomatic TSH elevation): − Monitor patient with appropriate endocrine function tests. − For suspected hypophysitis/hypopituitarism, consider consultation of an endocrinologist to guide assessment of early -morning ACTH, cortisol, TSH and free T4; also consider gonadotropins, sex hormones, and prolactin levels, as well as cosyntropin stimulation test (though it may not be useful in diagnosing early secondary adrenal insufficiency). − If TSH < 0.5 × LLN, or TSH >2 × ULN, or consistently out of range in 2 subsequent measurements, include free T4 at subsequent cycles as clinically indicated and consider consultati on of an endocrinologist. Grade 2 For Grade 2 endocrinopathy other than hypothyroidism and Type 1 diabetes mellitus, hold study drug/study regimen dose until patient is clinically stable.  If toxicity worsens, then treat as Grade 3 or Grade 4. Study drug/study regimen can be resumed once event stabilizes and after completion For Grade 2 (including those with symptomatic endocrinopathy): − Consult endocrinologist to guide evaluation of endocrine function and, as indicated by suspected endocrinopathy and as clinically indicated, consider pituitary scan. − For all patients with abnormal endocrine work up, except thos e with isolated hypothyroidism or Type 1 DM, and as guided by an endocrinologist, consider short -term corticosteroids (e.g., 1 to 2 mg/kg/day methylprednisolone or IV equivalent) and prompt initiation of treatment with relevant hormone replacement (e.g., hydrocortisone, sex hormones)."
101,page_101,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 102 de 123 of steroid taper. Patients with endocrinopathies who may require prolonged or continued steroid replacement (e.g., adrenal insufficiency) can be retreated with study drug/study regimen on the following conditions: 4. The event stabilizes and is controlled. 5. The patient is clinically stable as per investigator or treating physician’s clinical judgement. 6. Doses of prednisone are ≤10 mg/day or equivalent. − Isolated hypothyroidism may be treated with replacement therapy, without study drug/study regimen interruption, and without corticosteroids. − Isolated Type 1 diabetes mellitus (DM) may be treated with appropriate diabetic ther apy, without study drug/study regimen interruption, and without corticosteroids. − Once patients on steroids are improving, gradually taper immunosuppressive steroids (as appropriate and with guidance of endocrinologist) over ≥28 days and consider prophylac tic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a − For patients with normal endocrine workup (laboratory assessment or MRI scans), repeat laborat ory assessments/MRI as clinically indicated. Grade 3 or 4 For Grade 3 or 4 endocrinopathy other than hypothyroidism and Type 1 diabetes mellitus, hold study drug/study regimen dose until endocrinopathy symptom(s) are controlled. Study drug/study regimen can be resumed once event stabilizes and after completion of steroid taper. Patients with endocrinopathies who may require prolonged or continued steroid replacement (e.g., adrenal insufficiency) can be retreated with study drug/study regimen on the follo wing conditions: 4. The event stabilizes and is controlled. 5. The patient is clinically stable as per investigator or treating physician’s clinical judgement. 6. Doses of prednisone are ≤10 mg/day or equivalent. For Grade 3 or 4: − Consult endocrinologist to guide evaluation of endocrine function and, as indicated by suspected endocrinopathy and as clinically indicated, consider pituitary scan. Hospitalization recommended. − For all patients with abnormal endocrine work up, except thos e with isolated hypothyroidism or Type 1 DM, and as guided by an endocrinologist, promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day or equivalent, as well as relevant hormone replacement (e.g., hydrocortisone, sex hormones). − For adrenal crisis, severe dehydration, hypotension, or shock, immediately initiate IV corticosteroids with mineralocorticoid activity. − Isolated hypothyroidism may be treated with replacement therapy, without study drug/study regimen interruption, and without corticos teroids. − Isolated Type 1 diabetes mellitus may be treated with appropriate diabetic therapy, without study drug/study regimen interruption, and without corticosteroids. − Once patients on steroids are improving, gradually taper immunosuppressive steroids (as appropriate and with guidance of endocrinologist) over ≥28 days and consider prophylactic antibiotics, antifungals, and anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a Neurotoxicity (to include but not be limited to limbic encephalitis and autonomic neuropathy, Any Grade (depending on the type of neurotoxicity, refer General Guidance For Any Grade: − Patients should be evaluated to rule out any alternative etiology (e.g., disease progression, infections, metabolic syndromes, or medications)."
102,page_102,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 103 de 123 excluding Myasthenia Gravis and Guillain - Barre) to NCI CTCAE v4.03 for defining the CTC grade/severity) − Monitor patient for general symptoms (headache, nausea, vertigo, behavior change, or weakness). − Consider appropriate diagnostic testing (e.g., electromyogram and nerve conduction investigations). − Perform symptomatic treatment with neurological consult as appropriate. − Grade 1 No dose modifications. For Grade 1: − See “Any Grade” recommendations above. Grade 2 For acute motor neuropathies or neurotoxicity, hold study drug/study regimen dose until resolution to Grade ≤1. For sensory neuropathy/neuropathic pain, consider holding study drug/study regimen dose until resolution to Gra de ≤1. If toxicity worsens, then treat as Grade 3 or 4. Study drug/study regimen can be resumed once event improves to Grade ≤1 and after completion of steroid taper. For Grade 2: − Consider, as necessary, discussing with the study physician. − Obtain neurology consult. − Sensory neuropathy/neuropathic pain may be managed by appropriate medications (e.g., gabapentin or duloxetine). − Promptly start systemic steroids prednisone 1 to 2 mg/kg/day PO or IV equivalent. − If no improvement within 3 to 5 days despit e 1 to 2 mg/kg/day prednisone PO or IV equivalent, consider additional workup and promptly treat with additional immunosuppressive therapy (e.g., IV IG). Grade 3 or 4 For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to Grade ≤1 within 30 days. For Grade 4: Permanently discontinue study drug/study regimen. For Grade 3 or 4: − Consider, as necessary, discussing with study physician. − Obtain neurology consult. − Consider hospitalization. − Promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day or equivalent. − If no improvement within 3 to 5 days despite IV corticosteroids, consider additional workup and promptly treat with additional immu nosuppressants (e.g., IV IG). − Once stable, gradually taper steroids over ≥28 days. Peripheral neuromotor syndromes (such as Guillain -Barre and myasthenia gravis) Any Grade General Guidance For Any Grade: − The prompt diagnosis of immune -mediated peripheral neuromotor syndromes is important, since certain patients may unpredictably experience acute decompensations that can result in substantial"
103,page_103,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 104 de 123 morbidity or in the worst case, death. Special care should be taken for certain sentinel symptoms that may predict a more severe outcome, such as prominent dysphagia, rapidly progressive weakness, and signs of respiratory insufficiency or autonomic instability. − Patients should be evaluated to rule out any alternative etiology (e.g., disease progression, infections, meta bolic syndromes or medications). It should be noted that the diagnosis of immune -mediated peripheral neuromotor syndromes can be particularly challenging in patients with underlying cancer, due to the multiple potential confounding effects of cancer (and i ts treatments) throughout the neuraxis. Given the importance of prompt and accurate diagnosis, it is essential to have a low threshold to obtain a neurological consult. − Neurophysiologic diagnostic testing (e.g., electromyogram and nerve conduction investig ations, and “repetitive stimulation” if myasthenia is suspected) are routinely indicated upon suspicion of such conditions and may be best facilitated by means of a neurology consultation. − It is important to consider that the use of steroids as the primary treatment of Guillain -Barre is not typically considered effective. Patients requiring treatment should be started with IV IG and followed by plasmapheresis if not responsive to IV IG. Grade 1 No dose modifications. For Grade 1: − Consider, as necessary, discussing with the study physician. − Care should be taken to monitor patients for sentinel symptoms of a potential decompensation as described above. − Obtain a neurology consult. Grade 2 Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if it does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency or autonomic instability. For Grade 2: − Consider, as necessary, discussing with the study physician. − Care should be taken to monitor patients for sentinel symptoms of a potential decompensation as described above. − Obtain a neurology consult − Sensory neuropathy/neuropathic pain may be managed by appropriate medications (e.g., gabapentin or duloxetine). MYASTHENI A GRAVIS: o Steroids may be successfully used to treat myasthenia gravis. It is important to consider that steroid therapy (especially with high doses) may result in transient worsening of myasthenia and should typically be administered in a monitored settin g under supervision of a consulting neurologist. o Patients unable to tolerate steroids may be candidates for treatment with plasmapheresis or IV IG. Such decisions are best made in consultation with a neurologist, taking into"
104,page_104,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 105 de 123 account the unique needs of eac h patient. o If myasthenia gravis -like neurotoxicity is present, consider starting AChE inhibitor therapy in addition to steroids. Such therapy, if successful, can also serve to reinforce the diagnosis. GUILLAIN -BARRE: o It is important to consider here that t he use of steroids as the primary treatment of Guillain -Barre is not typically considered effective. o Patients requiring treatment should be started with IV IG and followed by plasmapheresis if not responsive to IV IG. Grade 3 or 4 For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency or autonomic instability. For Grade 4: Permanently discontinue study drug/study regimen. For Grade 3 or 4 (severe or life -threatening events): − Consider, as necessary, discussing with study physician. − Recommend hospitalization. − Monitor symptoms and obtain neurological consult. MYASTHENIA GRAVIS: o Steroids may be successfully used to treat myasthenia gravis. They should typically be administered in a monitored setting under supervision of a consulting neurologist. o Patients unable to tolerate steroids may be candidates for treatment with plas mapheresis or IV IG. o If myasthenia gravis -like neurotoxicity present, consider starting AChE inhibitor therapy in addition to steroids. Such therapy, if successful, can also serve to reinforce the diagnosis. GUILLAIN -BARRE: o It is important to consider here that the use of steroids as the primary treatment of Guillain -Barre is not typically considered effective. o Patients requiring treatment should be started with IV IG and followed by plasmapheresis if not responsive to IV IG. Myocarditis Any Grade General Guidance Discontinue drug permanently if biopsy - proven immune -mediated myocarditis. For Any Grade: − The prompt diagnosis of immune -mediated myocarditis is important, particularly in patients with baseline cardiopulmonary disease and reduced cardiac functio n. − Consider, as necessary, discussing with the study physician. − Monitor patients for signs and symptoms of myocarditis (new onset or worsening chest pain, arrhythmia, shortness of breath, peripheral"
105,page_105,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 106 de 123 edema). As some symptoms can overlap with lung toxicitie s, simultaneously evaluate for and rule out pulmonary toxicity as well as other causes (e.g., pulmonary embolism, congestive heart failure, malignant pericardial effusion). A Cardiology consultation should be obtained early, with prompt assessment of wheth er and when to complete a cardiac biopsy, including any other diagnostic procedures. − Initial work -up should include clinical evaluation, BNP, cardiac enzymes, ECG, echocardiogram (ECHO), monitoring of oxygenation via pulse oximetry (resting and exertion), and additional laboratory work -up as indicated. Spiral CT or cardiac MRI can complement ECHO to assess wall motion abnormalities when needed. − Patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression, other medications, or infections) Grade 1 (asymptomatic with laboratory (e.g., BNP) or cardiac imaging abnormalities ) No dose modifications required unless clinical suspicion is high, in which case hold study drug/study regimen dose during diagnostic work -up for other etiologies. If study drug/study regimen is held, resume after complete resolution to Grade 0. For Grade 1 (no definitive findings): - Monitor and closely follow up in 2 to 4 days for clinical symptoms, BNP, cardiac enzymes, ECG, ECHO, pulse oximet ry (resting and exertion), and laboratory work -up as clinically indicated. - Consider using steroids if clinical suspicion is high. Grade 2, 3 or 4 (Grade 2: Symptoms with mild to moderate activity or exertion ) (Grade 3: Severe with symptoms at rest or with minimal activity or exertion; intervention indicated ) (Grade 4: Life- threatening consequences; urgent intervention indicated (e.g., continuous IV therapy or mechanical - If Grade 2 -- Hold study drug/study regimen dose until resolution to Grade 0. If toxicity rapidly improves to Grade 0, then the decision to reinitiate study drug/study regimen will be based upon treating physician’s clinical judgment and after completion of steroid taper. If toxicity does not rapidly improve, permanently. discontinue study drug/study regimen. If Grade 3 -4, permanently discontinue study drug/study regimen. For Grade 2 -4: − Monitor symptoms daily, hospitalize. − Promptly start IV methylprednisolone 2 to 4 mg/kg/day or equivalent after Cardiology consultation has determined whether and when to complete diagnostic procedures including a cardiac biopsy. − Supportive care (e.g., oxygen). − If no improvement within 3 to 5 days despite IV methylprednisolone at 2 to 4 mg/kg/day, promptly start immunosuppress ive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general guidance before using infliximab. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a"
106,page_106,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 107 de 123 hemodynamic support) ) Myositis/Polymyositis (“Poly/myositis”) Any Grade General Guidance For Any Grade: − Monitor patients for signs and symptoms of poly/myositis. Typically, muscle weakness/pain occurs in proximal muscles including upper arms, thighs, shoulders, hips, neck and back, but rarely affects the extremities including hands an d fingers; also difficulty breathing and/or trouble swallowing can occur and progress rapidly. Increased general feelings of tiredness and fatigue may occur, and there can be new -onset falling, difficulty getting up from a fall, and trouble climbing stairs , standing up from a seated position, and/or reaching up. − If poly/myositis is suspected, a Neurology consultation should be obtained early, with prompt guidance on diagnostic procedures. Myocarditis may co -occur with poly/myositis; refer to guidance under Myocarditis. Given breathing complications, refer to guidance under Pneumonitis/ILD. Given possibility of an existent (but previously unknown) autoimmune disorder, consider Rheumatology consultation. − Consider, as necessary, discussing with the study physi cian. − Initial work -up should include clinical evaluation, creatine kinase, aldolase, LDH, BUN/creatinine, e rythrocyte sedimentation rate or C - reactive protein level , urine myoglobin, and additional laboratory work - up as indicated, including a number of pos sible rheumatological/antibody tests (i.e., consider whether a rheumatologist consultation is indicated and could guide need for rheumatoid factor, antinuclear antibody, anti -smooth muscle, antisynthetase [such as anti - Jo-1], and/or signal -recognition part icle antibodies). Confirmatory testing may include electromyography, nerve conduction studies, MRI of the muscles, and/or a muscle biopsy. Consider Barium swallow for evaluation of dysphagia or dysphonia . Patients should be thoroughly evaluated to rule out any alternative etiology (e.g., disease progression, other medications, or infections). Grade 1 (mild pain ) - No dose modifications. For Grade 1: − Monitor and closely follow up in 2 to 4 days for clinical symptoms and initiate evaluation as clinically indicated. − Consider Neurology consult. − Consider, as necessary, discussing with the study physician. Grade 2 (moderate pain associated with weakness; pain limiting Hold study drug/study regimen dose until resolution to Grade ≤1. - Permanently discontinue study For Grade 2: − Monitor symptoms daily and consider hospitalization. − Obtain Neurology consult, and initiate evaluation."
107,page_107,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 108 de 123 aASCO Educational Book 2015 “Managing Immune Checkpoint Blocking Antibody Side Effects” by Michael Postow MD. bFDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury – Premarketing Clinical Evaluation. AChE Acetylcholine esterase; ADL Activities of daily living; AE Adverse event; ALP Alkaline phosphatase test; ALT Alanine aminotransferase; AST Aspartate aminotransferase; BUN Blood urea nitrogen; CT Computed tomography; CTCAE Common Terminology Criteria for Adverse Events; ILD Interstitial lung disease; imAE immune -mediated adverse even t; IG Immunoglobulin; IV Intravenous; GI Gastrointestinal; LFT Liver function tests; LLN Lower limit of normal; MRI Magnetic resonance imaging; NCI National Cancer Institute; NCCN National Co mprehensive Cancer Network; PJP Pneumocystis jirovecii pneumon ia (formerly known as Pneumocystis carinii pneumonia); PO By mouth; T3 Triiodothyronine; T4 Thyroxine; TB Total bilirubin; TNF Tumor necrosis factor; TSH Thyroid -stimulating hormone; ULN Upper limit of normal. instrumental activities of daily living [ADLs]) drug/study regimen if it does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency. − Consider, as necessary, discussing with the study physician. − If clinical course is rapidly progressive (particularly if difficulty breathing and/or trouble swallowing), promptly start IV methylprednisolone 2 to 4 mg/kg/day systemic steroids along with receiving input from Neurology consultant − If clinical course is not rapidly progressive, start systemic steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV equivalent); if no improvement within 3 to 5 days, continue additional work up and start treatment with IV methylprednisolone 2 to 4 mg/kg/day − If after start of IV me thylprednisolone at 2 to 4 mg/kg/day there is no improvement within 3 to 5 days, consider start of immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to inflix imab label for general guidance before using infliximab. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -PJP treatment (refer to current NCCN guidelines for treatment of canc er-related infections [Category 2B recommendation]).a Grade 3 or 4 (pain associated with severe weakness; limiting self -care ADLs ) For Grade 3: Hold study drug/study regimen dose until resolution to Grade ≤1. Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to Grade ≤1 within 30 days or if there are signs of respiratory insufficiency. For Grade 4: - Permanently discontinue study drug/study regimen. For Grade 3 or 4 (severe or life -threatening events): − Monitor symptoms c losely; recommend hospitalization. − Obtain Neurology consult, and complete full evaluation. − Consider, as necessary, discussing with the study physician. − Promptly start IV methylprednisolone 2 to 4 mg/kg/day systemic steroids along with receiving input from Neurology consultant. − If after start of IV methylprednisolone at 2 to 4 mg/kg/day there is no improvement within 3 to 5 days, consider start of immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and refer to infliximab label for general guidance before using infliximab. − Consider whether patient may require IV IG, plasmapheresis. − Once the patient is improving, gradually taper steroids over ≥28 days and consider prophylactic antibiotics, antifungals, or anti -PJP treatment (refer to current NCCN guidelines for treatment of cancer -related infections [Category 2B recommendation]).a"
108,page_108,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 109 de 123 Infusion -Related Reactions Severity Grade of the Event (NCI CTCAE version 4.03) Dose Modifications Toxicity Management Any Grade General Guidance For Any Grade: − Manage per institutional standard at the discretion of investigator. − Monitor patients for signs and symptoms of infusion -related reactions (e.g., fever and/or shaking chills, flushing and/or itching, alterations in heart rate and blood pressure, dyspnea or chest discomfort, or skin rashes) and anaphylaxis (e.g., generalized urticaria, angioedema, wheezing, hypotension, or tachycardi a). Grade 1 or 2 For Grade 1: The infusion rate of study drug/study regimen may be decreased by 50% or temporarily interrupted until resolution of the event. For Grade 2: The infusion rate of study drug/study regimen may be decreased 50% or temporarily i nterrupted until resolution of the event. Subsequent infusions may be given at 50% of the initial infusion rate. For Grade 1 or 2: − Acetaminophen and/or antihistamines may be administered per institutional standard at the discretion of the investigator. − Consider premedication per institutional standard prior to subsequent doses. − Steroids should not be used for routine premedication of Grade ≤2 infusion reactions. Grade 3 or 4 For Grade 3 or 4: Permanently discontinue study drug/study regimen. For Grade 3 or 4: − Manage severe infusion -related reactions per institutional standards (e.g., IM epinephrine, followed by IV diphenhydramine and ranitidine, and IV glucocorticoid). CTCAE Common Terminology Criteria for Adverse Events; IM intramuscular; IV intravenous; NCI National Cancer Institute."
109,page_109,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 110 de 123 Non–Immune -Mediated Reactions Severity Grade of the Event (NCI CTCAE version 4.03) Dose Modifications Toxicity Management Any Grade Note: Dose modifications are not required for AEs not deemed to be related to study treatment (i.e., events due to underlying disease) or for laboratory abnormalities not deemed to be clinically significant. Treat accordingly, as per institutional standard. Grade 1 No dose modifications. Treat accordingly, as per institutional s tandard. Grade 2 Hold study drug/study regimen until resolution to ≤Grade 1 or baseline. Treat accordingly, as per institutional standard. Grade 3 Hold study drug/study regimen until resolution to ≤Grade 1 or baseline. For AEs that downgrade to ≤Grade 2 within 7 days or resolve to ≤Grade 1 or baseline within 14 days, resume study drug/study regimen administration. Otherwise, discontinue study drug/study regimen. Treat accordingly, as per institutional standard. Grade 4 Discontinue study drug/study regimen (Note: For Grade 4 labs, decision to discontinue should be based on accompanying clinical signs/symptoms, the Investigator’s clinical judgment, and consultation with the Sponsor.). Treat accordingly, as per institution al standard. Note: As applicable, for early phase studies, the following sentence may be added: “Any event greater than or equal to Grade 2, please discuss with Study Physician.” AE Adverse event; CTCAE Common Terminology Criteria for Adverse Events; NCI National Cancer Institute ."
110,page_110,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 111 de 123 APPENDIX 9: SUMMARY OF CHARACTER ISTICS PRODUCT AND I NVESTIVATOR’S BROCHURE SmPC – FLUOROURACILE TEVA® http://base -donnees -publique.medicaments.gouv.fr/ SmPC– ELVORINE® http://base -donnees -publique.medicaments.gouv.fr/ SmPC– IRINOTECAN® http://base -donnees -publique.medicaments.gouv.fr/ INFORMATIONS ON DURVALUMAB AND TREMILIMUMAB WILL BE PROVIDED IN THE INVESTIGATOR’S BROCHURE
111,page_111,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 112 de 123 APPENDIX 10: AUTHORIZED AND PROHI BITED CONCOMITTANT MEDICAT IONS Supportive medication/class of drug: Usage: Concomitant medications or treatments (e.g., acetaminophen or diphenhydramine) deemed necessary to provide adequate prophylactic or supportive care, except for those medications identified as “prohibited,” as listed above To be administered as prescribed by the Investigator Best supportive care (including antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control, and pain management [including palliative radiotherapy to non -target lesions, etc]) Should be used, when nece ssary, for all patients Inactivated viruses, such as those in the influenza vaccine Permitted Prohibited medication/class of drug: Usage: Any investigational anticancer therapy other than those under investigation in this study Should not be given concomitantly whilst the patient is on study treatment mAbs against CTLA -4, PD -1, or PD -L1 other than those under investigation in this study Should not be given concomitantly whilst the patient is on study treatment Any concurrent chemotherapy, radiothe rapy, immunotherapy, or biologic or hormonal therapy for cancer treatment other than those under investigation in this study Should not be given concomitantly whilst the patient is on study treatment. (Concurrent use of hormones for non - cancer -related cond itions [e.g., insulin for diabetes and hormone replacement therapy] is acceptable. Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable [e.g., by local surgery or radiotherapy])"
112,page_112,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 113 de 123 Immunosuppressive medications i ncluding, but not limited to, systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, and tumor necrosis factor -α blockers Should not be given concomitantly, or used for premedication prior to the I -O infusions. The following are allowed exceptions:  Use of immunosuppressive medications for the management of IP-related AEs .  short -term premedication for patients receiving combination agent durvalumuab ± tremelimumab where the prescribing information for the agent requires the use of steroids for documented hypersensitivity reactions .  Use in patients with contrast allergies.  In addition, use of inhaled, topical, and intranasal corticosteroids is permitted. A temporary period of steroids will be allowed if clinically indicated and considered to be essential for the management of non-immunotherapy related events experienced by the patient (e.g., chronic obstructive pulmonary disease, radiation, nausea, etc). Drugs with laxative properties and herbal or natural remedies for constipation Should be avoided through 90 days after the last dose of tremelimumab during the study . Sunitinib Should not be given concomitantly or through 90 days after the last dose of tremelimumab (acute renal failure has been reported with combination therapy of tremelimumab and sunitinib) . EGFR TKIs Should not be given concomitantly. Should be used with caution in the 90 days post last dose of durvalumab. Increased incidences of pneumonitis (with third generation EGFR TKIs) and increased incidence of transaminase increases (with 1st generation EGFR TKIs) has been reported when durvalumab has been given concomitantly. Live attenuated vaccines Should not be given through 30 days after the last dose of IP (including SoC). Herb al and natural remedies which may have immune -modulating effects Should not be given concomitantly unless agreed by the sponsor ."
113,page_113,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 114 de 123 APPENDIX 11: SERIOUS ADVERSE EVEN T REPORT FORM PRODIGE 59 – FFCD 1707 – DURIGAST T M SERIOUS ADVERSE EVENT REPORT FORM (SAE) CRA Initials  Page 1/3  SPONSOR : FFCD PRINCIPAL INVESTIGAT OR : Pr David TOUGERON Study title : A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second -line treatment of patients with advanced gastric or gastro -oesophageal junction adenocarcinoma . Randomized – non-comparative – multicenter phase II N° EudraCT : 2018 -002014 -13 Author of the declaration : Dr – Pr - CRA - Other , specify : ………………………………. Name : ................................ ................................ ............................ Cent er : ................................ ................................ ............ Phone : ................................ ................................ ............................ Fax : ................................ ................................ ................. SAE n° :  Type of report : initial follow -up n° :  Date of report :  SPACE RESERVED FOR D ATA CENTER (CRGA) Date of reception :  Sponsor reference for the event : ................................ . Patient N°  Patient’s initials :  Sex : Female Male FOLFIRI + durvalumab FOLFIRI + durvalumab + tremelimumab (irinotécan 150 mg/m2) FOLFIRI + durvalumab + tremelimumab (irinotécan 1 80 mg/m2) Date of birth :  Inclusion date :  Weight (kg) : Height (cm) :  Serious adverse event : Date of start :   Date of end :  Seriousness criteria Grade /severity Outcome hospitalization (or prolongation) medically significant durable or significant disability or incapacity life-threatening death congenital anomaly or fetal malformation  Coded as NCI -CTC 4.0 If not applicable, specify : 1 = mild 2 = moderate 3 = severe 4 = life -threatening 5 = death due to SAE recovered/resolved without sequelae recovered/resolved with sequelae recovering/resolving not recovered/resolved death If hospitalization Date of admission :  ongoing Date of discharge :  If death Date of death :  Death cause ________________________________ Specify : Death related to SAE Death for which SAE may have contributed Death related to SAE Description Please describe below the chronological sequence of events including the history of the disease and the relevant concomitant diseases existing in the context of the Serious Adverse Event."
114,page_114,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 115 de 123 PRODIGE 59 – FFCD 1707 – DURIGAST T M SERIOUS ADVERSE EVENT REPORT FORM (SAE) CRA Initials  Page 2/3 SAE n°:  initial follow -up Patient N° :  Drug Administration Last d ose Treatment modification due to SAE If arm B , specify treatment sequence when SAE occurs : FOLFIRI + durvalumab + tremelimumab FOLFIRI + durvalumab Irinotecan Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°: _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :    Folinic acid Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°: D-L L _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :   5-FU bolus Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°: _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :   5-FU infusion Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°:  _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :   Durvalumab Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°:  _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :  "
115,page_115,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 116 de 123 Tremelimumab Not applicable Date of first administration :    Date of last administration before SAE :   Cycle n°: _________ mg Dose not changed Dose reduced, specify : new dose : _________ mg Temporary withdrawal , specify date of reintroduction :   Definitive withdrawal , specify date :   PRODIGE 59 – FFCD 1707 – DURIGAST T M SERIOUS ADVERSE EVENT REPORT FORM (SAE) CRA Initials  Page 3/3 SAE n°:  initial follow -up Patient N° :  Disparition of event after stop or dose reduced of suspected drugs : Yes No Unknown Not applicable Recurrence of event after reintroduction of suspected drugs : Yes No Unknown Not applicable Concomitants drugs : (regular treatment of the patient or other drugs rece ived within 15 days ) Drugs Date of start Ongoing Date of end Dose Indication                     Causality assesment Irinotecan : related not related doubtful ly related or : not applicable Folinic acid : related not related doubtful ly related or : not applicable 5-FU bolus : related not related doubtful ly related or : not applicable 5-FU infusion : related not related doubtful ly related or : not applicable Durvalumab : related not related doubtful ly related or : not applicable Tremelimumab : related not related doubtful ly related or : not applicable If the causality assessment between SAE and study drugs are « not related », which is, to your opinion, the cause of SAE ? (tick the appropriate box(es)) Progression of cancer Preexisting condition, specify : ___________________________________ Concomitant drug, specify which one : ______________________________"
116,page_116,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 117 de 123 Other illness, specify : ____________________________ Other, specify : __________________________________ _ PLEASE ATTACH ANONYMIZED HOSPITALIZATION REPORT, AND, IF NEEDED BIOLOG ICAL TESTS, COMPLEMENTARY EXAMS … Form to fax at Data Center C RGA Dijon Fax : 03 80 38 18 41 DATE : NAME : SIGNATURE :"
117,page_117,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 118 de 123 APPENDIX 12: RULES FOR PUBLICATIO N FOR PRODIGE TRIALS PRODIGE RULES FOR PUBLICATION The rules for publication that will be used for this study will be those in effect at the time of the last inclusion. (partnership version of May 3, 2012) PRODIGE RULES FOR PUBLICATION Having a good -quality journal publish the PRODIGE trials quickly is a vital objective for disseminating advances in treatment. The PRODIGE coordination committee is responsib le for publication, deciding on: - when the preliminary and definitive results of a trial are published. All information arising from trials is confidential, at least until the sponsor, coordinating investigator and statistician have finished the appropriate analysis and verification of the trial. - the composition of the drafting committee (which generally comprises a maximum of seven members). The coordination committee may delegate these functions to the trial coordinator. It validates the choices made and ensures deadlines are met. If the coordination committee does not respond within 1 month of submission by the drafting committee, this may be taken as approval . 1. The drafting committee comprises: - The committee chair as defined by internal regulation - The most important contributors In collaborative, national and international trials, if the other associations have enrolled at least 10% of the sample population, the drafting committee comprises a representative chosen from among the investig ators of each of the other associations. Any coordinator from a country or association who has not enrolled any patients will not be on the drafting committee or be an author of the publication, but will be thanked at the end of the article. 2. The lead author undertakes to submit the article for publication within a time period specified by the coordination committee. This period must be no more than 1 year after the trial has closed. If the lead author cannot do this, the coordination committee may desi gnate a new author who becomes the lead author. To facilitate the writing of articles arising from the trials, a medical writer may be called on and writing workshops may be organized for the lead author in collaboration with the statistician. 3. Before each publication, the study project manager sends the coordination committee the planned list of authors accompanied by a table of inclusions for each investigator center. The coordination committee validates the number and order of authors before each publica tion in accordance with the PRODIGE rules for publication. If far from the coordination committee's meetings, validation is made by email. A period of 7 days without reply implies approval. 4. Title of the publication and oral communications : the title of the trial must be PRODIGE XX, followed by any name given by the sponsor group. 5. The publication's authors are ordered according to work contributed and number of patients enrolled: - A lead author - A limited number of investigators, by order of participation. Th ere is generally one investigator per center but the steering committee may decide to name two investigators for some centers. This rule may be weighted so that some small - and medium -sized centers that contribute significantly to enrollment may appear as authors. The coordination committee will approve any such weighting so that no party is wronged. - If he or she is not the lead author, the trial coordinator, or any person who contributes in a major way to the conception and/or conduct of the trial (such as a co-coordinator), is generally the last author. The coordination committee will decide should there be any disagreement. - The maximum number of authors permitted by the journals will be used. - Regardless of the number of patients included, at least one aut hor will represent one of the two partners (FFCD or UNICANCER -GI). - In spin -off publications and ancillary studies, the authors may be different from those of the original article and reflect the specialty in question – for instance, in trials on radiochemo therapy, an article on radiotherapy may be signed by the co -investigator radiotherapists of the centers that enroll. The first author of the original article is therefore the last author of the spin -off publication."
118,page_118,"PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 119 de 123 - The PRODIGE partnership is mentioned in the title or after the authors. If the trial is a collaborative study, the first association mentioned is the one that initiated the trial. The others are mentioned if they included at least 5% of the patients, in order of their contribution. - For trials sp onsored or managed by the FFCD, a member of the INSERM U 1231 research unit will be the second last author and will be mentioned as having ""equally contributed"" if this member is not the lead author so that this work done by the INSERM is taken into conside ration. - For trials sponsored or managed by UNICANCER, a representative of the sponsor will be included in the authors. - The statistician will be named among the authors, generally after the third place. The statistician may be the first or second author of a spin -off publication. All contributors who do not appear among the authors are mentioned at the end of the article. Study managers (such as the project manager or data manager) are also mentioned. One of these may occasionally be mentioned as an author if the PRODIGE coordination committee believes it to be justified. Partners are thanked, as are the patients and their families. The authors and sponsor are sent a copy of the manuscript for review before submission to a journal. To have their opinions taken into account, they undertake to reply within 15 working days, or 30 days in the summer. 6. Oral communications based on the trial results: An investigator may, after obtaining the approval of the PRODIGE coordination committee and trial steering commi ttee, present in his or her own name all or part of the trial results in an oral presentation. The authors are generally the same as in the written article, but the order of authorship may vary across articles and communications, and also depending on the conference where the presentation is being made. In certain cases, such as multidisciplinary studies or pathological, biological, endoscopic or imaging studies conducted alongside a therapeutic trial, other authors may be chosen depending on their work. Th e name of the trial remains PRODIGE XX (see § 3) and the other associations will be mentioned if necessary. 7. These rules must appear in the appendices of all PRODIGE trial protocols."
119,page_119,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 120 de 123 APPENDIX 13: INSURANCE CERTIFICAT E
120,page_120,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 121 de 123 APPENDIX 14: APPROVAL OF THE IRB
121,page_121,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 122 de 123
122,page_122,PRODIGE 59 – DURIGAST – Version 2.0 – 04.08.2020 ENG Page 123 de 123 APPENDIX 15: ANSM AUTHORIZATION
